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ABSTRACT 
Background:  
Assessment of the outcome of critical illness is complex. Severity scoring systems and 
organ dysfunction scores are traditional tools in mortality and morbidity prediction in 
intensive care, and they are also increasingly used in the clinical decision-making process, 
e.g. in qualifying patients for new treatments such as activated protein C in severe sepsis. 
Their ability to explain risk of death is impressive for large cohorts of patients, but for 
individual patients they lack sufficient clinical utility. Although events before intensive 
care unit (ICU) admission are prognostically important, the prediction models utilize data 
collected at and just after ICU admission. In addition, several biomarkers have been 
evaluated to predict mortality, e.g. in sepsis, but none has proven entirely useful in clinical 
practice. Therefore, new prognostic markers of critical illness are vital when evaluating the 
intensive care outcome.  
Patients and methods:  
In addition to two new biological markers of outcome, the impact of delay in emergency 
department (ED) on intensive care outcome, measured as hospital mortality and health-
related quality of life (HRQoL) at 6 months, was assessed in 1537 consecutive patients 
admitted to medical ICU. The concentration of cell-free plasma DNA with organ 
dysfunction, disease severity, and mortality rate was then evaluated in 228 ICU patients. 
Next, the predictive value of plasma DNA regarding ICU and hospital mortality and its 
association with the degree of organ dysfunction and disease severity was evaluated in 255 
patients with severe sepsis or septic shock. Finally, as potential regulators of apoptosis, 
heme oxygenase-1 (HO-1) gene polymorphisms and HO-1 plasma concentrations and their 
association with outcome in critical illness were evaluated. 
Main results:  
The hospital mortality rate was significantly lower in patients admitted to the medical ICU 
from the ED than from the non-ED. The length of ED stay was not associated with 
outcome of intensive care, but the HRQoL in the critically ill at 6 months was significantly 
lower than in the age- and sex-matched general population.  
In the ICU patient population, the maximum plasma DNA concentration measured during 
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the first 96 hours in intensive care correlated significantly with disease severity and degree 
of organ failure. Maximum cell-free plasma DNA concentration was independently 
associated with hospital mortality.  
In patients with severe sepsis or septic shock, the cell-free plasma DNA concentrations 
were significantly higher in ICU and hospital nonsurvivors than in survivors and showed a 
moderate discriminative power regarding ICU mortality. Plasma DNA was an independent 
predictor for ICU mortality, but not for hospital mortality. 
Increased concentrations of HO-1 were found in plasma of critically ill ICU patients, and 
the concentration was associated with the degree of organ dysfunction. The HO-1 +99C 
and long GT allele (>33 repeats) were in perfect linkage disequilibrium in this Finnish 
critically ill patient population. The HO-1 -413T/GT(L)/+99C haplotype was associated 
with HO-1 plasma levels and frequency of multiple organ dysfunction.  
Conclusions:  
Time spent in the ED prior to ICU admission seems not to affect the outcome of critically 
ill patients significantly. Plasma DNA and HO-1 concentrations may support the 
assessment of outcome or organ failure development in critically ill patients, although their 
value is limited and requires further evaluation. Significantly increased HO-1 
concentrations in critically ill patients were associated with the degree of organ 
dysfunction, suggesting that plasma HO-1 is associated with cell injury.  
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1 INTRODUCTION 
Predicting the outcome of critically ill patients is a challenging task. Traditionally, scoring 
systems measuring the severity of illness, e.g. the Acute Physiology and Chronic Health 
Evaluation II (APACHE II) (Knaus et al. 1985), or organ dysfunction, e.g. the Sequential 
Organ Failure Assessment (SOFA) (Vincent et al. 1996, Vincent et al. 1998), are used to 
predict mortality or morbidity of intensive care patients. These scores are also increasingly 
used to assist the clinical decision-making process by, for instance, qualifying patients for 
new treatments such as activated protein C in severe sepsis. For large cohorts of patients, their 
ability to explain the mortality risk is impressive, and they form the basis for clinical research. 
However, at the level of the individual patient, they lack apparent clinical utility. The 
prediction models that are used at present utilize only data collected at or just after intensive 
care unit (ICU) admission, although the events before admission are evidently prognostically 
important (Rapoport et al. 1990) and early treatment improves survival in, for example, septic 
shock (Rivers et al. 2001). Evidence indicates that the longer ICU patients are in hospital 
before ICU admission, the higher their mortality (Goldhill et al. 2004). However, only a few 
studies have characterized the length of emergency department (ED) stay and ICU procedures 
performed in the ED (Varon et al. 1994, Svenson et al. 1997).  
Several biomarkers have been evaluated for their ability to predict mortality in patients with 
sepsis and its sequelae severe sepsis and septic shock, but none has proven sensitive or 
specific enough for clinical practice. Severe sepsis and septic shock have remained challenges 
in intensive care, representing the major causes of death in ICU patients, with the hospital 
mortality rate varying from 30% to 60% in different studies (Angus et al. 2001, Alberti et al. 
2002, Karlsson et al. 2007). Acute severe illness activates multiple cascading pathways. The 
biological response to injury, inflammation, infection, or shock is complex and usually 
involves activation of the innate immune system. Apoptosis has a major role in the 
pathophysiological process in sepsis (Hotchkiss et al. 2005). Cell-free plasma DNA is a 
potential marker of apoptosis and necrosis (Fournie et al. 1993, Fournie et al. 1995, Jahr et al. 
2001, Jiang and Pisetsky 2005). Increased concentrations of cell-free plasma DNA have been 
found in various clinical conditions in which tissue injury occurs, including trauma, stroke, 
and myocardial infarction (Lo et al. 2000, Chang et al. 2003, Rainer et al. 2003). According to 
current evidence, the DNA is released into the circulation from apoptotic and necrotic cells 
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(Fournie et al. 1993, Fournie et al. 1995, Jahr et al. 2001, Jiang and Pisetsky 2005), although 
the exact mechanism remains unclear. Circulating DNA has been detected in the plasma of 
septic patients (Martins et al. 2000). Furthermore, elevated plasma levels of nucleosomes, in 
which fragmented DNA is packed during apoptosis, have been found in patients with severe 
sepsis and septic shock (Zeerleder et al. 2003).  Preliminary data from ICU patients have 
suggested that plasma DNA concentrations at ICU admission may be higher in nonsurvivors 
than in survivors (Wijeratne et al. 2004, Rhodes et al. 2006).  
Although the pathophysiology of critical illness is multifactorial, there may also be shared 
general gene response patterns to injury, and thus genetic studies in critical care settings have 
increased rapidly. Regardless of the insult, there are apparently common phenomena and hub 
mechanisms in critical illness that lead to further injury or repair. In addition to nuclear factor 
kappa B (NF-B), the family of heat shock proteins (HSPs) and their regulator, the heat shock 
factors, are also extremely conserved in cellular stress response systems. HSPs have many 
important functions, such as the capacity to act as protein chaperones by protecting vital 
protein structures and functions and regulating apoptosis (Mosser et al. 2000). Heme 
oxygenase-1 (HO-1), a conserved enzyme that degrades heme to biliverdin, carbon monoxide 
(CO), and free iron, is induced by stimuli and phenomena related to critical illness, including 
oxidative stress, hypoxia, ischemia-reperfusion, and cytokines (Eyssen-Hernandez et al. 1996, 
Terry et al. 1998, Schmidt et al. 2007). HO-1 and its catabolic products have been found to 
have anti-inflammatory, antiapoptotic, and antioxidant properties (Stocker et al. 1987, 
Brouard et al. 2000, Sarady-Andrews et al. 2005), which could be beneficial in many disease 
states such as critical illness. Increased expression of HO-1 has been demonstrated in, for 
example, critically ill patients with acute respiratory distress syndrome (ARDS) (Mumby et 
al. 2004). Several polymorphisms have been detected in the promoter region of the HO-1
gene. One of the most studied genetic variants is the GTn dinucleotide polymorphism, which 
has a length varying from 12 to 40 repeats and is apparently associated with the 
transcriptional activity of the gene (Yamada et al. 2000, Chen et al. 2002). Studies 
investigating HO-1 plasma concentrations and HO-1 gene polymorphisms in critically ill 
patients are scant. In addition, knowledge of the HO-1 genotype’s effect on plasma HO-1 
concentrations is lacking.  
We hypothesized that the surrogate markers of tissue injury/apoptosis would be helpful in 
evaluating outcome of critically ill patients. Hospital mortality and quality of life (QOL) at 6 
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months after intensive care and their association with ED delay were first evaluated in a large 
population of critically ill patients. The concentration of cell-free plasma DNA, a marker of 
apoptosis, was then measured in a group of critically ill mixed ICU patients, and its predictive 
value was separately evaluated in a more homogeneous group of patients in severe sepsis or 
septic shock in a large multicenter prospective study. Finally, as potential regulators of 
apoptosis, plasma HO-1 concentrations and HO-1 polymorphisms were analyzed in terms of 
association and predictive value in organ dysfunction and mortality.  
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2 REVIEW OF THE LITERATURE  
2.1 Outcome of critical illness  
The definition of critical illness is complex, comprising a variety of different clinical 
conditions. Critically ill, unstable patients are usually admitted to the intensive care unit 
(ICU), where intensive therapy, interventions, and monitoring can be provided (Task Force of 
the American College of Critical Care Medicine, Society of Critical Care Medicine 1999). A 
critically ill patient usually has one or more failing organ systems that need to be supported by 
the resources available in the ICU such as mechanical ventilation and renal replacement 
therapy. Causes behind failing organ functions are multiple. The majority of critically ill ICU 
patients’ deaths are caused by sepsis and its sequelae; the systemic inflammatory response 
syndrome (SIRS), severe sepsis, septic shock, and multiple organ failure. Despite the 
development of pharmacological agents against the excessive inflammatory process in sepsis 
and sophisticated forms of organ support, the sepsis mortality rates remain high, 30-60% in 
different studies (Angus et al. 2001, Alberti et al. 2002, Karlsson et al. 2007).  With cost-
constraints and a limited number of ICU beds, the challenge is to determine which patients 
would be most likely to benefit from the intensive care (Bone et al. 1993).  
2.1.1 Mortality
Short-term mortality, such as ICU, hospital, and 28-day mortality, as well as long-term 
mortality at 6 or 12 months have been considered objective and appropriate endpoint 
measures (Suter et al. 1994). During a 4-year period from 1998 to 2001, the overall hospital 
mortality rate was 16.8% in Finnish ICUs (Reinikainen et al. 2006). The hospital mortality 
was higher in winter than in other seasons even after adjustment of case mix (17.9% vs. 
16.4%, p=.003) (Reinikainen et al. 2006). Age, gender, and severity of disease have been 
shown to have an effect on mortality of Finnish ICU patients (Niskanen et al. 1996, 
Reinikainen et al. 2005, Reinikainen et al. 2007). 
A large Australian study demonstrated that the risk of death among hospital survivors after an 
intensive care episode is highest in the first 12 months, thereafter stabilizing but still being 
greater than in the general population for at least the next 14 years (Williams et al. 2008). An 
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episode of critical illness in itself shortens life expectancy, age, comorbidity, primary 
diagnosis, severity of physiologic derangement, and organ failure being the strongest 
determinants of long-term survival (Williams et al. 2008). In Finnish ICU patients, the 5-year 
mortality rate was 3.3 times higher than in the age- and gender-adjusted general population 
(Niskanen et al. 1996). However, depending on the diagnostic category, ICU patients’ 
survival paralleled that of the general population at an average of 2 years (Niskanen et al. 
1996). 
2.1.2 Health-related quality of life  
In addition to mortality, health-related quality of life (HRQoL) after intensive care is currently 
recommended as an outcome measure of critical care with a follow-up of at least 6 months 
(Angus and Carlet 2003). Many validated quality of life (QOL) measures are used in intensive 
care. In 1994, the European Society of Intensive Care Medicine listed the desired properties 
for instruments measuring QOL: reliability, criterion and content validity, responsiveness, 
discrimination, relative simplicity, and easy of administration (Suter et al. 1994). The 2002 
Brussels Round Table ‘Surviving Intensive Care’ recommended the EuroQol-5 Instrument 
(Brooks 1996) and the Medical Outcome Study Short Form 36 (Ware and Sherbourne 1992) 
for HRQoL evaluation (Angus and Carlet 2003). 
The 15D is a generic, standardized, self-administered measure of HRQoL (Sintonen 2001). 
The 15D questionnaire includes 15 dimensions: breathing, mental functions, speech 
(communication), vision, mobility, usual activities, vitality, hearing, eating, elimination, 
sleeping, distress, discomfort and symptoms, sexual activity, and depression (Appendix 1). 
Each dimension is divided into 5 levels (1 = best, 5 = worst), and preference weights are used 
to generate the 15D score over all dimensions. The maximum score is 1 (no problems on any 
dimension) and the minimum score is 0 (being dead). The 15D score has been found to 
correlate and perform equal well to the Medical Outcome Study Short Form 36 and the 
EuroQol-5 Instrument (Hawthorne et al. 2001), which are widely used in critical care.  
HRQoL outcomes 
The ideal outcome for ICU survivors is to attain their previous HRQoL or an HRQoL similar 
to a person of the same age, gender, and medical condition. Compared to general population, 
the HRQoL has been found to be lower at baseline before intensive care and from 6 months to 
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14 years after ICU discharge in ICU survivors according to several studies (see the review by 
Dowdy et al. 2005, Karlsson et al. 2009). ICU-related factors that predict post-ICU QOL are 
not yet fully understood. Age, length of stay in ICU, educational background, diagnosis, and 
presence of multiple organ dysfunction syndrome have been shown to have a significant 
impact on measures of QOL (Pettilä et al. 2000, Badia et al. 2001, Wehler et al. 2003, 
Kaarlola et al. 2004).  
Physical and social functioning and general health have been shown to remain significantly 
lower 6 months after ICU treatment than pre-ICU admission values (Hofhuis et al. 2008). In 
medical ICU patients suffering predominantly from cardiovascular and pulmonary disorders, 
physical health was better at 9 months after intensive care than at baseline prior to intensive 
care, although the pre-ICU HRQoL was lower than in the age-matched general population (Graf 
et al. 2003). Trauma patients had the most significant reduction in QOL after 1 year relative to 
the situation before intensive care, but in medical and unscheduled surgery patient populations 
the reduction was milder, whereas the HRQoL of patient undergoing scheduled surgery 
improved (Badia et al. 2001). Emotional aspects seem to be restored slowly. Compared with the 
HRQoL 1 year after intensive care, improvement was seen in psychological domains, but 
deterioration in physical functioning, pain, and general health 6 years after ICU discharge 
(Kaarlola et al. 2003). Linearly, despite recovering to pre-morbid levels after 1 year, physical 
QOL deterioriates again from 2.5 to 5 years after intensive care (Cuthbertson et al. 2010). 
Evidence suggests that the HRQoL of critically ill patients in general is lower than in the age-
matched general population already before ICU admission (Wehler et al. 2003, Hofhuis et al. 
2008, Karlsson et al. 2009). Moreover, poor QOL prior intensive care may even be related to 
hospital and 1-year mortality (Iribarren-Diarasarri et al. 2009). The results of patients treated in 
the ICU attaining their previous QOL are contradictory and may also depend on whether 
patients have chronic diseases. Survivors with unimpaired pre-admission HRQoL suffering 
from acute pathologies demonstrate deterioration in the physical health domain of QOL, 
whereas survivors with impaired pre-admission HRQoL or pre-existing disease have unchanged 
or even improved QOL (Wehler et al. 2003). In conclusion, if an ICU survivor has health 
problems or chronic diseases prior to ICU admission, HRQoL may be more easily attained. 
Patients with previous HRQoL similar to the general population may suffer from acute, 
unexpected illness, such as trauma, with more long-standing effects on future health and 
HRQoL. 
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2.1.3 Scoring systems 
When assessing the performance of a prediction tool, such as a disease severity scoring 
system, some important issues must be considered (Randolph et al. 1998). First, as a measure 
of validity, the patient group must be representative and adequately followed up. All of the 
important prognostic factors should be included or the accuracy of the model will suffer. The 
effect of each variable should be tested individually and also together to determine how these 
factors interact with each other. The outcomes should be clear and objectively defined to 
avoid bias. To confirm the results of a prediction tool, validation in another, independent 
patient population is necessary.  
Performance of the scoring system is evaluated by its accuracy, consisting of calibration and 
discrimination (see the review by Ruttiman 1994). Calibration, statistically measured by 
goodness-of-fit test, evaluates the degree of correspondence between estimated probabilities 
of mortality produced by a model and the actual mortality of the patients (Ruttiman 1994). 
Discrimination tests the ability of a method to classify patients to two outcome groups based 
on the estimates of the probability of hospital death (Ruttiman 1994). Discrimination can be 
expressed as sensitivity (true-positive fraction) and specificity (true-false fraction), and it can 
be graphically presented as a receiver operating characteristic (ROC) curve, which describes 
the ability of the method to distinguish between patients who live and those who die. The area 
under the curve (AUC) expresses the model’s ability to discriminate correctly between 
survivors and nonsurvivors (Hanley and McNeil 1982). The area may range from 0.5 (the 
method is not better than chance) to 1.0 (the method is perfect). Unfortunately, the present 
scoring systems do not achieve sufficient predictive accuracy to make treatment decisions 
(Beck et al. 2003). The confidence interval describes the precision of a measure and its width 
depends on the sample size, variability of a characteristic, and the level of desired confidence, 
normally 95% (Randolph et al. 1998).   
Several disease severity scoring systems have been developed to estimate mortality risk in 
critically ill patients. They are used to improve resource utilization, to classify and compare 
patient populations, in clinical trial enrollment, and to assist in the clinical decision-making 
process (Suter et al. 1994, Vincent et al. 2000). Their ability to explain mortality risk is 
impressive for different patient populations and they form the basis for outcome research in 
intensive care, but at the level of individual patients they lack outcome prediction power 
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(Lemeshow et al. 1995). Most of the scoring systems are physiology-based, but they take into 
account only the acute insult as a whole, not the underlying pre-existing physiological 
reserve. Due to inaccuracy in patient assessment and natural variation in patients’ response to 
stress and therapeutic interventions, outcome prediction is always associated with uncertainty 
(Ruttiman 1994). Uncertainty of prediction models can be reduced by using high cut-off 
levels to avoid false-positive predictions. However, a score represents only one simplified 
piece of information, and even with a 90% risk of death one of ten patients on average will 
survive. The scores have been developed in large, multicenter ICU patient populations and 
have been validated in independent data sets (Le Gall et al. 1993). The scoring systems are 
based on the quantification of case mix and the development of mathematical equations to 
estimate probabilities of outcome for intensive care patients. Outcome is usually measured as 
hospital mortality. Scoring systems describe the association between independent variables 
and the dependent variable (hospital mortality) in the form of a mathematical equation known 
as a multiple logistic regression equation (Ruttiman 1994). The equation for each scoring 
system can be then applied to a diagnostic group (e.g. in Acute Physiology and Chronic 
Health Evaluation II, APACHE II) or to a group of intensive care patients to estimate the 
expected hospital death rate (e.g. in Simplfied Acute Physiology Score II, SAPS II). 
Diagnosis classification can be difficult in many critically ill patients due to their multiple 
medical problems. The selection of a less significant diagnosis may lead to an inaccurate 
calculation of risk of death. 

Disease severity scoring systems
The APACHE system was developed in the United States between 1979 and 1982 based on 
5818 ICU admissions in 13 large tertiary care centers. Derived from the original APACHE, 
the APACHE II scoring system, introduced in 1985, reduced the number of physiological 
variables included (Knaus et al. 1985). The APACHE II score ranges from 0 to 71 and 
consists of 3 components: 1) acute physiology score comprising 12 physiological variables, 
the most deranged value in the first 24 hours in the ICU included, 2) age, and 3) history of 
severe chronic health conditions. Hospital mortality prediction is calculated for different 
diagnostic categories from the APACHE II score plus coefficients for post-emergency 
surgery. The APACHE II model was refined and re-evaluated in 1991 (APACHE III) (Knaus 
et al. 1991). 
The SAPS was introduced in 1984 (Le Gall et al. 1984). The SAPS II, including over 13 000 
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North American and European patients randomly divided into developmental and validation 
samples, provides an estimate of hospital mortality risk for each score value (Le Gall et al. 
1993). It includes 12 physiological variables, type of admission, and three variables related to 
underlying disease. It has good discriminative power (AUC 0.86-0.88), but the calibration is 
inadequate. SAPS II also lacks sufficient prediction power when applied to different countries 
(Harrison et al. 2006). The advantages of SAPS II are, however, its simplicity and 
availability.  
The APACHE II and SAPS II variables are presented in Table 1. 
Table 1. Comparison of APACHE II and SAPS II variables. 
APACHE II variables SAPS II variables 
Heart rate  (min)   Heart rate (min) 
Mean arterial pressure (mmHg)   Systolic arterial pressure (mmHg) 
Temperature (°C)   Temperature (°C)  
Respiratory rate (min)   
Oxygenation:  
a. FiO2  0.5: record A-aDO2 
b. FiO2 < 0.5: record only PaO2 (mmHg)  
Only if mechanically ventilated or with continuous 
positive airway pressure: 
PaO2 (mmHg or kPA)/FiO2   
Arterial pH  
(serum HCO3 if no arterial blood gases) 
Serum HCO3  
Hematocrit (%)    
White blood cell count (E9/l)  White blood cell count (E9/l) 
Creatinine (mg/100ml) 
-double points for acute renal failure  
Urine output (l/24h) 
Serum urea (mmol/l) or serum urea nitrogen (mg/dl) 
Serum bilirubin (µmol/l)  
Serum sodium (mmol/L)    Serum sodium (mmol/L)  
Serum potassium (mmol/L)  Serum potassium (mmol/L) 
Glasgow Coma Scale Glasgow Coma Scale 
Age (years) Age (years) 
Chronic Health Points: Liver insufficiency (cirrhosis, 
portal hypertension, hepatic failure), Cardiovascular 
(NYHA IV) , Respiratory (e.g. Chronic obstructive 
pulmonary disease), Renal (chronic dialysis), 
Immunosuppression (e.g. chemotherapy, steroid 
treatment, leukemia, acquired immune deficiency 
syndrome) 
Chronic diseases: Metastatic cancer, Hematologic 
malignancy, Acquired immune deficiency syndrome 
Type of admission: 
Medical, scheduled, or unscheduled surgery 
The APACHE system is the most widely used globally, but SAPS II has performed better in 
Europe (Moreno and Morais 1997). A multicenter study of 16 646 ICU patients in south 
England found a good discriminative power for APACHE II, APACHE III, and SAPS II 
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(AUC 0.835-0.867), but imperfect calibration for all three models (Beck et al. 2003). In an 
Italian single-center study, the SAPS II score overestimated and the APACHE II 
underestimated the mortality rate for high-risk ICU patients (Capuzzo et al. 2000). The lack of 
fit of the SAPS II and the APACHE II scores can be partly explained by differences in case 
mix between the patient population from which the model was derived and to which the 
model was applied (Harrison et al. 2006). Therefore, updated models have been developed. 
The SAPS 3, developed in 2002, takes into account a higher number of variables than SAPS 
II and also different geographical areas as well as organizational, structural, and resource use 
characteristics of the ICU, defined as “ICU variables” (Metnitz et al. 2005, Moreno et al. 
2005). In addition, the physiological data are collected from one hour before to one hour after 
ICU admission. 
Organ failure scoring 
Multiple organ dysfunction (MOD) is a major cause of mortality in critically ill ICU patients 
(Mayr et al. 2006). The number and magnitude of failing organ systems correlate with the 
mortality rate (Vincent et al. 1998, Moreno et al. 1999). Four organ dysfunction scores have 
been introduced: Sequential Organ Failure Assessment (SOFA), Multiple Organ Dysfunction, 
Logistic Organ Dysfunction, and Brussels scores. The European Society of Intensive Care 
Medicine organized a consensus meeting in 1994 to create the sepsis-related organ failure 
assessment score to describe and measure the degree of organ dysfunction over time for 
individuals and groups of patients, not to predict outcome (Vincent et al. 1996). The score 
was later renamed Sequential Organ Failure Assessment because it is not restricted to sepsis. 
The investigators highlighted that organ dysfunction should be considered a continuum rather 
than an event and a dynamic process that can vary with time. The evaluation should be based 
on a limited number of simple but objective routinely measured variables (Vincent et al. 
1998). The SOFA score consists of six organ systems (respiration, coagulation, liver, 
cardiovascular, central nervous system, and renal), each yielding a score from 0 (normal) to 4 
(most abnormal) (Table 2). Organ failure is defined by a SOFA score of 3 for any organ 
(Vincent et al. 1998). The use of SOFA score in assessing the incidence and severity of organ 
dysfunction was evaluated in a prospective multicenter study of 1449 critically ill ICU 
patients, and high SOFA scores were associated with increased mortality (Vincent et al. 
1998). The maximum and delta SOFA score (total maximum SOFA score minus admission 
total SOFA) can also be used to quantify present and developing organ dysfunction in ICU 
patients (Moreno et al. 1999). Although not developed for predicting mortality, the SOFA 
 20 
score –including fewer physiological parameters– seems to perform almost equally well as the 
APACHE II/III scores and SAPS II (see the review by Minne et al. 2008). Combining the 
SOFA score with an admission-based severity score results in superior prognostic 
performance compared to a single model (Minne et al. 2008).  
Table 2. The SOFA score. 
Organ dysfunction 0 points 1 points 2 points 3 points 4 points 
1. Respiratory 
Pa02/FiO2 (mmHg) 
*with mechanical 
ventilation 
400 <400 <300 <200* <100* 
2. Coagulation 
Platelet count x 109/l 150 <150 <100 <50 <20 
3. Liver   
Bilirubin (µmol/l) <20 20-32 33-101 102-204 >204 
4. Cardiovascular          
*µg/kg/min 
MAP>70 
mmHg 
MAP <70 
mmHg 
DA 5* 
or 
dobutamine 
DA >5* or 
epi  0.1* or 
NA  0.1* 
DA > 15* or 
epi > 0.1* or 
NA > 0.1* 
5. Neurologic 
Glasgow Coma Scale 15 13-14 10-12 6-9 <6 
6. Renal    
Creatinine (µmol/l)   
*Urine output  
<110 110-170 171-299 300-440 
*<500ml/day 
>440 
*<200ml/day 
DA, dopamine; epi, epinephrine; MAP, mean arterial pressure; NA, norepinephrine 
2.1.4 Emergency department delay and procedures 
The severity scoring systems utilize data collected within the first 24 hours in the ICU, 
although events before admission are prognostically important (Rapoport et al. 1990). In 
patients with septic shock, for instance, early rapid goal-directed fluid resuscitation has been 
shown to decrease hospital mortality (Rivers et al. 2001). Early recognition of critical illness 
is crucial, and early physiological warning signs have been investigated to detect deteriorating 
patients (Goldhill et al. 1999). 
Critically ill patients remain in the emergency department (ED) for significant periods of 
time. Delayed admission to ICU has been associated with higher mortality among critically ill 
 21 
patients. In a large multicenter study in which ED delay was divided into nondelayed and 
delayed categories based on the time (<6 hours and >6 hours) the patient waited for transfer to 
ICU after the decision of ICU admission was made, delayed ICU admission proved to be an 
independent risk factor for hospital mortality and was associated with longer ICU stay and 
mortality (Chalfin et al. 2007).  
However, contradictory and inadequate data exist on how the ED length of stay itself and 
procedures performed in the ED contribute to outcome of critically ill patients subsequently 
admitted to ICU. Only a few studies have characterized ED length of stay and the procedures 
performed in the ED on critically ill patients. The averige length of ED stay of critically ill 
patients has varied from 2.4 to 6.1 hours in different studies (Fromm et al. 1993, Varon et al. 
1994, Svenson et al. 1997, Nelson et al. 1998, Nguyen et al. 2000, Parkhe et al. 2002, Jones et 
al. 2005, Carr et al. 2007). A few studies have found that length of ED stay has not differed 
between survivors and nonsurvivors (Varon et al. 1994, Svenson et al. 1997, Nguyen et al. 
2000). One study showed that mortality rates, ICU length of stay, or APACHE II scores were 
not higher in patients staying in the ED longer than 24 hours (Tilluckdarry et al. 2005). By 
contrast, a study investigating the prognostic accuracy of three disease severity scoring 
systems in a critically ill ED patient cohort found that in-hospital nonsurvivors had 
significantly shorter ED stay than the in-hospital survivors (mean 2.6 vs. 4.2 hours, p<.0001) 
(Jones et al. 2005), and this outcome was repeated by Richardson et al. (2009) in patients with 
trauma. Duke and coworkers (2004) found that length of ED stay was an independent risk 
factor for hospital mortality (relative risk 1.06, p=.015), but they included only patients 
requiring mechanical ventilation and/or renal replacement therapy at ICU admission. Studies 
evaluating the impact of ED care on outcome in critically ill patients are summarized in Table 
3. 
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The results of length of ED stay may vary because of different patient inclusion criteria: some 
studies have included only ED patients admitted subsequently to the ICU and some have 
included ED patients requiring critical care in ED. The definition of critical care provided in 
ED may have solely comprised telemetry (Nelson et al. 1998). In addition, only a few studies 
have been designed to assess the effect of length of ED stay on patient outcome. 
In ED, the proportion of critically ill patients receiving central venous catheter has varied 
from 4% to 89%, and that of mechanically ventilated patients from 10% to 31% (Varon et al. 
1994, Svenson et al. 1997, Nelson et al. 1998, Nguyen et al. 2000). Nguyen et al. (2000) 
reported that 89% received intra-arterial blood pressure monitoring and 69% vasoactive or 
inotropic medication. Their study, however, included patients who were hypotensive or 
lactatemic and who presented with at least two SIRS criteria.  
Patients admitted to the ICU within 24 hours after hospital admission have been found to have 
lower predicted and actual mortality rates and to consume less resources (Rapoport et al. 
1990). The longer ICU patients are in hospital before ICU admission, the higher their 
mortality (Goldhill et al. 2004). Patients admitted to the ICU from hospital wards tend to be 
older and to more often have coexisting disease than patients admitted to the ICU directly 
from ED (Parkhe et al. 2002, Simpson et al. 2005).  Alterations in the patient’s condition and 
abnormal physiological values are found in ward patients before ICU admission (Goldhill et 
al. 1999). Heart rate, respiratory rate, and oxygen supplementation are the most important 
physiological determinants in ward patients requiring ICU treatment within 24 hours 
(Goldhill et al. 1999). The observed hospital mortality rate is significantly higher than that 
predicted by the SAPS II and APACHE II models in those critically ill patients admitted to 
ICU from the ward (Capuzzo et al. 2000).  
No scoring system has been validated for hospital mortality risk stratification in ED patients, 
but some studies have investigated the performance of severity scoring systems regarding 
mortality prediction in ED patients (Table 3). Their results have been variable, perhaps 
because the scoring systems used in intensive care are not validated for use in ED or for 
repeated measurements. In addition, patient characteristics and study inclusion criteria have 
differed.  
 24 
2.2 Biological perspectives and markers of critical illness 
  
2.2.1 Tissue injury and repair 
Acute severe illness activates multiple cascading pathways. Regardless of the insult, the 
biological response to injury, inflammation, infection, or shock is complex and usually 
involves activation of the innate immune system and common molecular patterns leading to 
burst of dozens of mediators. The response can generalize to SIRS and MOD if it escapes 
local control. Host response of septic patients is characterized by coagulopathy, inflammation, 
and endothelial injury, identified by increased concentrations of the following biomarkers 
indicating these phenomena: d-dimer, interleukin-6 (IL-6), soluble thrombomodulin, and 
prolonged prothrombin time. These responses are more impaired in patients with severe 
sepsis who die (Kinasewitz et al. 2004). Activation of strong pro-inflammatory response, such 
as in sepsis, is followed by increased anti-inflammatory cytokine levels and immune 
paralysis, tissue hypoxia, activation of coagulation, and dysregulated apoptosis (Gogos et al. 
2000, Hotchkiss et al. 2005, García-Segarra et al. 2007). Pathophysiological pathways 
activated in critical illness are charcterized in Figure 1. 
Infection
Inflammation
Trauma
LPS
MBL, TLR, CD14
Adhesion
molecules
Proinflammatory
cytokines
TNF-
IL-1
IL-6
…
Anti-inflammatory
cytokines
IL-10
IL-1ra
sTNFR
…
Tissue injuryHO-1
cell-free
plasma
DNA
Organ
dysfunction
Cytoprotection
NF-B
++
+
+
+
Figure 1. Pathophysiological pathways involved in critical illness. 
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Injury can be defined as interruption of molecular, cellular, or organ function resulting from 
such stimuli as hypoxia, ischemia, trauma, toxins, infection, or inflammation. Repair response 
that restores structure and function follows, including coagulation, leukocyte activation, 
apoptosis, proliferation, regeneration, remodeling, and revascularization. 
The magnitude of the body’s systemic inflammatory response, rather than the presence or 
absence of infection, is postulated to enhance the development of organ failure and be a more 
important determinant of patient survival. To avoid an excessive response, early recognition 
and management are essential. Increasing knowledge of these complex parallel 
pathophysiological cascades has enabled searches for novel biological markers to provide 
new information on the mechanisms of disease in critical illness and to serve as candidate 
prognostic markers in outcome prediction. Many studies have aimed at uncovering new 
biological markers of critical illness in order to identify those patients at highest risk and to 
predict outcome. Despite efforts, no reliable biological markers of illness severity or outcome 
have yet been discovered. The mechanisms underlying critical illness are very complex and 
heterogeneous, so finding a single predictive marker may remain elusive. 
2.2.2 Inflammatory response 
Nuclear factor kappa-B  
The cell surface receptors toll-like receptors (TLRs) and CD14 are crucial for bacterial 
recognition and induction of innate immune responses to infection, leading to activation of 
nuclear factor kappa-B (NF-B) and transcription of inflammatory genes (Medzhitov et al. 
1997).  
NF-B is a transcription factor regulating gene expression involved in immune and 
inflammatory responses. The mammalian NF-B family consists of five subunits: p50, p52, 
p65, reL, and reLB, which can homodimerize and heterodimerize in various combinations. 
These different combinations have varying activating abilities (Adib-Conquy et al. 2000). 
Inhibited NF-B exists normally in cellular cytoplasm and is activated by various stimuli, 
such as pro-inflammatory cytokines, leading to its phosphorylation by protein kinases and 
entry into the nucleus. NF-B activation increases transcription of chemokines, pro-
inflammatory cytokines, adhesion molecules, and antiapoptotic proteins (Chen et al. 2003).  
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NF-B activity was increased in mononuclear cells of septic and critically ill patients with 
SIRS who died in hospital compared with hospital survivors (Arnalich et al. 2000, Paterson et 
al. 2000). Despite septic nonsurvivors expressing more NF-B than survivors, the 
mononuclear cells of septic patients, particularly of nonsurvivors, seemed to have a decreased 
response to stimuli such as lipopolysaccharide (LPS) (Adib-Conquy et al. 2000). This 
phenomenon, referred to as endotoxin tolerance, appears to be mediated by the NF-B subunit 
p50 (Adib-Conquy et al. 2000). In a mouse model of gut ischemia-reperfusion injury, NF-B 
activation led to acute systemic inflammatory response and lung inflammation via tumor 
necrosis factor-alpha (TNF-), but provided protection against enterocyte apoptotic injury 
(Chen et al. 2003). Strong systemic inflammation response can thus be considered one of the 
leading mechanisms for MOD, and NF-B may serve as a potential therapeutic target for 
reducing overwhelming pro-inflammatory response and organ damage in critical illness. 
However, complete blocking may also be detrimental considering the major role of NF-B in 
host defense.  
Cytokines 
Pro-inflammatory cytokines are upregulated in the early stages of inflammation. TNF- and 
IL-1 are secreted rapidly in minutes, whereas IL-6, IL-8, and high mobility group box-1 
protein (HMGB-1) contribute later (Sundén-Cullberg et al. 2005) with anti-inflammatory 
cytokines such as IL-1 receptor antagonist (IL-1ra) and IL-10.  
Increased cytokine concentrations can be measured in the early phase of critical illness, and 
levels can stay high in circulation over several days (Kinasewitz et al. 2004, Kellum et al. 
2007, Rivers et al. 2007). However, the ability of monocytes to produce inflammatory 
cytokines seems to be downregulated in severe sepsis and septic shock (Brunialti et al. 2006). 
Septic patients with the most severe global tissue hypoxia had higher levels of inflammatory 
cytokines IL-1ra, TNF-, IL-8, and caspase-3, a marker of apoptosis, at 12-36 hours from 
hospitalization (Rivers et al. 2007), but the monocyte production of TNF-, IL-6, and IL-10 
under LPS stimulation in patients with severe sepsis or septic shock was impaired compared 
with healthy controls or patients with simple sepsis diagnosis only (Brunialti et al. 2006). The 
severity of disease and stage of infection affects the cytokine profile as well (Oberholzer et al. 
2005, Kellum et al. 2007). Interestingly, early temporal decrease in inflammatory cytokine 
levels can be seen by optimizing hemodynamics (Rivers et al. 2007), highlighting the benefit 
of early treatment. 
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Several recent studies have analyzed multiple cytokines simultaneously, showing significant, 
but inconsistent, correlations between cytokine concentrations, such as IL-6, IL-8, and 
monocyte chemoattractant protein-1, and mortality in patients with severe sepsis (Oberholzer 
et al. 2005, Bozza et al. 2007). However, clinical applicability is lacking. In 39 patients with 
sepsis or severe sepsis, IL-10 had the best discriminative power for mortality, with an AUC of 
0.90, although there were only five nonsurvivors (Heper et al. 2006). By measuring 17 
cytokines simultaneously in 60 patients with severe sepsis, only monocyte chemoattractant 
protein-1 was an independent predictor for 28-day mortality, with an odds ratio of 1.4, but the 
AUC was only moderate (0.715) (Bozza et al. 2007). By contrast, baseline IL-6 concentration 
was an independent predictor for 28-day mortality (p=.019) in a study population of 124 
patients with severe sepsis (Oberholzer et al. 2005). 
The high mobility group box-1 protein, originally identified as a nuclear DNA-binding 
protein, can also be secreted into extracellular milieu by endotoxin-stimulated macrophages or 
under cellular stress, particurlarly in necrosis, acting as a “late” pro-inflammatory cytokine 
(Scaffidi et al. 2002). Its biological activities and role in critical illness is not fully understood. 
In patients with sepsis, severe sepsis, or septic shock, the association of HMGB-1 levels and 
28-day survival was dependent on the laboratory methods, even though the levels remained 
very high for several days (Sundén-Cullberg et al. 2005). In patients with pneumonia, 
HMGB-1 concentrations were significantly higher in those who developed severe sepsis and 
died than in survivors in multivariate analysis (Angus et al. 2007). However, in a larger study 
of 247 patients with severe sepsis or septic shock, HMBG-1 had no predictive power for 
survival when measured at baseline or 72 hours later (Karlsson et al. 2008). 
Discrepancy exists about whether highly upregulated anti-inflammatory cytokine activation is 
more disadvantageous than strong pro-inflammatory response. Recent studies have searched 
for an optimal cytokine profile. The highest risk of death among patients with community-
acquired pneumonia and sepsis was in the combination of high levels of the pro-inflammatory 
IL-6 and the anti-inflammatory IL-10 (hazard ratio 20.5, p<.001) (Kellum et al. 2007), 
whereas in another study with 65 patients with severe sepsis the sustained anti-inflammatory 
profile, defined as persisting high IL-10 levels, was associated with adverse outcome (Gogos 
et al. 2000). IL-10 has also been found to be an independent predictor of hospital mortality in 
sepsis, although the AUC for fatal outcome was only moderate (0.71) (Hynninen et al. 2003). 
The inflammatory response itself as well as its regulation and time course may be too 
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complex for predicting the outcome of critically ill patients by cytokine measurements.    
Inadequate sample sizes and study designs are shortcomings and limitations in studies 
investigating the predictive value of inflammatory markers in critically ill patients. Although 
a marker may have an independent effect on mortality, the discriminative power may be 
deficient or a complete ROC analysis lacking. In addition, the magnitude of inflammatory 
response may be a matter of timing and the dynamic continuum at different stages of disease 
severity. 
2.2.3 Apoptosis 
Apoptosis has a major role in the pathophysiological process in sepsis (Hotchkiss et al. 2005). 
Apoptotic lymphocytes and gastrointestinal epithelial cells have been found in the spleen and 
colon of autopsy samples of septic patients (Hotchkiss et al. 1999). Depletion of B-
lymphocytes and CD4-positive T-cells by caspase-9-mediated apoptosis, and dendritic cells, 
but not macrophages, is seen more often in the spleens of patients with sepsis compared with 
critically ill nonseptic patients or patients with trauma (Hotchkiss et al. 2001, Hotchkiss et al. 
2002). Increased lymphocyte apoptosis is also found in the circulation of patients with sepsis 
(Le Tulzo et al. 2002, Hotchkiss et al. 2005), and this depletion of adaptive and innate 
immunity cells leads to immunoparalysis in sepsis. Apoptosis can be initiated by two 
divergent pathways: the death receptor-initiated pathway leading to caspase-8 activation, 
mediated by for example by Fas, and the mitochondrial pathway leading to caspase-9 
activation. Both of these mechanisms are activated in septic patients (Hotchkiss et al. 2005) 
and lead to activation of caspase-3 in the final common pathway of the apoptotic cell death 
programme. Increased levels of Fas/Apo-1, a humoral factor involved in the innate immunity 
response and cell death signal transduction, and other apoptosis-associated molecules have 
been detected in serum and peripheral blood mononuclear cells of ICU patients with SIRS, 
sepsis, and MOD (Papathanassoglou et al. 2001, Torre et al. 2003, Freitas et al. 2004). Both 
apoptotic and necrotic cell death occur in severe sepsis (Hofer et al. 2009). 
Cell-free plasma DNA 
An increased concentration of cell-free plasma DNA, a possible marker of apoptosis, has been 
found in various clinical conditions, including trauma, myocardial infarction, stroke, burn, 
cancer, head injury, and acute abdominal pain (Lo et al. 2000, Jahr et al. 2001, Chang et al. 
 29 
2003, Rainer et al. 2003, Chiu et al. 2006, Yurgel et al. 2007, Rainer et al. 2008). The 
predictive value of plasma DNA regarding mortality and morbidity has been evaluated in 
patients with stroke, chest pain, acute abdominal pain, and different trauma or injury (Lo et al. 
2000, Rainer et al. 2003, Chiu et al. 2006, Lam et al. 2006, Rainer et al. 2006, Yurgel et al. 
2007, Rainer et al. 2008), but several of these studies suffer from shortcomings in adequate 
statistical methods and patient sample sizes (Table 4). 
Cell-free DNA has been detected in the circulation of septic patients (Martins et al. 2000). In 
addition, patients with severe sepsis and septic shock have been shown to possess increased 
plasma levels of nucleosomes, in which fragmented DNA is packed during apoptosis 
(Zeerleder et al. 2003). However, only a few studies have investigated the cell-free plasma 
DNA concentration in critically ill ICU patients (Martins et al. 2000, Wijeratne et al. 2004, 
Pachl et al. 2005, Rhodes et al. 2006) (Table 5). Although the results appear promising, 
inadequate patient sample sizes, no confidence intervals for AUCs, and the preliminary nature 
of these studies limit their value.  
Evidence suggests that DNA is released into the circulation by apoptosis (Jahr et al. 2001, 
Jiang and Pisetsky 2005, Atamaniuk et al. 2006, Atamaniuk et al. 2008), although the exact 
mechanism remains obscure. Other possible additive mechanisms, such as necrotic cell death 
and active secretion, may also exist (Stroun et al. 2001, Jahr et al. 2001). Cell-free plasma 
DNA derived from patients undergoing hemodialysis and from 6-hour ultra-marathon runners 
showed typical apoptotic layers in gel electrophoresis (Atamaniuk et al. 2006, Atamaniuk et 
al. 2008). After the 6-hour run, plasma DNA concentration increased and the mononuclear 
mRNA expression shifted to pro-apoptotic state compared with the pre-run situation 
(Atamaniuk et al. 2008). Information from sex-mismatched transplantation patients suggested 
that most of the plasma DNA is of hematopoietic origin in healthy transplant recipients (Lui 
et al. 2002, Lui et al. 2003).  
The exact characteristics of plasma DNA kinetics and clearance have not yet been specified. 
Clearance of fetal DNA in maternal plasma after delivery is rapid, with a mean half-life of 
16.3 minutes (Lo et al. 1998). After hemodialysis, increased cell-free plasma DNA 
concentrations are normalized back to pre-dialysis concentrations 30 minutes after finishing 
the session (García Moreira et al. 2006). Atamaniuk and co-workers (2008) found that plasma 
DNA concentration increased after a 6-hour ultra-marathon and returned to normal levels in 
 30 
24 hours, whereas in ICU patients with severe trauma plasma DNA increased early after 
injury and concentrations remained high for days, especially if organ failure developed (Lam 
et al. 2003). The circulating plasma DNA has been proposed to be eliminated in the liver and 
kidneys. Nucleotides are predominantly metabolized in the liver in mice (Gauthier et al. 
1996). In humans, approximately 0.5–2% of the cell-free plasma DNA crosses the kidney 
barrier and is excreted in urine (Botezatu et al. 2000). The pre-dialysis plasma DNA 
concentrations of patients with chronic renal insufficiency did not differ significantly from the 
values of healthy controls (García Moreira et al. 2006). However, no clinical study has 
evaluated the impact of liver and renal failure on cell-free plasma DNA concentrations. 
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Table 5. Cell-free plasma DNA studies in critically ill ICU patients. 
Study Subjects pDNA valuea Results   Comments 
__________________________________________________________________________________________ 
Martins 18 patients  pDNA is found in septic 11 sepsis patients 
2000 11 controls  patients 
Wijeratne  94 patients 5493 GE/ml pDNA higher in non- ICU mortality= 
2004 22 controls 1970 GE/ml survivors univariately hospital mortality (34%) 
   (p<.001)   
AUC for mortality 0.889  
Pachl  94 patients  In medical patients Own method 
2005 86 controls    apoptotic pDNA  
higher in nonsurvivors  
   (n=15), p<.05, AUC 0.71 
  
Rhodes 52 patients 80 ng/ml pDNA independent predictor 13 ICU nonsurvivors   
2006 10 controls 17 ng/ml for ICU mortality (OR 1.002) 
   AUC for hospital mortality 0.79 
__________________________________________________________________________________________ 
amedian; AUC, area under curve; GE, genome equivalent (1 GE=0.0066 ng); ICU, intensive care unit; OR, odds 
ratio; pDNA, plasma DNA 
2.2.4 Stress response 
In addition to NF-B, another extremely conserved cellular stress response system is the heat 
shock protein (HSP) family and their regulator, heat shock factors. HSPs have many 
important functions, such as the capacity to act as protein chaperones, protecting vital protein 
structures and functions, providing cytoprotection against cellular stress, and regulating 
apoptosis (Mosser et al. 2000). Two cellular response mechanisms, the heat shock response 
and NF-B activation, interact with each other. Heat shock factor-1 inhibits NF-B activity by 
preventing NF-B phosphorylation, cytoplasmic release, and DNA binding, presumably by 
competing for the same or a very close binding site on the genome (Song et al. 2008). This 
may partly explain the inflammation-induced immune suppression universally seen in 
critically ill patients.  
Upregulating the heat stress response after initiation of endotoxemia protected rats against this 
 33 
lethal stimulus (Chu et al. 1997). Induced HSP70 expression in lungs attenuated activation of 
the key pro-inflammatory transcription factor NF-B and protected against experimental 
sepsis-induced acute respiratory distress syndrome (ARDS) in rats (Weiss et al. 2007). In 
septic patients, HSP70 and other HSP levels are elevated and apoptosis decreased in blood 
mononuclear leukocytes measured by flow cytometry (Hashiguchi et al. 2001). In children 
with septic shock, HSP70 levels are greater than in nonseptic ICU patients and controls 
(Wheeler et al. 2005). Polymorphisms in the genes encoding HSP70 have not been associated 
with outcome in critically ill surgical patients or in patients with community-acquired 
pneumonia (Schroeder et al. 1999, Waterer et al. 2003, Bowers et al. 2006). 
Heme oxygenase-1 
Heme oxygenase (HO) was originally identified in 1969 by Tenhunen and colleagues 
(Tenhunen et al. 1969). Three isoforms, HO-1, HO-2 and HO-3, have been found to date. HO 
catalyzes the oxidative degradation of heme to carbon monoxide (CO), free iron, and 
biliverdin. Biliverdin is subsequently reduced to bilirubin by biliverdin reductase (Stocker et 
al. 1987), and iron is sequestered by ferritin (Figure 2). HO-1 is highly inducible and is 
upregulated by various stress stimuli and phenomena related to critical illness such as 
hypoxia, heat shock, oxidative stress, cytokines, endotoxin, ischemia-reperfusion, and heme 
(Eyssen-Hernandez et al. 1996, Carraway et al. 1998, Terry et al. 1998, Schmidt et al. 2007). 
HO-1 is expressed in a variety of cells and tissues, e.g. in macrophages in the bone marrow, in 
circulating monocytes, in liver, in spleen, and in kidney (Morimoto et al. 2001, Yachie et al. 
2003, Schaer et al. 2006, Schmidt et al. 2007). In the cell, HO-1 is localized in the 
endoplasmic reticulum, but it may also compartmentalize in other subcellular organelles and 
migrate to the nucleus (Lin et al. 2007). 
Increased expression of HO-1 mRNA has been found in the blood cells of premature infants 
with respiratory distress syndrome and pediatric cancer patients with SIRS (Schmidt et al. 
2004, Farkas et al. 2008), and increased expression of HO-1 protein in the lung tissue of 
patients with ARDS (Mumby et al. 2004), in monocytes of SIRS patients (Mohri et al. 2006), 
and in macrophages within the bone marrow of patients dying from severe sepsis or septic 
shock (Schaer et al. 2006).  
 34 
Heme Biliverdin
Bilirubin
Carbon monoxide
Fe++
Heme Oxygenase
Biliverdin
Reductase
Ferritin
Figure 2. HO and its reaction products. 
Only a few studies have investigated the plasma concentrations of HO-1. Elderly patients with 
Alzheimer’s disease have been found to have significantly lower plasma HO-1 levels than 
elderly controls (Schipper et al. 2000), and patients with silicosis had significantly higher serum 
HO-1 concentrations than patients with chronic obstructive pulmonary disease and controls 
(Sato et al. 2006). Ten patients with adult-onset Still’s disease had much higher HO-1 serum 
levels than patients with rheumatic, liver, or hematological disease (Kirino et al. 2005). The 
serum levels of HO-1 were also higher in pregnant women with pre-eclampsia than in healthy 
pregnant controls (Eide et al. 2008).  
HO-1 is a cytoprotective enzyme with an important role in cellular defense; antioxidative, anti-
inflammatory, antiapoptotic, and antiproliferative effects are mediated by HO reaction products 
(Stocker et al. 1987, Brouard et al. 2000, Otterbein et al. 2003, Sarady-Andrews et al. 2005). In 
murine model of aortic transplantation, the attenuation of proliferation and inflammation by IL-
10 was mediated through HO-1 (Chen et al. 2005). HO-1-deficient mice have exhibited a 
dysregulated and highly enhanced inflammatory response with widespread apoptosis of 
immune cells in response to LPS (Tracz et al. 2007). The genetic deficiency of HO-1 is also 
extremely disadvantageous, leading to hepatomegaly, lymph node swelling, and anemia 
(Yachie et al. 1999). HO-1 induction protected against ischemia/reperfusion injury and 
improved microcirculation in the rat liver (Schmidt et al. 2007). HO-1 has also shown protective 
effects in lung injury models and on renal tubuli in oxidative injuries (Morimoto et al. 2001).  
 35 
The human HO-1 gene, located in chromosome 22, has several polymorphisms. Evidence 
suggests that at least two HO-1 polymorphisms are functional. A short GT dinucleotide repeat 
length allele and one of the single-nucleotide polymorphisms (SNPs), a -413A allele, have 
been shown to enhance transcriptional activity of HO-1 gene relative to the long GT and  
-413T alleles (Chen et al. 2002, Hirai et al. 2003, Ono et al. 2003, Ono et al. 2004, Brydun et 
al. 2007). HO-1 polymorphisms have been associated with various clinical conditions, such as 
outcome of organ transplantation and susceptibility to emphysema, coronary artery disease, 
restenosis after peripheral angioplasty and coronary stenting, and ARDS (Yamada et al. 2000, 
Kaneda et al. 2002, Chen et al. 2004, Ono et al. 2004, Schillinger et al. 2004, Tiroch et al. 
2007, Buis et al. 2008, Sheu 2009).  
Metabolites of heme 
There is vast evidence from experimental and animal studies of anti-inflammatory and 
antioxidative actions of bilirubin and CO, products of heme catabolism by HO-1, although the 
exact molecular mechanisms are unknown. Bilirubin and carboxyhemoglobin could serve as 
surrogate markers of HO activity in clinical setting.  
CO shares some functional similarities with another diatomic gaseous monoxide, nitric oxide, 
which has a well-described role as a signaling molecule. CO has cytoprotective, 
antiproliferative, and anti-inflammatory effects mediated at least partly by the mitogen-
activated protein kinase pathway (Otterbein et al. 2000, Otterbein et al. 2003).  HO-1-derived 
CO increased inflammatory cells’ bacterial phagocytosis in a mouse model of abdominal 
sepsis (Chung et al. 2008), and CO inhalation showed protection against organ injury in a 
murine model of hemorrhagic shock by decreasing hypoxia and inflammation (Zuckerbraun 
et al. 2005). The exact mechanisms behind these protective and homeostatic effects of CO 
remain elusive. Increased exhaled CO concentrations have been reported in critically ill 
patients relative to healthy volunteers, and the concentrations also correlated significantly 
with arterial carboxyhemoglobin and serum biliverdin concentrations, indicating enhanced 
heme metabolism in critically ill patients (Morimatsu et al. 2006). Both very low and very 
high levels of arterial carboxyhemoglobin have been associated with increased mortality in 
patients requiring cardiothoracic intensive care (Melley et al. 2007). Hence, even though 
potentially protective, excessive induction of HO-1 may be deleterious, and there may be an 
optimal range for HO-1 induction. Whole-blood CO levels had a good correlation with 
monocyte HO-1 expression in 36 ICU patients with severe sepsis or septic shock and in 21 
 36 
nonseptic ICU controls (R=0.4) (Takaki et al. 2010). By contrast, bilirubin concentrations did 
not correlate with HO-1 expression. 
Biliverdin, a byproduct of heme degradation by HO-1, is reduced to bilirubin by biliverdin 
reductase. Bilirubin is metabolized in the liver to mono- and diglucuronides. The conjugated 
bilirubin passes to bile and feces, where it is degraded to urobilinogens by intestinal 
microorganisms. Bilirubin was considered a cytotoxic waste product until its antioxidant 
potential was recognized twenty years ago (Stocker et al. 1987). Bilirubin has been shown to 
have antioxidative, anti-inflammatory, and antiproliferative properties (Stocker et al. 1987, 
Sarady-Andrews et al. 2005, Öllinger et al. 2005, Overhaus et al. 2006). In animal models of 
endotoxemia and sepsis, the administration of bilirubin or biliverdin has improved the 
symptoms and survival and attenuated leukocyte adhesion, tissue inflammation, and injury 
(Sarady-Andrews et al. 2005, Overhaus et al. 2006, Kadl et al. 2007). The mechanisms by 
which bilirubin and biliverdin may mediate their anti-inflammatory actions include decreasing 
NF-B activation, modulation inflammatory response by augmenting IL-10 and reducing IL-6 
production, and inducing HO-1 expression (Sarady-Andrews et al. 2005, Overhaus et al. 
2006). In critical care medicine, bilirubin may not be as good a surrogate marker for HO-1 
expression as CO because bilirubin levels are also affected by its synthesis and clearance. 
However, a balance in production and elimination is important since hyperbilirubinemia may 
lead to fatal kernicterus in neonates, and marked hyperbilirubinemia was associated with 
homozygous short HO-1 GT repeat polymorphism in a boy with autoimmune hemolytic 
anemia (Immenschuh et al. 2007). 
2.2.5 Other prognostic markers 
  
The results of large studies investigating other prognostic markers in ICU patients are listed in 
Table 6. The size of the patient populations varies markedly and, therefore, previous smaller 
single-center studies with less than 100 patients for investigations of procalcitonin (PCT) and 
antithrombin III (Pettil et al. 2002), PCT (Dahaba et al. 2006), PCT, IL-10 and C-reactive 
protein (Heper et al. 2006), lactate, PCT, pro-brain natriuretic peptide (NT-proBNP), and 
cytokines (Phua et al. 2008) have been excluded. Based on the results of these studies, the 
predictive power of NT-proBNP in both sepsis and general intensive care settings seems 
promising, as does the dynamic approach with PCT. The varying results of predictive values 
of different biomarkers may be due to the heterogeneity of individual responses created by 
 37 
genetic factors, but the timing of sampling, the outcome measures, and laboratory methods 
used may also be variable. Some markers may possess a relatively short half-life, and the 
actual time elapsed between the trigger of acute illness and admission to ICU is often 
unknown. Therefore, the dynamic approach rather than the static approach may be more 
fruitful in monitoring clinical and biological signs in critical care. 
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2.3 Genetic associations 
The human genome consists of 23 chromosome pairs with approximately 30 000 genes. 
Variation in DNA sequence occurring more often than 1% in the population is termed 
polymorphism. One natural base-pair alteration in the arrangement of DNA sequence is 
known as SNP, occurring on average every 1/1000 base pairs. Another type of polymorphism 
is variable number of tandem repeats (VNTR), known also as microsatellite polymorphism, in 
which a varying number of nucleotide repeats occur in different individuals.  
A rapid increase in knowledge and advancements in technical development have led to an 
increase in genetic studies of critical illness. The common approach to genetic association 
studies of critical illness is to choose candidate genes involved in the pathophysiological 
pathways or defense mechanisms such as inflammation or coagulation. Interest centers around 
SNPs or microsatellite polymorphisms that alter the gene product’s protein structure, affect 
gene transcription activity, or cause other functional changes. However, rather than 
demonstrating causality, a polymorphism associated with a certain outcome or phenotype is 
considered a marker of association. Despite many polymorphisms investigated in different 
critically ill patient populations, the results have remained inconsistent, and many studies 
have failed to replicate the previous positive results. Some reasons for this have been tendered 
including underpowered sample sizes and inadequate statistical significances, which have led 
to false-positive results; difficulty in defining phenotype or control population adequately; 
and inaccurate methods and deficient technical reliability (see reviews by Peters et al. 2003 
and Clark and Baudouin 2006) (Table 7). 
Table 7. Methodological problems in genetic association studies of critical illness (modified 
from Peters et al. 2003, Clark and Baudouin 2006). 
______________________________________________________________ 
Lack of reproducibility 
Inadequate sample size and lack of power 
Multiple testing (several SNPs, creation of subgroups, different outcomes) 
Difficulty in phenotype or control population definition 
Functional significance of polymorphism not known 
SNP (marker) in linkage disequilibrium with the disease locus 
Technical problems and reliability 
______________________________________________________________ 
 40 
2.3.1 Cytokines 
Several polymorphisms have been found in the genes encoding cytokines, and they are 
thought to influence the interindividual variability in cytokine release, consequently playing 
part in susceptibility to and outcome of critical illness. For example, approximately 60% of 
the variation in TNF and 75% of that in IL-10 production is apparently genetically determined 
(Westendorp et al. 1997). 
  
Evaluation of the relationship between several cytokine polymorphisms and corresponding 
cytokine production has yielded varying results. The following cytokine gene polymorphisms 
at loci: TNF- -308; TNF-d3; interferon gamma +874; IL-10 -1082, -819, and -592; and IL-13
+2043, -1055 and corresponding cytokine production in stimulated peripheral blood 
mononuclear cells in vitro was investigated in 44 liver transplant recipients and 30 matched 
controls. In healthy volunteers, the presence of TNF-d3 microsatellite polymorphism and the 
IL-10 -1082A allele was associated with higher TNF- production on day 1 (p=.026) and 
higher IL-10 production on days 1 and 2 (p=.04 and p=.002), respectively; no other 
significant associations were found (Warle et al. 2003). By contrast, higher IL-10 production 
after LPS stimulation has been associated with the IL-10 -1082G allele in healthy controls and 
patients with sepsis measured from peripheral mononuclear cells (Stanilova et al. 2006) and 
with -1082GG carriers with pneumococcal infection measured from whole blood (Schaaf et 
al. 2003). These varying genotype effects can be due to the different cellular sources and 
varying incubation protocols used (Warle et al. 2003). In addition, ethnic differences in the 
frequencies of cytokine polymorphisms exist (Watanabe et al. 2005 b).  One major point to 
consider is linkage disequilibrium (LD), which means nonrandom association between 
different genetic markers. Genetic markers, i.e. alleles in certain loci, occurring close to each 
other in the same chromosome are likely to be associated with each other. By genotyping 
several associated SNPs of a gene or beyond, one can obtain haplotypes, certain groupings of 
alleles that are inherited as a unit. Haplotype-based analysis significantly improves the power 
to detect genetic associations in complex traits such as in critical illness (Zhang et al. 2002). 
Studies investigating cytokine polymorphisms in critically ill patients are summarized in 
Tables 8-11. 
 41 
Interleukin-10  
The anti-inflammatory cytokine IL-10 gene has several polymorphisms that have been 
investigated in critically ill patients. The results from these studies are summarized in Table 8. 
The CC genotype of the SNP -592C/A has been associated with improved ICU survival in 67 
critically ill patients (Lowe et al. 2003), whereas a moderately large study with 550 sepsis 
patients revealed that IL-10 haplotype -592C/734G/3367G, which also includes the -1082 A 
allele, was associated with higher 28-day mortality in patients with sepsis from pneumonia 
(n=158), but not in patients with sepsis of an extrapulmonary origin (Wattanathum et al. 
2005). In 197 Japanese critically ill patients, the IL-10 -1082A/G, -819T/C, and -592A/C 
polymorphisms were not associated with mortality, but patients with the IL-10 -592CC 
genotype had a higher mortality in the sepsis subgroup compared with the AA genotype 
(n=86, p=.03) (Nakada et al. 2005). However, no correction for multiple testing or adjustment 
for other variables were performed. By contrast, the IL-10 -1082G/A genotype was not 
associated with mortality in two studies with sepsis patients (Garnacho-Montero et al. 2006, 
Stanilova et al. 2006) or with 69 patients with pneumococcal infection, but the prevalence of 
the GG genotype was higher in patients with pneumococcal septic shock (Schaaf et al. 2003). 
The IL-10 genotype has also not been associated with the outcome of 88 patients with 
multiple organ failure (Reid et al. 2002).  
The reason for these inconsistent results may lie in small sample sizes, differences in patient 
populations, and LD. Instead of haplotype-based analysis, investigation of separate SNPs may 
lead to confusing or conflicting results because polymorphisms in the IL-10 gene are in LD 
with each other (Wattanathum et al. 2005). The univariate association between polymorphism 
and outcome yielded a weakly significant p-value in two of these studies (Lowe et al. 2003, 
Nakada et al. 2005). 
Tumor necrosis factor-
The first study investigating the SNP at the -308 position in the key pro-inflammatory 
cytokine TNF- gene promoter (G -> A transition) in septic shock was a multicenter study of 
seven ICUs, 89 patients, and 87 controls. The A allele, also known as TNF2, was found to be 
associated with susceptibility and mortality in septic shock (Mira et al. 1999), but this result 
has been difficult to replicate in further studies. The TNF- -308A allele has been associated 
with mortality in sepsis subgroups of different ICU patients, but no adjustment for other 
variables was reported (Tang et al. 2000, Nakada et al. 2005). In MOD, no association 
 42 
between TNF- -308G/A polymorphism and outcome was found (Reid et al. 2002). One study 
reported an association between TNF- -238A allele and ICU mortality in 215 patients with 
severe SIRS or sepsis (Pappachan et al. 2009). The largest study in patients with severe sepsis 
or septic shock by far included 213 Caucasian patients and found no association between the 
TNF polymorphisms and mortality (Gordon et al. 2004). The advantage of the study was that 
it included four common polymorphisms of the TNF gene and five polymorphisms of the two 
soluble TNF receptor genes, sTNFRSF1A and sTNFRSF1B, and investigated the association 
with outcome also with extended haplotypes. The authors calculated that this patient 
population would have 80% power to detect a difference between the two groups with a p-
value of 0.05 and with an estimated relative risk for mortality of 2.5.  
The role of TNF- in critical illness continues to be investigated. The TNF- -308A allele was 
associated with a higher risk for severe sepsis in patients with trauma (O’Keefe et al. 2002) 
and for mortality in SIRS patients (Watanabe et al. 2005 b). Menges and coworkers (2008) 
showed in an elegant study with 159 trauma patients that a certain TNF- haplotype with the  
-308A allele is significantly associated with the development of sepsis syndrome (odds ratio 
7.1) and with mortality (odds ratio 7.7). The positive result for sepsis susceptibility, but not 
for mortality, was replicated in a smaller validation sample of 78 trauma patients (Menges et 
al. 2008). Carriage of the TNF -308A allele was associated with expression of genes 
representing stronger pro-inflammatory and apoptotic responses, measured by transcriptome 
messenger RNA microarray analysis from peripheral blood (Menges et al. 2008). In 
conclusion, the -308A allele has been recently shown to be associated with development of 
sepsis, but not sepsis mortality, by a systematic review and meta-analysis (Teuffel et al. 
2010). Results of the TNF- studies in critically ill patients are summarized in Table 9. 
TNF- polymorphisms are in LD with other polymorphisms of nearby genes, such as HSP-70, 
which also possess a significant role in the inflammation process (Schroeder et al. 1999), 
making assessment of TNF- gene variations even more complicated. In addition, only a few 
studies have analyzed TNF haplotypes instead of single SNPs (Waterer et al. 2001, Gordon et 
al. 2004, Menges et al. 2008). The inconsistent results of TNF- studies may also derive from 
methodological inadequacies (see the review by Peters et al. 2003). No consensus on the 
functionality of TNF- gene variants yet exists.  
 43 
Interleukin-6 
In 326 surgical ICU patients, the pro-inflammatory IL-6 gene promoter polymorphism  
-174G/C was not associated with sepsis susceptibility. In the sepsis subgroup (n=50), the GG 
genotype was associated with better survival, but its independent effect was not evaluated 
(Schlüter et al. 2002). By contrast, two studies comprising 533 and 288 critically ill patients 
found no association between the -174G/C polymorphism and mortality (Sutherland et al. 
2005 a, Ortlepp et al. 2006). By constructing IL-6 haplotypes, carriage of two copies of 
certain haplotypes (–174/1753/2954: C/C/G, G/G/G, or G/C/C) increased mortality risk after 
adjustment for age, gender, and diagnosis (p=.02, hazard ratio 1.83), but was not associated 
with disease severity or organ dysfunction (Sutherland et al. 2005 a). This study addresses the 
effectiveness of the haplotype-based analysis in determining genetic associations with 
phenotype. Results of IL-6 studies in critically ill patients are summarized in Table 10. 
Interleukin-1 family 
Several polymorphisms have been found in IL-1 family genes, which include pro-inflammatory 
cytokines IL-1 and IL-1 and the anti-inflammatory IL-1ra, located in chromosome 2 near 
each other within the cluster of human major histocompatibility complex. The polymorphism in 
the IL-1A gene intron 6 contains a VNTR, and the IL-1B gene has an AvaI polymorphic site at 
position -511. The IL-1ra gene contains a polymorphic region in intron 2 containing VNTR. 
The IL-1 A2, IL-1 B2, and IL-1ra VNTR2 alleles were associated with an increased mortality 
risk in 60 septic patients (Ma et al. 2002), and the IL-1ra VNTR2 allele with poorer outcome in 
113 Japanese SIRS patients (Watanabe et al. 2005 b). However, neither of these studies 
evaluated the independent effects of the polymorphisms on outcome nor performed corrections 
for multiple testing or haplotype analysis. LD has been found between IL-1B polymorphism at 
position -511 and the VNTR polymorphism in the IL-RA gene (Watanabe et al. 2005 b). The IL-
1ra VNTR polymorphism was not associated with the outcome of 533 critically ill medical 
patients (Ortlepp et al. 2006). Despite the shortcoming of the previous studies, the IL-1ra
VNTR homozygous allele 2 was independently associated with 30-day mortality in 78 patients 
with severe sepsis (Arnalich et al. 2002), but not with ICU mortality in an 88-patient subgroup 
with septic shock (García-Segarra et al. 2007). However, both of these studies are likely to have 
inadequate small sample sizes. Homozygous allele 2 was also associated with lower IL-1ra 
production ex vivo in unstimulated and LPS-stimulated peripheral mononuclear cells of healthy 
controls and patients (Arnalich et al. 2002). Results of the IL-1 family genes in critically ill 
patients are summarized in Table 11. 
 44 
Binding of bacterial ligands to the TLR/IL-1 receptor superfamily activates the IL-1 receptor-
associated kinase, leading to NF-B activation. Patients with the variant haplotype of IL-1 
receptor-associated kinase-1 had increased 60-day mortality and higher in vitro expression of 
NF-B in peripheral neutrophils than wild-type haplotypes (Arcaroli et al. 2006). The study 
had adequate power for detecting association, but the independent effect of the IL-1 receptor-
associated kinase-1 haplotype on mortality was not tested. Also the promoter 
insertion/deletion polymorphism of the NFKB1 gene has been investigated in ARDS patients  
(Adamzik et al. 2007 a).
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2.3.2 Antigen recognition  
CD14, a receptor for wide range of bacterial products including LPS, can be found as 
membrane-bound to leukocytes or in soluble form (sCD14). Results of its promoter 
polymorphism -159C/T in critically ill patients are contradictory. The CD14 gene 
polymorphism -159C/T was not associated with outcome in studies with 197 Japanese 
critically ill patients, 77 surgical ICU patients with SIRS, 247 critically ill patients possessing 
at least 2 of 4 SIRS criteria, and 319 patients with Gram-negative sepsis (Agnese et al. 2002, 
Nakada et al. 2005, Sutherland et al. 2005 b, Jessen et al. 2007). The -260C/T polymorphism 
was associated in univariate analysis and in Kaplan Meier hazard function analysis with 
survival in 87 critically ill ICU patients, but in multiple regression analysis it failed to have an 
independent effect on mortality (D’Avila et al. 2006). In a small subgroup of septic patients 
(n=52), TT genotype was associated with improved survival after adjustment for age and 
degree of organ dysfunction (D’Avila et al. 2006). By contrast, in 90 patients with septic 
shock, the -159TT genotype was independently associated with mortality, with an odds ratio 
of 5.3 (Gibot et al. 2002). The CD14 -159TT genotype has also been associated with a higher 
prevalence of bacterial infections at admission to ICU in 252 critically ill patients (Sutherland 
et al. 2005 b). 
Mutations in the TLR4 gene (Asp299Gly and Thr399Ile) have been associated with 
susceptibility to Gram-negative infection and septic shock (Agnese et al. 2002, Lorenz et al. 
2002), but not with outcome of 77 surgical ICU patients with SIRS (Agnese et al. 2002). The 
TLR2 -16933AA genotype has been associated with significantly increased prevalence of 
sepsis on ICU admission, but not with 28-day survival in 237 critically ill patients (Sutherland 
et al. 2005 b).  
In a recent large study with over 6000 patients from several African countries, the UK, and 
Vietnam, the Toll interleukin-1 receptor domain-containing adaptor protein gene S180L 
heterozygosity was associated with protection against infectious diseases such as invasive 
pneumococcal disease, invasive bacterial disease, malaria, and tuberculosis. The Toll 
interleukin-1 receptor domain-containing adaptor protein gene encodes the Mal protein 
essential for TLR2 and TLR4 downstream signaling, leading to NF-B activation, which the 
heterozygote state is likely to reduce (Khor et al. 2007). 
 50  
Mannose-binding lectin (MBL), a liver-derived protein, is involved in recognition of bacteria. 
The MBL haplotype has been associated with susceptibility to infection, sepsis, severe sepsis, 
septic shock, and ARDS in critically ill patients (Sutherland et al. 2005 b, Gordon et al. 2006, 
Gong et al. 2007), but not with outcome in patients with invasive pneumococcal infection, 
severe sepsis, or septic shock (Kronborg et al. 2002, Gordon et al. 2006). In critically ill 
patients, the MBL2 structural variant A/O was significantly associated with improved late 
survival compared with the normal A/A genotype and the variant O/O (Hellemann et al. 
2007), and the codon 54BB genotype (including to the O variant) was associated with higher 
mortality in ARDS patients (Gong et al. 2007). 
Studies investigating CD14, TLR, and MBL polymorphisms in critically ill patients are 
summarized in Table 12.  
In conclusion, these polymorphisms of genes related to innate immunity instead of affecting 
the mortality risk of critically ill patients, alter the host recognition and clearance of bacteria. 
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2.3.3 Coagulation 
The protein C gene has two SNPs, -1641A/G and -1654T/C, which are in complete LD in a 
Chinese Han population, constituting three haplotypes: -1641A/-1654T, -1641A/-1654C, and 
-1641G/-1654C (Chen et al. 2008). The protein C haplotype -1641A/-1654C was associated 
with more severe organ dysfunction and with a higher 28-day mortality in multiple regression 
analysis after Bonferroni correction for multiple testing in Chinese patients with severe sepsis 
(Chen et al. 2008). In patients with severe sepsis (n=62), protein C -1641AA genotype was 
associated with higher mortality, and this result could be replicated in a larger similarly 
characterized patient cohort (n=402), although the association was completely confined to the 
-1641A/-1654C haplotype (Walley and Russell 2007). In addition, in a third cohort with 
patients undergoing elective cardiopulmonary bypass graft surgery, patients carrying the AA 
genotype had higher IL-6 concentrations after the operation as an indicator of greater 
systemic inflammatory response (Walley and Russell 2007).  
Plasminogen activator inhibitor-1 (PAI-1) inhibits fibrinolysis. Patients with meningococcal 
infection whose first-degree relatives were homozygous for the PAI-1 deletion polymorphism 
(4G allele) were more likely to develop septic shock than carriers of the other genotypes 
(4G/5G or 5G/5G) (odds ratio 5.9) (Westendorp et al. 1999). The PAI-1 4G4G genotype has 
been associated with a higher mortality rate and higher plasma PAI-1 concentrations than 
other genotypes in severely injured patients and in patients with septic shock after adjustment 
for SAPS II scores, although the odds ratio (2.2) was quite low (Menges et al. 2001, García-
Segarra et al. 2007). In addition, the PAI-1 4G allele was associated with increased expression 
of PAI-1, and the 4G/G/C/A haplotype at the PAI4G/5G, PAI2846, PAI4588, and PAI7343 
was associated with increased susceptibility to community-acquired pneumonia in elderly 
Caucasians (Yende et al. 2007).  
Studies investigating Protein C and PAI-1 polymorphisms in critically ill patients are 
summarized in Table 13.  
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2.3.4 Other proteins
The homozygous deletion of a 284 base-pair marker in the human angiotensin-converting 
enzyme gene (DD allele) is associated with higher predicted mortality and illness severity than 
insertion allele (I) in children with meningococcal disease (Harding et al. 2002). This 
polymorphism was not associated with severe sepsis or sepsis-induced ARDS susceptibility 
or mortality in 212 patients with severe sepsis –nor was an association found after adjustment 
for other variables (Villar et al. 2008), in contrast to previous studies finding an association 
with mortality in ARDS patients (Marshall et al. 2002, Jerng et al. 2006, Adamzik et al. 2007 
b).  
A moderately large study investigating five candidate gene polymorphisms in 533 critically ill 
medical patients failed to find any association between C-reactive protein gene SNP 
1059G/C, connective tissue growth factor gene SNP -477G/C, or chemocine receptor 2 gene 
polymorphisms and hospital mortality (Ortlepp et al. 2006). 
In ICU patients with severe sepsis, homozygous carriers of the tandem repeat of the CXCL2
chemokine gene (also known as macrophage inflammatory protein-2) had in multiple 
regression analysis lower ICU mortality than patients with either one tandem repeat 
polymorphism or noncarriers (Villar et al. 2007). Because the functional role of this CXCL2
gene polymorphism is still unknown and was not further investigated in the study, the value 
of this finding remains obscure. 
By sequencing the HMGB-1 gene, acting as a late mediator of inflammation, in 239 ICU 
patients with SIRS and in 103 controls, ten genetic variants were found and one 
polymorphism (-1377Adel) was associated with delayed mortality (p=.01) (Kornblit et al. 
2008). 
 55  
3 AIMS OF THE STUDY
Objectives of this study were to investigate new measures and biological markers of critical 
illness and to evaluate their predictive value and association with mortality, severity of illness, 
and development and degree of organ dysfunction. Specific aims were as follows: 
 1. To evaluate the relation of emergency department delay to outcome measured by hospital 
mortality and health-related quality of life in critically ill medical intensive care unit patients 
(I). 
2. To investigate the concentrations of cell-free plasma DNA and its association with disease 
severity and mortality in critically ill patients (II). 
3. To study the predictive value of cell-free plasma DNA for mortality and the association of 
cell-free plasma DNA with severity of illness and organ dysfunction in patients with severe 
sepsis and septic shock (III). 
 4. To evaluate the associations of the heme oxygenase-1 gene GTn repeat length 
polymorphism, two single-nucleotide polymorphisms, and plasma concentrations with 
mortality, degree of organ dysfunction, and disease severity in critically ill patients (IV). 
All 1675 concecutive
patients in the medical
ICU 1.7.2002-30.6.2004
Study I
1537 patients
138 re-
admissions
excluded
244 patients in three
ICUs
1.1.2004-30.7.2005
Studies II and IV
228/231 patients
adequate
blood sample
not obtained
The Finnsepsis Study
1.11.2004-28.2.2005
470 patients ACCP/SCCM 
Concensus Criteria for
severe sepsis or septic shock
fulfilled
Study III 
255 patients
Consent for 
laboratory samples
and at least one
sample obtained
Altogether 2023 patients in Studies I-IV
Figure 3. Flowchart of inclusion in Studies I–IV. 
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4 PATIENTS AND METHODS
4.1 Patients 
Altogether 2023 patients were included in Studies I-IV. The flowchart of patient inclusions is 
presented in Figure 3. The demographic data of study patients are presented in Table 14. 
Study I 
Study I was a follow-up study conducted in a 9-bed medical ICU at Helsinki University 
Hospital. All 1675 consecutive ICU admissions between July 1, 2002 and June 30, 2004 were 
included. After re-admissions were excluded, the final study population comprised 1537 
patients 1016 of whom were admitted from ED. The 15D questionnaire was sent to those 
patients admitted to the ICU after December 28, 2002 and known to be alive six months after 
intensive care (n=747). 
Studies II and IV 
Studies II and IV are the two parts of a prospective study conducted from January 2004 to 
July 2005 in two medical-surgical ICUs and one medical ICU. Initially, 244 patients were 
included after receiving a written informed consent from the patient or their near-relative; 13 
patients were subsequently excluded because of inadequate blood samples. However, Study II 
included only 228 patients since 3 patients were accidentally excluded. Study IV contained all 
231 patients. In conclusion, two different biological mechanisms were investigated in the 
same patient population in Studies II and IV.  
To determine the reference range for plasma HO-1 in Study IV, plasma samples of 58 healthy 
volunteers (28 women, 30 men) –a part of a larger cohort designed to provide reference 
values for routine laboratory parameters (the Nordic Reference Interval Project) (Rustad et al. 
2004)– were used. 
Study III 
Study III was a substudy of a prospective observational cohort study on the incidence and 
prognosis of sepsis in Finland (the Finnsepsis Study), conducted in 24 Finnish ICUs over a 4-
month period from November 1, 2004 to February 28, 2005 (Karlsson et al. 2007). All adult 
patients aged over 18 years admitted to the participating ICUs during the study period were 
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screened daily for the criteria of severe sepsis and septic shock according to the American 
College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM). All patients 
fulfilling the criteria of known or suspected infection, with two or more SIRS criteria, and at 
least one sepsis-induced, new organ failure were included to the Finnsepsis Study (N=470). 
Informed consent was obtained from 255 patients or their legal representative, and these 
patients were included in Study III. 
Table 14. Demographics of patients in Studies I–IV. 
 Patient cohort I Patient cohort II Patient cohort III 
Study I III II/IV 
Number of patients 1537 255 228/231 
Age, years 58 (46–71) 60 (49–72) 58 (48–68) 
Male gender 922 (60%) 176 (69%) 154 (67%) 
APACHE II score 21 (15–27) 23 (18–29) 23 (17–29) 
SOFA score on day 1 7 (4–10) 8 (6–11) 8 (6–11) 
ICU mortality 194 (12.6%) 34 (13.3%) 17 (7.4%) 
Hospital mortality 375 (24.4%) 67 (26.3%) 45 (19.7%/19.5%) 
Data are expressed as number (percentage) or median (interquartile range) 
4.2 Study designs 
Study I 
All consecutive admissions to a medical ICU during a two-year period were analyzed to 
evaluate the impact of ED length of stay on outcome, measured as hospital mortality and 
HRQoL 6 months after intensive care. If a patient had more than one admission to the ICU, 
only the first one was included. For those patients admitted to the ICU from ED, the ED 
length of stay data were collected from hospital records. Mortality data and the 15D measure 
of the HRQoL for those known to be alive were collected.   
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Study II 
In this study, we evaluated the concentrations of cell-free plasma DNA in 228 critically ill 
patients and the associations between plasma DNA and hospital mortality, degree of organ 
failure, and disease severity. Three blood samples were drawn: the first as soon as possible 
after ICU admission, the second on the following morning, and the third 48 h from the second 
sample. These samples were then grouped as the first, second, and third to fourth day 
samples. 
Study III 
The predictive value of the cell-free plasma DNA was evaluated regarding mortality in a 
large, unselected patient population with severe sepsis and septic shock. Disease severity and 
degree of organ failure were also assessed with APACHE II, SAPS II, and SOFA scores.  
Blood samples for plasma DNA analyses were obtained from 252 patients at study inclusion 
and from 220 patients 72 h thereafter. ICU, hospital, and 1-year mortality data were collected.  
Study IV 
In this study, three heme oxygenase-1 gene polymorphisms and HO-1 plasma concentrations 
in serial samples were investigated in 231 critically ill patients, and whether they are 
associated with each other. The correlations of the HO-1 polymorphisms and plasma 
concentrations with hospital mortality, degree of organ failure, and disease severity were also 
analyzed. For the plasma HO-1 concentration analysis, the first-day sample was available for 
160 study patients, the second-day sample for 162 patients, and the third- to fourth-day 
sample for 187 patients. The SNP information was available for all 231 study patients and the 
GTn repeat length result for 230 patients. The analysis of GTn repeat length failed for one 
patient. The locations of the -413A/T, +99G/C, and GTn polymorphisms in the HO-1 gene 
nucleotide sequence are presented in Appendix 2. 
The clinical study characteristics are summarized in Table 15.  
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Table 15. Summary of Studies I-IV. 
Study Design Patients Aim Main variables Endpoint 
I Retrospective/ 
prospective 
1537 
patients in 
one medical 
ICU 
To investigate whether 
length of ED stay is 
associated with outcome in 
critically ill patients 
admitted to medical ICU 
Length of stay in 
ED 
Hospital 
mortality 
(HRQoL at 
6 months) 
II* Prospective 228* ICU 
patients in 
three ICUs 
To assess plasma DNA 
concentration and its 
association with disease 
severity and mortality in 
critically ill ICU patients  
Maximum plasma 
DNA during 96 h in 
ICU, APACHE II 
and SOFA scores 
Hospital 
mortality 
III Prospective 255 patients 
with severe 
sepsis or 
septic shock 
in 24 ICUs 
To evaluate the predictive 
value of plasma DNA for 
ICU and hospital mortality 
in patients with severe sepsis 
Plasma DNA at 0 
and 72 h, APACHE 
II, SAPS II, and 
SOFA scores 
ICU, 
hospital, 
and 1-year 
mortality 
IV Prospective 231 ICU 
patients in 
three ICUs 
To evaluate the association 
of HO-1 gene 
polymorphisms and plasma 
HO-1 concentrations with 
mortality and disease 
severity in critically ill 
patients 
Plasma HO-1 on 
first ICU day, HO-1
polymorphisms, 
APACHE II, SAPS 
II, and SOFA 
scores 
Hospital 
mortality 
*same patients included in the Study IV 
APACHE, Acute Physiology and Chronic Health Evaluation; ED, emergency department; HRQoL, Health-
related quality of life; HO-1, heme oxygenase-1; ICU, intensive care unit, SAPS, Simplified Acute Physiology 
Score; SOFA Sequential Organ Failure Assesment 
4.3 Laboratory measurements 
Cell-free plasma DNA (II, III) 
Blood samples were drawn from patients into EDTA tubes (II and IV) or lithium heparin 
tubes (III). The plasma fraction was separated as soon as possible by centrifugation at 1600 g 
(+4°C) for 10 min and stored at -80°C (II and IV) or -20°C or below at the enrolling site 
before being sent to Helsinki University Hospital, where samples were stored at -80°C (Study 
III). Plasma samples were centrifuged at 16000 g for 10 min before DNA extraction to 
remove any residual cells (Swinkels et al. 2003). DNA was extracted from 200-l plasma 
samples using the QIAamp DNA Blood Mini Kit (Qiagen) according to the blood and body 
fluid protocol recommended by the manufacturer. Plasma DNA was measured in duplicate 
samples by real-time quantitative PCR assay for the -globin gene (Lo et al. 1998) using the 
ABI PRISM 7000 sequence detection system (Applied Biosystems). The sequences were as 
follows: forward primer 5-GCA CCT GAC TCC TGA GGA GAA-3, reverse primer 5- 
CAC CAA CTT CAT CCA CGT TCA-3, and a single-labeled fluorescent MGB-probe 5’-
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FAM-TCT GCC GTT ACT GCC CT-MGB-NFQ, where MGB is a minor groove binding 
molecule and NFQ a nonfluorescent quencher molecule. We used a 10-fold serial dilution of 
human genomic DNA (Roche) as a standard curve. Results are expressed as genome 
equivalents (GE)/ml; 1 GE equals 6.6 pikograms of DNA.  
To determine the precision of the real-time quantitative PCR method, we performed PCR runs 
8 times in duplicate with 2 samples and a standard curve. The interassay coefficient of 
variation for the threshold cycle values of PCR analyses was 0.5% to 2.1% over the whole 
dynamic range from 2x102 to 2x106 GE/ml, with the highest imprecision in the range from 
2x102 to 2x103 GE/ml. 
Heme oxygenase-1 in plasma (IV) 
The plasma fraction was separated as soon as possible from blood samples drawn into EDTA 
tubes by centrifugation 1600 g (+4°C) for 10 min and stored at -80°C. HO-1 plasma 
concentration was measured by human HO-1 quantitative sandwich ELISA (Stressgen, 
Victoria, Canada) according to the manufacturer’s instructions. One hundred microliters of 
standards and samples prepared in sample diluent was added to wells of an anti-HO-1 
immunoassay plate, incubated at room temperature for 30 minutes, and washed six times with 
washing buffer. Next, 100 µl of anti-human HO-1 antibody was added, incubated at room 
temperature for 60 minutes, and washed. Then, 100 µl of horseradish peroxidase conjugate 
was added, incubated at room temperature for 30 minutes, and washed. Finally, the plates 
were incubated with 100 µl of tetramethylbenzidine substrate at room temperature for 15 
minutes in the dark, and a stop solution was added. The results were measured by absorbance 
at 450 nm. The assay is specific for human HO-1, with no cross-reaction with other human 
HO isoforms. 
Heme oxygenase-1 polymorphisms (IV) 
Genomic DNA was isolated from whole blood using Puregene DNA Isolation Kit (Gentra 
Systems, Minneapolis, MN). Two single-nucleotide polymorphisms, -413A/T (rs2071746) 
and +99G/C (rs2071747), were determined by allelic discrimination using the 5’ nuclease 
TaqMan assay on an ABI Prism 7000 Sequence Detection System (Applied Biosystems, 
Foster City, CA) according to the manufacturer’s protocol. The following primers and probes 
were used for -413A/T: forward 5’-TGACATTTTAGGGAGCTGGAGACA-3’, reverse 5’-
AGGCGTCCCAGAAGGTT CCA-3’, probe for A allele 5’-FAM-
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CCCACCAGGCTATTGCTCTGAGCA-Tamra-3’, and probe for T allele 5’VIC-
CCCACCAGGCTTTTGCTCTGAGC-Tamra-3’ (Ono et al. 2004). TaqMan SNP Genotyping 
assay was used for +99G/C (Applied Biosystems). 
Genotyping of the GTn repeat length polymorphism in the HO-1 promoter was performed by 
PCR using a 5’ FAM-labeled forward primer 5’-FAM-AGAGCCTGCAGCTTC TCAGA-3’ 
and reverse primer 5’-ACAAAGTCTGGCCATAGGAC-3’. The length of PCR products was 
determined by fragment analysis using a capillary sequencer (ABI3730xl DNA Analyzer, 
Applied Biosystems). GeneScan-500 LIZ (Applied Biosystems) was used as a size marker. 
The number of GTn repeats was determined using the GeneMaker 1.4 software 
(SoftGenetics).  
In all measurements, the investigators performing the analyses were unaware of the patients’ 
clinical course. 
Other measurements 
Routine laboratory measurements were taken daily as part of patient follow-up and for organ 
failure and disease severity scores, although no specific laboratory sample protocol existed 
(II–IV). The measurements included serum bilirubin, C-reactive protein, creatinine, urea 
concentrations, and platelet count. In Study III, the estimated creatinine clearance was 
calculated using the Cockcroft and Gault formula (Cockcroft and Gault 1976). 
4.4 Interventions 
Besides drawing of blood samples (II–IV) and HRQoL assessment (15D) (I) after consent, 
patients were treated according to the discretion of the attending physicians without 
therapeutic interventions or specific treatment protocols. 
4.5 Data collection 
Patient information, collected and stored in the Finnish intensive care quality consortium’s 
database (Intensium Ltd., Kuopio, Finland), included demographic data, diagnosis by 
International Classification of Diseases 10th edition, SAPS II (Le Gall et al. 1993), APACHE 
II score (Knaus et al. 1985), daily SOFA score (Vincent et al. 1998), and ICU and hospital 
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mortality (I, II, IV). In Study III, which included patients from 24 ICUs from 21 hospitals, 
data were collected daily by local study nurses or investigators. Data were stored through the 
Finnish intensive care quality consortium (Intensium Ltd.). 
4.6 Outcome measures 
Mortality 
The ICU mortality (III), hospital mortality (I–IV), and one-year mortality (III) data were 
recorded from hospital records and Statistics Finland. 
Health-related quality of life 
Quality of life was assessed using the generic 15D measure (I) (Sintonen 2001). The 15D 
questionnaire consists of 15 dimensions: breathing, mental functions, speech 
(communication), vision, mobility, usual activities, vitality, hearing, eating, elimination, 
sleeping, distress, discomfort and symptoms, sexual activity, and depression. Respondents 
were asked to choose the alternative best describing one’s present health status from five 
alternatives. The responses are divided into 5 levels (1=best, 5=worst). A weighted 15D score 
is generated on the scale from 1 (no problems on any dimension) to 0 (being dead). The 15D 
questionnaire is presented in Appendix 1. The 15D questionnaire of HRQoL was mailed for 
self-administration to the patients admitted to the ICU after December 28, 2002 and known to 
be alive at 6 months after medical ICU admission. The results from the study population were 
compared with those from the age- and gender-matched general Finnish population obtained 
from Health 2000 health examination survey (Aromaa and Koskinen 2004). 
Disease severity scores 
The SOFA (Vincent et al. 1998) score evaluates status of the following organ systems 
separately: central nervous system, coagulation, cardiovascular, respiration, hepatic, and 
renal. The SOFA scores were calculated daily (III), in the first 24 h at ICU admission (I), or 
daily during the first four days in the ICU (II and IV) to assess the degree of organ 
dysfunction. The APACHE II score (Knaus et al. 1985) and SAPS II (Le Gall et al. 1993) 
were calculated in the first 24 h in the ICU to evaluate the severity of illness (I–IV). 
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4.7 Statistical analyses 
Kolmogorov-Smirnov test was used to test if a variable is normally distributed. Because 
most of the main quantitative data was not normally distributed, nonparametric statistics was 
used.
Nonparametric Mann-Whitney U-test was used for comparisons of continuous variables 
between two independent samples, e.g. between survivors and nonsurvivors (I–IV). 
Chi-square and Fisher’s Exact tests were used for comparisons of categorical variables (I–
IV). The Fisher’s Exact test was used if the number of cases in a sample was lower than five. 
Bivariate correlations for continuous, not normally distributed variables were determined with 
nonparametric Spearman’s correlation, such as those between cell-free plasma DNA or 
plasma HO-1 concentration and disease severity scores or ED length of stay and the 15D 
score of HRQoL (I–IV). 
Variables significantly associated with plasma DNA or HO-1 concentration were tested by 
linear regression analysis to determine the independent factors that would best predict the 
value of the dependent variable (plasma DNA or HO-1). Because plasma DNA and HO-1 
values were not normally distributed, log-transformed plasma DNA and HO-1 was used (III–
IV).
Kruskal-Wallis test, a nonparametric test comparing the difference in the median values of 
two or more samples, was used in Studies III and IV to evaluate whether a difference was 
present in the plasma DNA or HO-1 values between quartiles of SOFA scores. In Study III, 
Bonferroni correction was also used because of multiple comparisons.
Kaplan-Meier analysis was applied to evaluate the one-year mortality differences according 
to the best cut-off value of baseline plasma DNA concentration in Study III. 
Multivariate forward logistic regression analysis was used to test the independent effect of 
the variables on outcome (II–IV). 
The discriminative power of plasma DNA and plasma HO-1 regarding mortality was 
evaluated with ROC analysis, and AUC was calculated with a 95% confidence interval (III–
IV). To evaluate the correct classification rate, sensitivity, specificity, and likelihood ratios, 
the best predictive cut-off values maximizing the sum of sensitivity and specificity were 
defined using the GraphROC for Windows (Kairisto and Poola 1995) (III and IV), presented 
in Table 16. 
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Table 16. Defining the correct classification rate, sensitivity, specificity, and positive and 
negative predictive values regarding death. 
  Condition 
Dead Alive 
Test result Positive A C A+C 
 Negative B D B+D 
  A+B C+D  
A=True positive     C=False positive 
B=False negative    D=True negative 
Sensitivity= true positives/(true positives+false negatives)=A/(A+B) 
Specificity=true negatives/(true negatives+false positives)=D/(C+D) 
Positive prediction value=true positives/(true positives + false positives)=A/(A+C) 
Negative prediction value=true negatives/(true negatives + false negatives)=D/(D+B) 
Correct classification rate=(true positives + true negatives)/all=(A+D)/(A+B+C+D)
    
The standardized mortality ratio (SMR) was calculated as the ratio of actual mortality rate to 
expected mortality rate (I). The probability of hospital mortality rate was calculated using the 
SAPS II score (Le Gall et al. 1993). 
The analyses were performed using the SPSS 12.0. statistical software (SPSS, Chicago, IL). 
The GraphROC for Windows (Kairisto and Poola 1995) was used in ROC analysis. The 
demographic data are expressed as median and interquartile range (IQR). The 2-tailed level of 
p<.05 was considered statistically significant in all tests. 
In Study IV, Hardy-Weinberg equilibrium was calculated for the HO-1 polymorphisms with 
the Pearson’s correlation and Fisher’s exact tests. Pairwise LD measures were determined 
using Haploview 4.0 software. Haplotypes were constructed using the solid spine of LD 
algorithm and Haploview software (Barrett et al. 2005). In addition to the marker-by-marker 
analysis, we evaluated the associations also by haplotype-based analysis, which is considered 
more powerful in detecting associations (Zhang et al. 2002). The Genetic Power Calculator 
was used for power calculations (Purcell et al. 2003). With a relative risk of 2.5 for the 
heterozygotes and 3 for minor allele homozygotes regarding hospital mortality, the Study IV 
sample had 83% power to detect association with the +99G/C polymorphism. 
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6 RESULTS 
6.1 Association of emergency department length of stay with mortality and health-
related quality of life (I) 
The study showed that the ED length of stay was associated with neither hospital mortality 
nor HRQoL at six months after intensive care in the 1016 patients admitted to the ICU from 
the ED (p=.82 and p=.34, respectively). The flowchart for Study I patients is presented in 
Figure 4.  
The median ED length of stay before ICU admission was 4.8 h (280 min, IQR 3.1–7.6 h). 
Patients admitted to the medical ICU from the ED were younger than patients admitted from 
elsewhere (median age 56 years vs. 63 years, p=.001), and they had lower disease severity 
and organ dysfunction scores (median APACHE II score 20 vs. 23, p=.001, median first-day 
SOFA score 7 vs. 8, p=.001). They also had shorter length of stay in the ICU (ED vs. non-ED 
patients median 1.56 vs. 2.06 days, p<.001). 
Of the 747 patients to whom the 15D questionnaire was sent, 251 (34%) returned it. Five 
patients had to be excluded from the analysis, as their questionnaires contained more than 
three missing answers. Responders and nonresponders did not differ from each other in terms 
of age, gender, length of ED or ICU stay, or SOFA and APACHE II scores (p=.24–.87). The 
15D score of the responders (median 0.83, IQR 0.70–0.90) was significantly lower than in the 
age- and sex-matched general Finnish population, and also on all 15 dimensions (p<.001– 
p=.008), as presented in Figure 5.  
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Figure 4. Patient flow of Study I patients, places of admission, and discharge. 
Figure 5. The 15D profiles (mean 15D score) of the Study I patients (n=246) six months after 
intensive care and the general age- and sex-matched Finnish population. 
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6.2 Association of cell-free plasma DNA with mortality and severity of disease in 
critically ill patients (II) 
In Study II, maximum DNA concentration in 228 critically ill patients during the first four 
days in ICU was higher in hospital nonsurvivors than in survivors (median 9366 GE/ml, IQR 
4228–21 159 GE/ml vs. median 6506 GE/ml, IQR 2854–13 745 GE/ml, p=.035; Figure 6). In 
logistic regression analysis including age, gender, APACHE II score, maximum SOFA score 
during the first 96 h in the ICU, and maximum plasma DNA; maximum cell-free plasma 
DNA was independently associated with hospital mortality (p=.049) as well as with 
maximum SOFA score (p<.001), age (p=.003), and gender (p=.01). 
   
Maximum DNA levels were higher in patients with infection (n=58) than in other patients 
(median 12 019, IQR 5449–19 583 GE/ml vs. median 5808 GE/ml, IQR 2695–11 645 GE/ml, 
p<.001). A significant correlation existed between maximum DNA concentration and 
APACHE II score (r=.17, p=.01) and maximum SOFA score during the first 96 h (r=.25, 
p<.001), especially with the liver (p=.04), coagulation (p=.02), renal (p=.01), cardiovascular 
(p=.001), and pulmonary (p<.001) SOFA scores. The maximum cell-free plasma DNA 
concentration was not associated with age, gender, or mechanical ventilation. 
Figure 6. Maximum cell-free plasma DNA concentrations in hospital survivors and 
nonsurvivors (line: median, box: interquartile range, whiskers: 95% confidence interval). 
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6.3 Predictive value of plasma DNA in patients with severe sepsis or septic shock (III) 
The median cell-free plasma DNA concentration at baseline was 8070 GE/ml (IQR 3883–18 
934 GE/ml) and 7457 GE/ml 72 h thereafter (IQR 3668–16 311 GE/ml) in patients with 
severe sepsis or septic shock. The cell-free plasma DNA concentration was higher in ICU 
nonsurvivors than in survivors at admission (median 15 904 vs. 7522 GE/ml, p<.001) as well 
as 72 h later (median 15 176 vs. 6758 GE/ml, p=.004). Hospital nonsurvivors had higher 
plasma DNA levels than survivors at both time-points (baseline median 12 386 vs. 7678 
GE/ml, p=.009 and 72-hour median 11 428 vs. 6414 GE/ml, p=.008). The increasing or 
decreasing plasma DNA concentration was not associated with ICU or hospital mortality 
(p=.42–.93). 
The AUC regarding ICU mortality was 0.71 (95% CI 0.62–0.80) for the DNA concentration 
at inclusion and 0.70 (95% CI 0.57–0.82) for the DNA concentration 72 h later (Figure 7). 
Compared with plasma DNA, the maximum lactate value on the first day as well as the SAPS 
II score had slightly higher AUCs for ICU mortality (0.77, 95% CI 0.68–0.85, and 0.75, 95% 
CI 0.65–0.84, respectively), whereas the first-day SOFA score had slightly lower AUC for 
ICU mortality (0.69, 95% CI 0.58–0.80). Regarding hospital mortality, plasma DNA had less 
discriminative power; the AUC for the baseline DNA concentration was 0.61 (95% CI 0.53–
0.69) and for the 72-h DNA concentration 0.63 (95% CI 0.53–0.72). In ROC analysis, the 
best cut-off value of plasma DNA at baseline for ICU mortality was 12 000 GE/ml, with a 
sensitivity of 67% (95% CI 51–80%), specificity of 67% (95% CI 62–72%), positive 
likelihood ratio of 2.03 (95% CI 1.49–2.76), and correct classification rate of 67%. The best 
cut-off value of plasma DNA after 72 h was 12 500 GE/ml, with a sensitivity of 60% (95% CI 
39–78%), specificity of 70% (95% CI 64–75%), positive likelihood ratio of 2.00 (95% CI 
1.32–3.03), and correct classification rate of 69%.  
The 1-year mortality rate in Study III was 40% (102/255). The Kaplan-Meier survival curve 
for the best plasma DNA cut-off value at baseline is presented in Figure 8. 
The Study III patients did not differ from the rest of the Finnsepsis study cohort concerning 
basic characteristics, severity of disease or organ dysfunction, or mortality. 
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Figure 7. ROC curves for plasma DNA concentration at baseline (AUC 0.71, 95% CI 0.62–
0.80) and 72 h later (AUC 0.70, 95% CI 0.57–0.82) regarding mortality in the intensive care 
unit.
Figure 8. Kaplan-Meier survival curve according to plasma DNA concentration at baseline. 
The cut-off value is the best for predicting ICU mortality. 
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The variables significantly associated with hospital mortality (SAPS II score minus SAPS age 
points, admission SOFA score, age, lactate value, cardiovascular comorbidity, and plasma 
DNA value at inclusion and 72 h later) were included in multiple logistic regression analysis. 
The SAPS II score (p=.001) and cardiovascular comorbidity (p=.015) were independent 
predictors of hospital mortality. The variables significantly associated with ICU mortality 
(SAPS II score minus SAPS age points, admission SOFA score, age, lactate value, and 
plasma DNA value at inclusion and 72 h later) were included in separate multiple logistic 
regression analysis.  The first-day plasma DNA concentration (p=.005) and the SAPS II score 
(p=.008) were independent predictors of ICU mortality. 
The variables significantly correlated with baseline cell-free plasma DNA concentration were 
first-day SOFA score (r=0.29, p<.001), maximum SOFA score (r=0.30, p<.001), APACHE II 
score (r=0.18, p=.005), SAPS II score (r=0.22, p=.001), maximum first-day lactate 
concentration (r=0.40, p<.001), first-day plasma creatinine concentration (r=0.15, p=.018), 
first-day lowest estimated creatinine clearance (r=0.16, p=.013), first-day lowest platelet 
count (r=0.24, p<.001), first-day lower urine output (r=0.24, p<.001), and first-day urea 
concentration (r=0.21, p=.005). Neither age nor gender correlated with DNA concentrations 
(p=.32–.77 and p=.06–.77, respectively). First-day maximum lactate value (p=.003) and 
SOFA score on the first day of intensive care (p=.015) were independently associated with 
plasma DNA concentration at baseline in linear regression analysis. 
6.4 Frequencies of HO-1 polymorphisms (IV) 
The frequency of the +99GG genotype was 89.6% (207/231) and of the +99GC genotype 
10.4% (24/231). The frequencies of the -413A/T genotypes were as follows: AA 35.5% 
(82/231), AT 48.5% (112/231), and TT 16.0% (37/231). The two SNP polymorphisms were 
in Hardy-Weinberg equilibrium. The GTn repeat length range was 18–40, the most frequent 
repeat lengths being 30 (47.6%) and 23 (18.6%). The distribution is presented in Figure 9. 
The analysis of GTn polymorphism failed for one patient. The GTn polymorphism was 
divided into short (S) (26 GT repeats), medium (M) (27–33 GT repeats), and long (L) (>33 
GT repeats) alleles by its trimodal distribution. S allele frequency was 36%, M allele 
frequency 59%, and L allele frequency 5%. The allele frequencies did not differ between men 
and women. 
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Figure 9. Distribution of HO-1 GTn repeat length polymorphism. 
Strong LD existed between all polymorphisms studied. The D’ measure of LD between the 
two SNPs was 1.0, while the r2 value, which takes allele frequencies into account, was 0.08. 
The most common allele of the repeat length polymorphism, GT(30), was in complete LD 
(D’=1) with the +99G and -413A alleles. The next frequent alleles, GT(23) and GT(24), were 
in complete LD with the +99G and -413T alleles. The group of L alleles was in perfect LD 
(both D’ and r2=1) with the +99C allele. The different haplotypes were constructed from the 
three polymorphisms and their relative frequencies are presented in Table 17. The most 
frequent haplotypes were -413A/GT(M)/+99G (57%), T/GT(S)/G (34%), and T/GT(L)/C 
(5%). 
6.5 HO-1 plasma concentrations (IV) 
The HO-1 plasma concentration’s reference range (95% CI), derived from healthy volunteers 
(n=58), was 0.66–2.39 nanograms per milliliter. The concentration did not differ between men 
and women. The first-day plasma sample for HO-1 concentration was available for 160 study 
patients, the second-day sample for 162 patients, and the third- to fourth-day sample for 187 
patients. The plasma HO-1 concentrations of study patients were significantly higher than the 
reference values at all time-points (first-day HO-1 6.9 ng/ml, IQR 5.1–9.9 ng/ml; second-day 
HO-1 6.6 ng/ml, IQR 4.9–9.3 ng/ml; third- to fourth-day HO-1 6.4 ng/ml, IQR 4.9–8.1 ng/ml 
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in study patients vs. 1.5 ng/ml, IQR 1.1–1.8 ng/ml in healthy volunteers, p<.001). One patient 
was excluded from further analysis because of extremely high HO-1 concentration due to 
autoimmune hemolytic anemia (maximum 407 ng/ml). 
Table 17. Heme oxygenase-1 haplotype frequencies. 
Haplotype Frequency (%) -413A/T GT(n) +99G/C Frequency (%) 
A/GT(M)/G 57.3 A GT(30) G 47.6 
  A GT(31) G 4.3 
  A GT(M, except 30,31)  G 5.4 
      
T/GT(S)/G 34.2 T GT(23) G 18.6 
  T GT(24) G 9.5 
  T GT(S, except 23,24) G 6.1 
      
T/GT(L)/C 5.2 T GT(L) C 5.2 
      
A/GT(S)/G 2.2 A GT(S, except 23,24) G 2.2 
      
T/GT(M)/G 1.1 T GT(M, except 30,31) G 1.1 
6.6 Association of HO-1 polymorphisms with HO-1 plasma concentrations and outcome 
(IV) 
Compared with other haplotypes, patients with the +99C and the long GT allele (included in 
the -413T/GT(L)/+99C haplotype) had significantly lower HO-1 concentration at all time-
points (Figure 10). From the 24 patients carrying the -413T/GT(L)/+99C haplotype, 14 had 
the first-day plasma HO-1 value. The -413T allele was also associated with lower third- to 
fourth-day HO-1 plasma concentrations than AA homozygotes (6.1 vs. 6.9 ng/ml, p=.021). 
Patients with the -413T/GT(L)/+99C haplotype had less frequently MOD (SOFA score > 6) 
(46%) than patients with other haplotypes (70%) (p=.017) on the first day in the ICU. No 
association emerged between HO-1 polymorphisms and hospital mortality or severity of 
disease measured with APACHE II and SAPS II scores (data not shown).  
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6.7 Association of HO-1 plasma concentrations with outcome (IV)  
A significant correlation existed between the first- and second-day HO-1 concentrations and 
the first- and second-day bilirubin values (r=0.27, p=.001 and r=0.26, p=.001, respectively), 
the first-day HO-1 concentration and the first-day C-reactive protein concentration (r=0.18, 
p=.02), the disease severity scores APACHE II and SAPS II (r=0.27, p=.001 and r=0.17, 
p=.038, respectively), and the first-day and maximum SOFA scores (r=0.32, p<.001 and 
r=0.34, p<.001, respectively) (Figure 11). In the linear regression analysis, renal failure 
(p=.02) and ventilation failure (p=.02) were associated independently with HO-1 values on 
the first day in the ICU when organ failures were analyzed separately. Patients with MOD on 
the first day of intensive care had significantly higher HO-1 concentrations at all time-points 
than patients with no MOD (first-day HO-1 7.8 vs. 6.1 ng/ml, p=.015; second-day HO-1 6.9 
vs. 5.6 ng/ml, p=.003; third- to fourth-day HO-1 6.5 vs. 5.6 ng/ml, p=.004; respectively). Men 
had higher second-day and third- to fourth-day HO-1 concentrations than women (p<.001 and 
p=.001, respectively), while their disease and organ failure scores did not differ from 
women’s scores. Age did not correlate with HO-1 concentrations. In the linear regression 
analysis to identify variables independently associated with first-day HO-1 concentration, 
first-day C-reactive protein values, gender, SAPS II score, SOFA score, and carriage of 
T/GT(L)/C haplotype were included. First-day SOFA score (p=.001) and T/GT(L)/C 
haplotype (p=.03) were independently associated with first-day HO-1 concentrations.  
Hospital mortality for those 160 patients with first-day plasma HO-1 was 21% (33/160), and 
the standardized hospital mortality ratio was 0.56. Patients with first-day plasma HO-1 did not 
differ from patients without the plasma sample regarding hospital mortality, gender, SOFA 
scores, SAPS II score, or carriage of T/GT(L)/C haplotype (data not shown), but they were 
slightly younger (median 57 vs. 61 years, p=.04). The first-day HO-1 concentrations did not 
differ significantly between hospital survivors and nonsurvivors. For hospital mortality, the 
first-day HO-1 value produced an AUC of 0.59 (95% CI 0.47–0.71). 
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Figure 10. Patients with the -413T/GT(L)/+99C haplotype had a significantly lower plasma 
HO-1 concentration at all time-points than patients with other haplotypes. Concentrations are 
shown as median (line) and interquartile range (box) and 5th and 95th percentiles (whiskers).  
* p<.05, ** p<.01 and *** p<.001. (Figure 3 from Study IV). 
Figure 11. First-day plasma HO-1 concentrations in the first-day SOFA score quartiles. 
Concentrations are shown as median (line) and interquartile range (box) and 5th and 95th 
percentiles (whiskers). ** p<.01 compared with other groups. (Figure 4 from Study IV). 
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6.8 Mortality (I–IV) 
In Study I, the hospital mortality rate in the whole study population was 24.4% (375/1537). 
Patients admitted from the ED had a significantly lower hospital mortality rate than non-ED 
admitted patients (20.0% vs. 33.0%, p<.001). Patients who died in hospital were older 
(median 66 vs. 55 years, p<.001) and had higher disease severity scores than survivors 
(median APACHE score 27 vs. 19, p<.001 and median first-day SOFA score 10 vs. 7, 
p<.001). 
In Study III, the ICU, hospital, and one-year mortality rates were 13.3% (34/255), 26.3% 
(67/255), and 40.0% (102/255), respectively.   
In the patient population consisting of Studies II and IV, the hospital mortality rate was 19.7% 
(45/228) (II) and 19.5% (45/231) (IV). The hospital mortality for those 160 patients (of 231) 
with first-day plasma HO-1 was 21% (33/160), and the standardized hospital mortality ratio 
was 0.56.  
The SMRs of the studies are presented in Table 18. In all studies, the expected mortality was 
higher than the actual mortality according to SAPS II score. 
Table 18. Standardized mortality ratios of Studies I––IV. 
 N Standardized mortality ratio 
Study I N=1537 0.68 
Studies II and IV N=228/231 0.51 
Study III N=255 0.74 
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7 DISCUSSION 
Strengths and weaknesses of the study 
This study has several strengths. First, the evaluation of the association between delay in ED 
prior to intensive care admission was not associated with outcome of critically ill medical 
patients and was one of the largest studies focusing on this topic to date. Second, the 
applicability of cell-free plasma DNA in evaluating outcome and disease severity was 
investigated prospectively in two distinct sufficiently large multicenter patient populations: in 
both a mixed critically ill patient population as well as in ICU patients with severe sepsis or 
septic shock. In addition, the predictive value of plasma DNA in severe sepsis or septic shock 
was properly evaluated for the first time. Third, several polymorphisms as well as plasma 
concentrations of HO-1 were evaluated in a novel Finnish critically ill patient population.  
The study also has some limitations. First, in Study I, the length of ED stay was extracted 
retrospectively from the hospital routine database, and thus, may be slightly unreliable. 
Second, the ED interventions might have offered useful information about the process of care, 
but these were not recorded in Study I. Third, an inadequate 15D questionnaire response rate 
limited further interpretation of study results. 
Fourth, lacking knowledge of the origin, mechanisms of release, and kinetics of circulating 
cell-free DNA can be considered a limitation in Studies II and III. The mechanisms causing 
cellular damage and increased plasma DNA levels may occur in different tissues and by 
several mechanisms due to the heterogeneity of critical illness. However, there is increasing 
knowledge about the origin of circulating DNA. Almost all DNA found in plasma and serum 
of healthy individuals is apoptotic genomic DNA (Suzuki et al. 2008, Beck et al. 2009). The 
exact role of the liver and kidneys in elimination of plasma DNA is unclear. Nucleotides are 
predominantly metabolized in the liver in mice (Gauthier et al. 1996), and approximately 0.5-
2% of cell-free plasma DNA crosses the kidney barrier and is excreted in urine in human 
(Botezatu et al. 2000). No significant difference was found in pre-dialysis plasma DNA 
concentrations of hemodialysis patients with chronic renal insufficiency and individuals in the 
healthy control group (García Moreira et al. 2006). However, to our knowledge, no clinical 
study has yet evaluated the impact of the liver and renal failure on cell-free plasma DNA 
concentrations.  
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Fifth, the timing of the plasma DNA concentration as well as the plasma HO-1 concentration 
in Studies II–IV may consequently also be variable. Sixth, there are various methods for 
measuring circulating DNA, the most common being real-time PCR. Nucleosomal DNA can 
be measured by the ELISA method. Nucleosome ELISA has been reported to be highly 
comparable with the serum real-time PCR method and to a lesser extent with the plasma real-
time PCR method (Holdenrieder et al. 2005). Seventh, Studies II and III may also possess 
some methodological limitations. In addition to hemolysis, residual white blood cells or 
platelets in circulating plasma DNA measurements may provide a source of error. However, 
because high-speed centrifugation at 16 000 g after storage has been shown to completely 
eliminate cellular contamination in these assays (Swinkels et al. 2003), it seems unlikely that 
residual blood cells or platelets would provide a source of error in plasma DNA 
measurements. If the blood processing is delayed, EDTA is the recommended anticoagulant. 
Within 6 h of phlebotomy, the use of EDTA, heparin, or citrate as anticoagulant produces 
similar quantitative plasma DNA results (Lam et al. 2004). Because the blood samples were 
collected in heparin tubes in Study III, we cannot exclude that this pre-analytical factor had an 
effect on the results. Prolonged storage has also been demonstrated to decrease plasma DNA 
levels by approximately 30% per year (Sozzi et al. 2005). Several studies have shown that 
various factors related to blood sampling, processing, and storage may have effect on plasma 
DNA concentrations, and thus, standardized pre-analytical protocols are required in general as 
well as for better data comparability of different plasma DNA studies. 
Eighth, in Study III, seasonal variation in sepsis epidemiology and outcome cannot be 
excluded because of the 4-month study period and a slight seasonal variation in mortality 
rates (Reinikainen et al. 2006). In addition, only approximately half of the Finnsepsis study 
patients were included. These patients did not, however, differ from patients without consent 
for blood samples. Ninth, due to the nature of Study III, there was no standardized therapy.  
Tenth, in Study IV, it cannot be excluded that the investigated HO-1 polymorphisms could be 
in LD with another genetic marker associated to a greater extent with higher HO-1 induction 
and disease susceptibility. The heterogeneity of the study population may have influenced the 
interpretation of results. The lack of a control group for HO-1 polymorphisms is another 
limitation. 
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Finally, the role and origin of plasma HO-1 are unknown. Plasma HO-1 is suggested to 
represent “leakage” from tissues, which is supported by the finding that in pregnant women 
with pre-eclampsia the HO-1 gene and protein expression is increased in decidua basalis and 
serum HO-1 levels are elevated compared with healthy pregnant controls (Eide et al. 2008). 
Thus, the potential interplay between HO-1 polymorphisms and HO-1 plasma concentration is 
not yet clear and warrants further evaluation.  
Association of emergency department length of stay with mortality and health-related quality 
of life 
One of the purposes of Study I was to characterize the patient population for forthcoming 
studies investigating new biological markers. Only a few studies have evaluated the impact of 
ED length of stay on outcome in critically ill patients, and the results have not been uniform. 
Three studies found that the ED length of stay was not associated with patient outcome 
(Varon et al. 1994, Svenson et al. 1997, Nguyen et al. 2000), and one study found that staying 
in the ED longer than 24 hours did not affect outcome (Tilluckdarry et al. 2005). Interestingly, 
two studies noted that nonsurvivors had a significantly shorter ED length of stay than 
survivors (Jones et al. 2005, Richardson et al. 2009), whereas Duke and coauthors (2004) 
found that longer ED stay was an independent risk factor for hospital mortality. These studies 
differed fundamentally in their case-mix and sample size; the study of Duke et al. (2004) 
included 691 patients   over 7-fold that of Jones et al. (2005)   requiring mechanic ventilation 
or renal replacement therapy in the ED. The results of Study I support the findings of the 
majority, as the ED length of stay was not associated with hospital mortality. To our 
knowledge, Study I the second largest one on this topic, including over 1000 patients admitted 
to ICU from ED.  
The HRQoL at 6 months after intensive care was also evaluated, and the length of ED stay 
had no impact on it. In accordance with previous studies, the HRQoL of patients was 
significantly lower than in the age- and sex-matched general population. Although the 
difference was significant on all 15 dimensions of the 15D score, the values of single 
dimensions varied either markedly (e.g. usual activities) or just slightly (e.g. discomfort and 
symptoms) (Figure 5). These differences can be explained by the 15D score including several 
dimensions that are affected by individual experiences and subjective opinions. In addition, a 
patient group may find some of the 15D questions irrelevant for their well-being. 
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Interpretation of findings is often hindered by different case-mix, different hospital treatment 
protocols (are critically ill patients transferred directly to ICU as soon as the critical illness is 
observed or are investigations performed and treatments started in the ED), and different aims 
of the studies. Nowadays, ED crowding and a lack of an appropriate number of ICU beds may 
force patients to wait increasingly longer in the ED for ICU admission. It is vital to critically 
review the process of care in the ED because of the benefits of early treatment, such as early 
goal-directed therapy and early treatment with antibiotics, which reduce mortality in sepsis 
(Rivers et al. 2001, Nguyen et al. 2007). To highlight the importance of time, the newest 
prediction model, SAPS 3, takes into account the time spent in hospital before ICU admission 
(Moreno et al. 2005). 
   
Plasma DNA concentrations in critically ill patients
Investigating new predictive markers in critically ill patients is an unending process. Although 
cytokines, for instance, have been investigated extensively during the last decades, none of 
them has proven to be clinically useful as a prognostic tool. Common pathophysiological 
pathways, including inflammation and stress response, are activated early in critical illness, 
and potential new markers should represent such common phenomenona.  
Two novel markers, cell-free plasma DNA and HO-1, were investigated in Studies II  IV. 
Plasma DNA is thought to be released into circulation as a result of cell death, another 
common phenomenon in critical illness. Plasma DNA could reflect the degree of cellular 
injury of the body, therefore serving as a potential biomarker for critically ill patients. The 
study shows that the concentration of cell-free plasma DNA is increased in critically ill 
patients – in a mixed ICU population as well as in patients with severe sepsis or septic shock 
– even though the mechanisms of critical illness are divergent. In a mixed ICU population, the 
maximum DNA concentration during the first days of intensive care was an independent risk 
factor for hospital mortality, whereas in patients with severe sepsis or septic shock the 
baseline plasma DNA value was an independent risk factor for ICU mortality. The maximum 
value of a marker may not necessarily be as useful in clinical practice. 
In Study III, the degree of lactatemia correlated independently with the admission plasma 
DNA concentration. This may reflect the effect of septic shock-induced tissue hypoxia on 
apoptotic or necrotic cell death because apoptosis is induced by oxygen deprivation caused by 
hypoperfusion and tissue hypoxia in sepsis. The plasma DNA levels correlated with disease 
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severity and degree of organ failure in Studies II and III, and a significant correlation between 
plasma DNA and SOFA score was also found in previous studies (Wijeratne et al. 2004, 
Rhodes et al. 2006). This correlation could be explained by release of DNA from injured cells 
and tissues in organ failure. By contrast, cell-free plasma DNA itself may exacerbate tissue 
injury. According to a recent study, extracellular histones, around which DNA is packed, 
were cytotoxic to endothelium in vitro, their increased level was accompanied acute renal 
failure in baboons, and injection of histones into mice caused characteristics of sepsis (Xu et 
al. 2009). Moreover, the antibody to histone protected mice in different models of sepsis (Xu 
et al. 2009). It remains for future studies to investigate whether plasma DNA is a cause or 
consequence of organ failure.   
Because plasma DNA (and HO-1) may have different expression profiles and varying half-
lives during critical illness, investigating the concentrations in serial samples instead of single 
measurements could provide more information. 
Clinical importance of plasma DNA in outcome prediction in septic shock
In patients with severe sepsis or septic shock, cell-free plasma DNA concentrations were 
significantly higher in ICU and hospital nonsurvivors than in survivors at baseline or 72 hours 
later. The baseline plasma DNA concentration was an independent risk factor for ICU but not 
hospital mortality. The discriminative power of plasma DNA regarding mortality was, 
unfortunately, only moderate, limiting its clinical applicability. 
Two earlier studies evaluating the predictive value of plasma DNA in critically ill patients 
included much smaller patient populations than Studies II and III (Wijeratne et al. 2004, 
Rhodes et al. 2006). Both of these studies had promising results, with plasma DNA values 
being significantly higher in nonsurvivors than in survivors, one of the studies showing that 
plasma DNA was an independent predictor of ICU mortality, albeit with a low odds ratio of 
1.002 (Rhodes et al. 2006). Both studies also demostrated fairly good discriminative power 
for plasma DNA regarding mortality, one with an AUC of 0.889 for intensive treatment unit 
mortality (Wijeratne et al. 2004) and the other with an AUC of 0.79 for hospital mortality 
(Rhodes et al. 2006). The results from Studies II and III are in accordance with previous 
results, although the predictive value of plasma DNA was not as good in severe sepsis or 
septic shock. Rhodes et al. (2006) found that a subgroup of patients with severe sepsis or 
septic shock (n=19) had higher plasma DNA levels than other ICU study populations, but the 
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sample size was relatively small and the study was not designed to evaluate the performance 
or predictive power of plasma DNA in sepsis. In addition, the number of deaths was 
insufficient to evaluate the independent effect of plasma DNA on mortality.   
Comparing studies investigating new biological markers and their performance in outcome 
prediction in critical illness, none has demonstrated a clear usefulness in clinical practice. 
Indeed, only a few studies have possessed notably larger sample sizes than this Study. Jensen 
et al. (2006) showed with 472 patients that an increasing procalcitonin level in critically ill 
patients was independently associated with 90-day mortality. Meyer et al. (2007) found that 
NT-proBNP at ICU admission was an independent risk factor for hospital mortality, but the 
discriminative power of this factor remained only moderate. The difficulty seems to be in 
finding a marker that possesses good discriminative power and also has an independent effect 
on patient outcome.    
HO-1 polymorphisms and HO-1 plasma concentrations in critically ill patients 
In the Study IV patient population, the +99C allele was in complete LD with the long GT 
allele, a finding also reported by Gulesserian et al. (2005). Because neither the frequency nor 
the functionality of the +99G/C polymorphism has been investigated in other clinical studies, 
it remains for future research to determine which one of these two polymorphisms is of 
greater functional importance. A few studies have suggested a greater functional importance 
of the -413A/T polymorphism relative to the GTn repeat length polymorphism (Ono et al. 
2004, Buis et al. 2008), but according to the results of Study IV the -413T allele had only a 
minor effect on the third- to fourth-day HO-1 plasma concentration compared with AA 
homozygotes. A few studies have also reported LD between GTn polymorphism and -413A/T 
SNP (Buis et al. 2008, Sheu et al. 2009, Song et al. 2009); however, the GTn microsatellite 
polymorphism was analyzed for the first time so far together with both -413A/T and +99G/C 
SNPs in Study IV. The GTn repeat length has previously been divided into two or three 
categories, with the lowest L allele length varying from 26 to 33 repeats. This inconsistency 
in the classification of GTn alleles may have affected the interpretation of results and the 
functional importance of this polymorphism, even though the GTn distribution in Study IV is 
in agreement with earlier studies with Caucasian patient populations (Turpeinen et al. 2007). 
The carriers of the -413T/GT(L)/+99C haplotype had significantly lower concentrations of 
plasma HO-1, and this haplotype, as well as the SOFA score, had an independent effect on the 
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first-day plasma HO-1 levels. The carriers of the long GT allele, included in the  
-413T/GT(L)/+99C haplotype, also had less MOD – contrary to many studies finding the 
short GT to associate with a better outcome in many intensive care-related diseases. However, 
the long GT allele has recently been shown to protect also against ARDS (Sheu et al. 2009).  
Plasma HO-1 can be considered a surrogate marker of HO-1 expression, supported by earlier 
results that transcriptional activity and ability to enhance the expression of the HO-1 gene 
decreases with increasing numbers of GTn repeats (Hirai et al. 2003, Brydun et al. 2007, Song 
et al. 2009). There may also be a potential therapeutic window for HO-1 expression. Melley et 
al. (2007) have suggested an optimal range of HO-1 expression based on carboxyhemoglobin 
measurements in critically ill patients. Based on the results of Study IV, the  
-413T/GT(L)/+99C haplotype may thus prevent possible deleterious effects of HO-1 
overexpression and reaction products. Because the plasma HO-1 levels, the degree of organ 
failure, and the -413T/GT(L)/+99C haplotype were associated with each other, increased HO-
1 may also have detrimental effects such as the release of pro-oxidative free iron 
(Immenschuh et al. 2007). HO-1 expression can thus be used as a marker of oxidative stress 
among the critically ill; the increase of HO-1 is likely to represent a defensive response 
against acute illness and organ injury in order to repair the underlying injury. Accordingly, 
arterial blood CO, bilirubin levels, and monocyte HO-1 protein expression were recently 
shown to be higher in patients with severe sepsis or septic shock relative to nonseptic patients 
(Takaki et al. 2010), suggesting that the higher HO-1 plasma levels may simply reflect the 
magnitude of stress and potentially could be used as a marker of disease severity in critically 
ill patients.  
The HO-1 plasma concentration seems to be a marker of severe illness and altered physiology 
because the plasma HO-1 levels were significantly higher in critically ill patients than in 
controls and were associated significantly with disease severity, measured by APACHE II, 
SAPS II, and SOFA scores.  The results suggest that increased plasma HO-1 reflects the 
degree of organ or cell injury, a proposition supported by an earlier finding that pregnant 
women with pre-eclampsia have increased HO-1 mRNA and protein expression in decidua 
basalis as well as elevated serum HO-1 levels relative to healthy pregnant controls (Eide et al. 
2008). Plasma HO-1 level was particularly associated with renal and ventilation failure, which 
may reflect the magnitude of oxidative stress in lungs and kidneys, as HO-1 protects renal 
tubuli from oxidative injuries in renal diseases (Morimoto et al. 2001). Plasma HO-1 was 
associated also with bilirubin concentration, which is a degradation product of heme and 
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could therefore be considered an indirect measure of HO-1 activity, although impaired 
elimination of bilirubin increases its levels as well.  
The HO-1 polymorphism and plasma concentrations were not associated with mortality in the 
critically ill, which may be partly explained by the heterogeneity of the study population. In a 
recent single-center study, a common haplotype S-TAG (GTn, rs2071746, rs2071748, 
rs5755720) was associated with an increased risk of ARDS, and the L-AGA haplotype was 
associated with increased plasma HO-1 levels in a ARDS subpopulation (Sheu et al. 2009), 
contrary to the results of Study IV. 
In infectious diseases, such as sepsis, the causative pathogen is likely to affect the results of 
genetic association studies. According to a recent meta-analysis, MBL variant-genotypes and 
SNPs in genes encoding NF-B inhibitors and Toll interleukin-1 receptor domain-containing 
adaptor protein were associated with invasive pneumococcal disease, whereas homozygous 
IL-1ra +2081C carriers were associated with invasive meningococcal disease (Brouwer et al. 
2009). 
Ethnic differences in allele distributions complicate the interpretation of the results of genetic 
association studies. In response to this problem, Watanabe and co-workers (2010) showed that 
SNP in the first intron of the lymphotoxin- (+252) gene was significantly associated with 
severe sepsis susceptibility in 854 patients with severe sepsis; this study contained an 
equivalent number of age-, gender-, outcome-, and race-matched nonseptic ICU controls. 
Future perspectives and clinical implications  
In ED care, apart from the importance of the time frame, recording the ED procedures and 
treatments, recognizing and providing early treatment of critical illness, and setting targets 
and creating treatment protocols for critically ill ED patients are crucial. These steps would 
also make comparisons of results easier. To highlight the importance of time, the newest 
prediction model, SAPS 3, takes into account the time spent in hospital before ICU admission 
and only considers values near the admission to ICU (Moreno et al. 2005). 
To further elucidate the role of plasma DNA in cell death and critical illness, the circulating 
DNA of critically ill patients should be profiled by sequencing and the concentration 
compared with other markers of cell death such as cytokeratin-18 (Roth et al. 2004, Hofer et 
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al. 2009). It would be intriguing to investigate whether the association of plasma DNA with 
mortality and organ dysfunction is influenced by levels of extracellular histones and 
nonhistone DNA-binding protein HMGB-1. The effect of renal and liver function on plasma 
DNA concentrations should be assessed separately.  
Standardized pre-analytical protocols are required for better data comparability of different 
plasma DNA studies in the future. With the method used in Studies II and III, results are 
obtained within three hours. The turnaround time could be decreased to two hours by using 
novel fast real-time PCR systems, which would make the method more applicable for clinical 
settings.  
HO-1 is an intriguing factor for future studies, as all its metabolites are functional. For 
example, IL-10 has been shown to mediate its inflammatory actions through HO-1, a 
phenomenon known as therapeutic funnel (Chen et al. 2005). HO-1 may have a biphasic 
response profile; both low and high expression profiles can be deleterious. To clarify the role 
of HO-1 in critical illness and in multiple organ dysfunction, an ideal future study would 
include information of genetic variation in HO-1 gene, cell HO-1 protein expression, HO-1 
mRNA expression, HO-1 enzymatic activity, and plasma HO-1 levels. 
Future genetic association studies in critical care must investigate multiple polymorphisms of 
single or several genes in adequately powered representative patient populations in order to 
detect the most important genetic markers and favorable genotypes in, for example, balanced 
inflammatory/anti-inflammatory response in severe sepsis. These goals can best be reached in 
a timely manner by conducting prospective observational multicenter trials, avoiding the 
inadequate sample sizes and inherent biases of single-center studies (reviewed by Bellomo et 
al. 2009), and, meticulously reporting according to recommended guidelines. 
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8 CONCLUSIONS 
1. Emergency department length of stay is not associated with hospital mortality or health-
related quality of life six months after intensive care in medical critically ill patients. 
2. Cell-free plasma DNA concentrations are elevated in critically ill patients and are   
significantly higher in hospital nonsurvivors than in survivors.  
3. The baseline cell-free plasma DNA concentration is independently related to ICU 
mortality in patients with severe sepsis or septic shock, but the discriminative power for 
mortality is only moderate, limiting its clinical applicability. The degree of organ 
dysfunction is independently associated with the levels of the baseline cell-free plasma 
DNA; this factor may thus serve as a marker of the degree of tissue damage and organ 
dysfunction. 
4. Plasma HO-1 concentrations are significantly increased in critically ill patients and 
associate independently with organ dysfunction. Critically ill patients with the HO-1  
-413T/GT(L)/+99C haplotype may have lower plasma HO-1 concentrations and less 
frequent multiple organ dysfunction. Neither the genotype nor the HO-1 plasma 
concentration was associated with hospital mortality in the Finnish mixed critically ill 
patient population. 
 87  
9 ACKNOWLEDGMENTS 
My most sincere gratitude and respect are owed to my supervisors Professor Kari Pulkki and 
Docent Ville Pettilä. Your support, help, and encouragement have made this thesis possible. 
You always have had time for my questions. Professor Kari Pulkki, your patient guidance and 
support with details as well as with the big picture have been invaluable. Your knowledge and 
innovative ideas in laboratory medicine are admirable.  Docent Ville Pettilä, without your 
deadlines, goal-directed vision, knowledge in statistics and critical care medicine, and prompt 
answers whenever I needed help, this thesis would not have been completed. 
I thank the official reviewers, Professor Onni Niemelä and Docent Jyrki Tenhunen, for giving 
supportive comments and constructive criticisms on a tight time schedule. Your comments 
were very helpful and improved the dissertation immensely. 
My sincere gratitude is owed to Professor Pirkko Vihko for the opportunity to complete this 
dissertation at the Department of Clinical Chemistry. 
I am especially thankful to Docent Liisa-Maria Voipio-Pulkki who introduced me to this 
subject, to intensive care, and to medical research, which was an important step for my future 
career and a prerequisite for this dissertation. 
Docent Veli-Pekka Harjola, Docent Sinikka Pohjola-Sintonen, Professor Ulf-Håkan Stenman, 
and Professor Matti Vuoristo are greatly acknowledged for providing excellent facilities for 
my studies.  
I thank Maritta Putkiranta for expert technical assistance and enormous help with the 
management of laboratory samples. Jarkko Lakkisto is thanked for skillful technical 
assistance. Seija Leskinen, I thank for help with the blood samples at Jorvi Hospital. Mervi 
Laaksonen is thanked for secretary assistance. 
My sincere gratitude is owed to the personnel of Meilahti Intensive Care Units 22 and 23 and 
the Jorvi Intensive Care Unit for invaluable collaboration, which made this study possible. I 
thank especially Marko Kivioja, Taina Nieminen, Maiju Salovaara-Hiltunen, Sari Sutinen, 
 88  
and Mirja Vauramo. All of the investigators and study nurses participating in the Finnsepsis 
study are warmly thanked for their contributions.  
I thank all of my coauthors for their contributions to the studies. Päivi Lakkisto, MD, is 
particularly thanked for her expertise in laboratory medicine and her patience during 
numerous manuscript editing sessions. I wish you all the best with your own dissertation. I 
thank Marjut Varpula, PhD, for your essential contribution to this thesis and encouraging 
example. I am also grateful to Sari Karlsson, PhD, Mari Kaunisto, PhD, Docent Risto P. 
Roine, Docent Esko Ruokonen, Pirjo Räsänen, PhD, and Tero Varpula, PhD, for their efforts 
and insightful comments.  
Arto Orpana, PhD, Professor Aarno Palotie, Professor Harri Sintonen, and Docent Minna 
Tallgren are acknowledged for valuable help and advice.  
I thank my colleagues at Peijas Hospital for excellent company and collaboration.  
I am grateful to my friends and relatives for joyful moments and for reminding me that life 
outside of work exists. Johanna, I thank you for our therapeutic weekly jogging sessions. 
Sirkka, your wonderful book gave me strength when I needed it. I thank my mother Riitta and 
father Seppo for loving, trusting, and supporting me in all aspects of my life. My brother 
Kapo, I thank for unfailing friendship and understanding. My heartfelt thanks are owed to my 
beloved Kari. I am so grateful to have you beside me. You are the love of my life.     
Financial support from the Helsinki University Central Hospital EVO grants, the 
Instrumentarium Foundation, and Duodecim is gratefully acknowledged.  
Helsinki, April 2010 
Katri Saukkonen 
 89  
10 REFERENCES 
Adamzik M, Frey UH, Rieman K, Sixt S, Beiderlinden M, Siffert W, Peters J. Insertion/deletion polymorphism 
in the promoter of NFKB1 influences severity but not mortality of acute respiratory distress syndrome. Intensive 
Care Med 2007 a; 33: 1199–1203. 
Adamzik M, Frey UH, Sixt S, Knemeyer L, Beiderlinden M, Peters J, Siffert W. ACE I/D but not AGT (-6)A/G 
polymorphism is a risk factor for mortality in ARDS. Eur Respir J 2007 b; 29: 482–488. 
Adib-Conquy M, Adrie C, Moine P, Asehnoune K, Fitting C, Pinsky M, Dhainaut JF, Cavaillon JM. NF-kB 
expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. 
Am J Respir Crit Care Med 2000; 162: 1877–1883. 
Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, Lowry SF. Human Toll-like receptor 4 
mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Inf 
Dis 2002; 186: 1522–1525. 
Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, 
Boulme R, Lepage E, Le Gall R. Epidemiology of sepsis and infection in ICU patients from an international 
multicentre cohort study. Intensive Care Med 2002; 28: 108–121. 
Angus DC, Carlet J, 2002 Brussels Roundtable Participants. Surviving intensive care: A report from the 2002 
brussels roundtable. Intensive Care Med 2003; 29: 368–377. 
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in 
the united states: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303–
1310. 
Angus DC, Yang LH, Kong L, Kellum JA, Delude RL, Tracey KJ, Weissfeld L, for the GenIMS Investigators. 
Circulating high-mobility group box-1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia 
and pneumonia with severe sepsis. Crit Care Med 2007; 35: 1061–1067. 
Arcaroli J, Silva E, Maloney JP, He Q, Svetkauskaite D, Murphy JR, Abraham E. Variant IRAK-1 haplotype is 
associated with increased nuclear factor–B activation and worse outcomes in sepsis. Am J Respir Crit Care 
Med 2006; 173: 1335–1341. 
Arnalich F, Garcia-Palomero E, Lopez J. Predictive value of nuclear factor-B activity and plasma cytokine 
levels in patients with sepsis. Inf Imm 2000; 68: 1942–1945. 
Arnalich F, Lopez-Maderuelo D, Codoceo R, Lopez J, Solis-Garrido LM, Capiscoli C, Fernandez-Capitán C, 
Madero R, Moniel C. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe 
sepsis. Clin Exp Immunol 2002; 127: 331–336. 
Aromaa A, Koskinen S. Health and functional capacity in Finland. Baseline results of the Health 2000 health 
examination survey. Publ Natl Public Health Inst 2004; Series B12/2004. 
Atamaniuk J, Ruzicka K, Stuhlmeier KM, Karimi A, Eigner M, Mueller MM. Cell-free plasma DNA: A marker 
for apoptosis during hemodialysis. Clin Chem 2006; 52: 523–526. 
Atamaniuk J, Stuhlmeier KM, Vidotto C, Tschan H, Dossenbach-Glaninger A, Mueller MM. Effects of ultra-
marathon on circulating DNA and mRNA expression of pro- and anti-apoptotic genes in mononuclear cells. Eur 
J Appl Physiol 2008; 104: 711–717. 
Badia X, Diaz-Prieto A, Gorriz MT, Herdman M, Torrado H, Farrero E, Cavanilles JM. Using the EuroQol-5D 
to measure changes in quality of life 12 months after discharge from an intensive care unit. Intensive Care Med 
2001; 27: 1901–1907. 
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of ld and haplotype maps. 
Bioinformatics 2005; 21: 263–265. 
 90  
Beck DH, Smith GB, Pappachan JV, Millar B. External validation of the SAPS II, APACHE II and APACHE III 
prognostic models in South England: a multicentre study. Intensive Care Med 2003; 29: 249–256.  
Beck J, Urnovitz HB, Riggert J, Clerici M, Schütz E. Profile of the circulating DNA in apparently healthy 
individuals. Clin Chem 2009; 55: 730–738. 
Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med 2009; 37: 
3114–3119. 
Bone RC, McElwee NE, Eubanks DH, Gluck EH. Analysis of indications for intensive care unit admission. 
Clinical efficacy assessment project: American college of physicians. Chest 1993; 104: 1806–1811.  
Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananév V, Bazin I, Garin A, 
Narimanov M, Knysh V, Melkonyan H, Umansky S, Lichtenstein A. Genetic analysis of DNA excreted in urine: 
A new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 
2000; 46: 1078–1084. 
Bowers DJ, Calvano JE, Alvarez SM, Coyle SM, Macor MA, Kumar A, Calvano SE, Lowry SF. Polymorphisms 
of heat shock protein-70 (HSPA1B and HSPA1L loci) do not influence infection or outcome risk in critically ill 
surgical patients. Shock 2006; 25: 117–122. 
Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza 
PT. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007; 11: R49. 
Brooks R. with the EuroQol Group. EuroQoL: the current state of play. Health Policy 1996; 37: 53–72. 
Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AMK, Soares M. Carbon monoxide generated 
by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 2000; 192: 1015–1025.  
Brouwer MC, de Gans J, Heckenberg SGB, Zwinderman AH, van der Poll T, van de Beek D. Host genetic 
susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect 
Dis 2009; 9: 31–44.  
Brunialti MKC, Martins PS, de Carvalho LB, Machado FR, Barbosa LM, Salomao R. TLR2, TLR4, CD14, 
CD11B, and CD11C expressions on monocytes surface and cytokine production in patients with sepsis, severe 
sepsis and septic shock. Shock 2006; 25: 351–357. 
Brydun A, Watari Y, Yamamoto Y, Okuhara K, Teragawa H, Kono F, Chayama K, Oshima T, Ozono R. 
Reduced expression of heme oxygenase-1 in patients with coronary atherosclerosis. Hypertens Res 2007; 30: 
341–348. 
Buis CI, van der Steege G, Visser DS, Nolte IM, Hepkema BG, Nijsten M, Slooff MJH, Porte RJ. Heme 
oxygenase-1 genotype of the donor is associated with graft survival after liver transplantation. Am J Transplant 
2008; 8: 377–385. 
Capuzzo M, Valpondi V, Sgarbi A, Bortolazzi S, Pavoni V, Gilli G, Candini G, Gritti G, Alvisi R. Validation of 
severity scoring systems SAPS II and APACHE II in a single-center population. Intensive Care Med 2000; 26: 
1779–1785.  
Carr BG, Kaye AJ, Wiebe DJ, Gracias VH, Schwab CW, Reilly PM. Emergency department length of stay: a 
major risk factor for pneumonia in intubated blunt trauma patients. J Trauma 2007; 63: 9–12. 
Carraway MS, Ghio AJ, Taylor JL, Piantadosi CA. Induction of ferritin and heme oxygenase-1 by endotoxin in 
the lung. Am J Physiol Lung Cell Mol Physiol 1998; 275: 583–592. 
Chalfin DB, Trzeciak S, Likourezos A, Baumann BM, Dellinger RP, DELAY-ED study group. Impact of 
delayed transfer of critically ill patients from the emergency department to the intensive care unit. Crit Care Med 
2007; 35: 1477–1483.  
Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT. Elevated cell-free serum DNA detected in patients with 
 91  
myocardial infarction. Clinica Chimica Acta 2003; 327: 95–101. 
Chen LW, Egan L, Li ZW, Greneti FR, Kagnoff MF, Karini M. The two faces of IKK and NF-B inhibition: 
prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nature 
Med 2003; 9: 575–581. 
Chen QX, Wu SJ, Wang HH, Lv C, Cheng BL, Xie GH, Fang XM. Protein C -1641A/-1654C haplotype is 
associated with organ dysfunction and the fatal outcome of severe sepsis in Chinese Han population. Hum Genet 
2008; 123: 281–287. 
Chen S, Kapturczak MH, Wasserfall S, Glushakova OY, Campbell-Thompson M, Deshane JS, Joseph R, Cruz 
PE, Hauswirth WW, Madsen KM, Croker BP, Berns JS, Atkinson MA, Flotte TR, Tisher CC, Agarwal A. 
Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-
dependent pathway. Proc Natl Acad Sci USA 2005; 102: 7251–7256. 
Chen YH, Chau LY, Lin MW, Chen LC, Yo MH, Chen JW, Lin SJ. Heme oxygenase-1 gene promotor 
microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J 
2004; 25: 39–47. 
Chen YH, Lin SJ, Lin MW, Tsai HL, Kuo SS, Chen JW, Charng MJ, Wu TC, Chen LC, Ding PYA, Pan WH, 
Jou YS, Chau LY. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with 
susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002; 111: 1–8. 
Chiu TW, Young R, Chan LYS, Burd A, Lo DYM. Plasma cell-free DNA as an indicator of severity of injury in 
burn patients. Clin Chem Lab Med 2006; 44: 13–17. 
Chu EK, Ribeiro SP, Slutsky AS. Heat stress increases survival rates in lipopolysaccharide-stimulated rats. Crit 
Care Med 1997; 25: 1727–1732. 
Chung SW, Liu X, Macias AA, Baron RM, Perrella MA. Heme oxygenase-1–derived carbon monoxide 
enhances the host defense response to microbial sepsis in mice. J Clin Invest 2008; 118: 239–247. 
Clark MF, Baudouin SV. A systematic review of the quality of genetic association studies in human sepsis. 
Intensive Care Med 2006; 32: 1706–1712. 
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41. 
Cuthbertson BH, Roughton S, Jenkinson D, MacLennan G, Vale L. Quality of life in the five years after 
intensive care: a cohort study. Crit Care 2010; 14: R6. 
Dahaba AA, Hagara B, Fall A, Rehak PH, List WF, Metzler H. Procalcitonin for early prediction of survival 
outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006; 97: 503–508. 
D’Avila LC, Albarus MH, Franco CR, Agular BB, Oliveira JR, Dias FS, Alho CS. Effect of CD14 -260C>T 
polymorphism on the mortality of critically ill patients. Immun Cell Biol 2006; 84: 342–348. 
Dowdy GDW, Eid MP, Sedrakyan A, Mendez-Tellez PA, Pronovost PJ, Herridge MS, Needham DM. Quality of 
life in adult survivors of critical illness: a systematic review of the literature. Intensive Care Med 2005; 31: 611–
620. 
Duke G, Green J, Briedis J. Survival of critically ill medical patients is time-critical. Crit Care Resusc 2004; 6: 
261–267. 
Eide IP, Isaksen CV, Salvesen KA, Langaas M, Schonberg SA, Austgulen R. Decidual expression and maternal 
serum levels of heme oxygenase 1 are increased in pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 272–
279. 
Eyssen-Hernandez R, Ladoux A, Frelin C. Differential regulation of cardiac heme oxygenase-1 and vascular 
endothelial growth factor mRNA expressions by hemin, heavy metals, heat shock and anoxia. FEBS Lett 1996; 
382: 229–233. 
 92  
Farkas I, Maroti Z, Katona M, Endreffy E, Monostori P, Máder K, Túri S. Increased heme oxygenase-1 
expression in premature infants with respiratory distress syndrome. Eur J Pediatr 2008; 167: 1379–1383. 
Fournie GJ, Courtin JP, Laval F, Chale JJ, Pourrat JP, Pujazon M-C, Lauque D, Carles P. Plasma DNA as a 
marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing 
human tumours. Cancer Lett 1995; 91: 221–227. 
Fournie GJ, Martres F, Pourrat JP, Alary C, Rumeau M. Plasma DNA as cell death marker in elderly patients. 
Gerontology 1993; 39: 215–221. 
Freitas ID, Fernandez-Somoza M, Essenfeld-Sekler E, Cardier JE. Serum levels of the apoptosis-associated 
molecules, tumor necrosis factor-/tumor necrosis factor type-I receptor and Fas/FasL, in Sepsis. Chest 2004; 
125: 2238–2246. 
Fromm RE Jr, Gibbs LR, McCallum WG, Niziol C, Babcock JC, Gueler AC, Levine RL. Critical care in the 
emergency department: a time-based study. Crit Care Med 1993; 21: 970–976. 
Garred P, J Strøm J, Quist L, Taaning E, Madsen HO. Association of mannose-binding lectin polymorphisms 
with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 2003; 
188: 1394–1403. 
García Moreira V, de la Cera Martı´nez T, Gonzalez EG, Garcıa BP, FVA Menendez. Increase in and clearance 
of cell-free plasma DNA in hemodialysis quantified by real-time PCR. Clin Chem Lab Med 2006; 44: 1410–
1415. 
García-Segarra G, Espinosa G, Tassies D, Oriola J, Aibar J, Bové A, Castro P, Reverter JC, Nicolás JM. 
Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of 
white descent. Intensive Care Med 2007; 33: 1354–1362. 
Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jiménez R, Barroso S, Ortiz-Leyba C. 
Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 
polymorphisms in patients with sepsis. Crit Care 2006; 10: R111.  
Gauthier VJ, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice. J 
Immunol 1996; 156: 1151–1156. 
Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism within the 
CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30: 969 –973. 
Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with 
severe sepsis: A marker for prognosis and future therapeutic options. J Inf Dis 2000; 181: 176–180. 
Goldhill DR, McNarry AF, Hadjianastassiou VG. The longer the patients are in hospital before intensive care 
unit admission the higher their mortality. Intensive Care Med 2004; 30: 1908–1913. 
Goldhill DR, White SA, Sumner A. Physiological values and procedures in the 24 h before ICU admission from 
the ward. Anaesthesia 1999; 54: 529–534. 
Gong MN, Thompson BP, Williams PL, Zhou W, Wang MZ, Pothier L, Christiani DC. Interleukin-10 
polymorphism in position -1082 and acute respiratory distress syndrome. Eur Respir J 2006; 27: 674–681. 
Gong MN, Zhou W, Williams PL, Thompson BP, Pothier L, Christiani DC. Polymorphisms in the mannose 
binding lectin-2 gene and acute respiratory distress syndrome. Crit Care Med 2007; 35: 48–56. 
Gordon AC, Lagan AL, Aganna E, Cheung L, Peters CJ, McDermott MF, Millo JL, Welsh KI, Holloway P, 
Hitman GA, Piper RD, Garrard CS, Hinds CJ. TNF and TNFR polymorphisms in severe sepsis and septic shock: 
a prospective multicentre study. Genes Imm 2004; 5: 631–640. 
Gordon AC, Waheed U, Hansen TK, Hitman GA, Garrard SC, Turner MW, Klein NJ,  Brett SJ, Hinds CJ. Mannose-
binding lectin polymorphisms in severe sepsis: relationship to levels, incidence, and outcome. Shock 2006; 25: 88–93. 
 93  
Graf J, Koch M, Dujardin R, Kersten A, Janssens U. Health-related quality of life before, 1 month after, and 9 
months after intensive care in medical cardiovascular and pulmonary patients. Crit Care Med 2003; 31: 2163–
2169.  
Gulesserian T, Wenzel C, Endler G, Sunder-Plassmann R, Marsik C, Mannhalter C, Iordanova N, Gyöngyösi M, 
Wojta J, Mustafa S, Wagner O, Huber K. Clinical restenosis after coronary stent implantation is associated with 
the heme oxygenase-1 gene promoter polymorphism and the heme oxygenase-1 +99G/C variant. Clin Chem 
2005; 51: 1661–1665. 
Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. 
Radiology 1982; 143: 29–36. 
Harding D, Baines PB, Brull D, Vassiliou V, Ellis I, Hart A, Thomson AP, Humphries SE, Montgomery HE. 
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion 
polymorphism. Am J Respir Crit Care Med 2002; 165: 1103–1106. 
Harrison DA, Brady AR, Parry GJ, Carpenter JR, Rowan K. Recalibration of risk prediction models in a large 
multicenter cohort of admissions to adult, general critical care units in the United Kingdom. Crit Care Med 2006; 
34: 1378–1388.  
Hashiguchi N, Ogura H, Tanaka H, Koh T, Nakamori Y, Noborio M, Shiozaki T, Nishino M, Kuwagata Y, 
Shimazu T, Sugimoto H. Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes 
in patients with sepsis. J Trauma 2001; 51: 1104–1109. 
Hawthorne G, Richardson H, Day NA. A comparison of the assessment of quality of life (AQoL) with four other 
generic utility instruments. Ann Med 2001; 33: 358–370.  
Hellemann D, Larsson A, Madsen HO, Bonde J, Jarløv JO, Wiis J, Faber T, Wetterslev J, Garred P. 
Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal 
outcome in intensive care patients. Hum Mol Genet 2007; 16: 3071–3080. 
Heper Y, Akalın EH, Mıstık R, Akgöz S, Töre O, Göral G, Oral B, Budak F, Helvaci S. Evaluation of serum C-
reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and 
prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock. Eur J Clin 
Microbiol Infect Dis 2006; 25: 481–491. 
Hirai H, Kubo H, Yamaya M, Nakayama K, Numasaki M, Kobayashi S, Suzuki S, Shibahara S, Sasaki H. 
Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-
induced apoptosis in lymphoblastoid cell lines. Blood 2003; 102: 1619–1624. 
Hofer S, Brenner T, Bopp C, Steppan J, Lichtenstern C, Weitz J, Bruckner T, Martin E, Hoffmann U, Weigand 
M. Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic 
dysfunction. Crit Care 2009; 13: R93. 
Hofhuis JGM, Spronk PE, van Stel HF, Schrijvers GJP, Rommes JH, Bakker J. The impact of critical illness on 
perceived health-related quality of life during ICU treatment, hospital stay, and after hospital discharge. A long-
term follow-up study. Chest 2008; 133: 377–385. 
Holdenrieder S, Stieber P, Chan LYS, Geiger S, Kremer A, Nagel D, Lo YMD. Cell-free DNA in serum and 
plasma: comparisons of ELISA and quantitative PCR. Clin Chem 2005; 2005; 51: 1544–1546. 
Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE. Accelerated lymphocyte death in 
sepsis occurs by both the death receptor and mitochondrial pathway. J Immunol 2005; 174: 5110–5118. 
Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE. 
Apoptotic cell death in patients with sepsis, shock, or multiple organ dysfunction. Critical Care Med 1999; 27: 
1230–1251. 
Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH. Depletion of dendritic cells, but not macrophages, in 
patients with sepsis. J Immunol 2002; 168: 2493–2500. 
 94  
Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE, Hui JJH, Chang KC, Osborne DF, Freeman BD, Cobb 
JP, Buchman TG, Karl IE. Sepsis-induced apoptosis causes progressive profound depletion of B and CD41 T 
lymphocytes in humans. J Immunol 2001; 166: 6952–6963. 
Hynninen M, Pettila V, Takkunen O, Orko R, Jansson SE, Kuusela P, Renkonen R, Valtonen M. Predictive 
value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels 
in critically ill patients with sepsis. Shock 2003; 20: 1–4. 
Immenschuh S, Shan Y, Kroll H, Santoso S, Wössmann W, Bein G, Bonkovsky HL. Marked hyperbilirubinemia 
associated with the heme oxygenase-1 gene promoter microsatellite polymorphism in a boy with autoimmune 
hemolytic anemia. Pediatrics 2007; 119: 764–767. 
Iribarren-Diarasarri S, Aizpuru-Barandiaran F, Muñoz-Martínez T, Loma-Osorio Á, Hernández-López M, Ruiz-
Zorrilla JM, Castillo-Arenal C, Dudagoitia-Otaolea JL, Martínez-Alutiz S, Vinuesa-Lozano C. Health-related 
quality of life as a prognostic factor of survival in critically ill patients. Intensive Care Med 2009; 35: 833–839. 
Jahr S, Hentze H, English S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood 
plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer 
Res 2001; 61: 1659–1665. 
Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early 
identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596–2602. 
Jerng JS, Yu CJ, Wang HC, Chen KY, Cheng SL, Yang PC. Polymorphism of the angiotensin-converting 
enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med 2006; 34: 1001-1006. 
Jessen KM, Lindboe SB, Petersen AL, Eugen-Olsen J, Benfield T. Common TNF-, IL-1, PAI-1, uPA, CD14 
and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. BMC 
Infect Dis 2007; 7: 108. 
Jiang N, Pisetsky DS: The effect of inflammation on the generation of plasma DNA from dead and dying cells in 
the peritoneum. J Leukoc Biol 2005; 77: 1-7. 
Jones AE, Fitch MT, Kline JA. Operational performance of validated physiologic scoring systems for predicting 
in-hospital mortality among critically ill emergency department patients. Crit Care Med 2005; 33: 974–978. 
Kaarlola A, Pettilä V, Kekki P. Quality of life six years after intensive care. Intensive Care Med 2003; 29: 1294–
1299.  
Kaarlola A, Pettilä V, Kekki P. Performance of two measures of general health-related quality of life, the EQ-5D 
and the RAND-36 among critically ill patients. Intensive Care Med 2004; 30: 2245–2252.  
Kadl A, Pontiller J, Exner M, Leitinger N. Single bolus injection of bilirubin improves the clinical outcome in a 
mouse model of endotoxemia. Shock 2007; 28: 582–588. 
Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests –
GraphROC for Windows. Scand J Clin Lab Invest 1995; 55: 43–60. 
Kaneda H, Ohno M, Taguchi J, Togo M, Hashimoto H, Ogasawara K, Aizawa T, Ishizaka N, Nagai R. Heme 
oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with 
coronary risk factors. Artrioscler Thromb Vasc Biol 2002; 22: 1680–1685. 
Karlsson S, Pettilä V, Tenhunen J, Laru-Sompa R, Hynninen M, Ruokonen E for the Finnsepsis Study Group. 
HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 
2008; 34: 1046–1053. 
Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettilä V for the Finnsepsis Study Group. Long-term  
outcome and quality-adjusted life years after severe sepsis. Crit Care Med 2009; 37: 1268–1274. 
Karlsson S, Varpula M, Ruokonen E, Pettilä V, Parviainen I, Ala-Kokko TI, Kolho E, Rintala EM for the 
 95  
Finnsepsis Study Group. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the 
Finnsepsis study. Intensive Care Med 2007; 33: 435–443. 
Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude R, Angus 
DC for the GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: 
Results of the genetic and inflammatory markers of sepsis (GenIMS) study. Arch Int Med 2007; 167: 1655–
1663.  
Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, Frodsham AJ, Walley AJ, Kyrieleis O, 
Khan A, Aucan C, Sega S, Moore CE, Knox K, Campbell SJ, Lienhardt C, Scott A, Aaby P, Sow OY, Grignani 
RT, Sillah J, Sirugo G, Peshu N, Williams TN, Maitland K, Davies RJO, Kwiatkowski DP, Day NP, Yala D, 
Crook DW,  Marsh K, Berkley JA, O’NeillLAJ, Hill AVS. A Mal functional variant is associated with protection 
against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nature Gen 2007; 39: 523–528. 
Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut 
JF. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, 
regardless of causative micro-organism. Crit Care 2004; 8: R82. 
Kirino Y, Takeno M, Iwasaki M, Ueda A, Ohmo S, Shirai A, Kanamori H, Tanaka K, Ishigatsubo Y. Increased 
serum HO-1 in hemophagocytic syndrome and adult-onset Still’s disease: use in the differential diagnosis of 
hyperferritinemia. Arthritis Res Ther 2005; 7: R616–R624. 
Knaus WA, Drapper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. 
Crit Care Med 1985; 13: 818–829. 
Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, Murphy DJ, Lotring T, 
Damiano A, Harrell FE. The APACHE III prognostic system. Risk prediction of hospital mortality for critically 
ill hospitalized adults. Chest 1991; 100: 1619–1636. 
Kornblit B, Munthe-Fog L, Madsen HO, Strøm J, Vindeløv L, Garred P. Association of HMGB1 polymorphism 
with outcome in patients with systemic inflammatory response syndrome. Crit Care 2008; 12: R83. 
Kotanidou A, Karsaliakos P, Tzanela M, Mavrou I, Kopterides P, Papadomichelakis E, Theodorakopoulou M, 
Botoula E, Tsangaris I, Lignos M, Ikonomidis I, Ilias I, Armaganidis A, Orfanos SE, Dimopoulou I. Prognostic 
importance of increased plasma amino-terminal pro-brain natriuretic peptide levels in a large noncardiac, general 
intensive care unit population. Shock 2009; 31: 342–347. 
Kronborg G, Weis N, Madsen HO, Pedersen SS, Wejse C, Nielsen H, Skinhøj P, Garred P. Variant mannose-
binding lectin alleles are not associated with susceptibility to or outcome of invasive pneumococcal infection in 
randomly included patients. J Infect Dis 2002; 185: 1517–1520. 
Lam NYL, Rainer TH, Chan LYS, Joynt GM, Lo YMD. Time course of early and late changes in plasma DNA 
in trauma patients. Clin Chem 2003; 49: 1286–1291. 
Lam NYL, Rainer TH, Chiu RWK, Lo YMD. EDTA is a better anticoagulant than heparin or citrate for delayed 
blood processing for plasma DNA analysis. Clin Chem 2004; 50: 256–257. 
Lam NYL, Rainer TH, Wong LKS, Lam W, Lo YMD. Plasma DNA as a prognostic marker for stroke patients 
with negative neuroimaging within the first 24 h of symptom onset. Resuscitation 2006; 68: 71–78. 
Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a 
European/North American multicenter study. JAMA 1993; 270: 2957–2963. 
Le Gall JR, Loirat P, Alperovitch A, Glaser P, Granthil C, Mathieu D, Mercier P, Thomas R, Villers D. A 
simplified acute physiology score for ICU patients. Crit Care Med 1984; 12: 975–977. 
Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Tattevin P, Thomas R, Fauchet R, Drénou 
B. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002; 
18: 487–494. 
 96  
Lee CC, Chen SY, Tsai CL, Wu SC, Chiang WC, Wang JL, Sun HY, Chen SC, Chen WJ, Hsueh PR. Prognostic 
value of mortality in emergency department sepsis score, procalcitonin, and c-reactive protein in patients with 
sepsis at the emergency department. Shock 2008; 29: 322–327. 
Lemeshow S, Klar J, Teres D. Outcome prediction for individual intensive care patients: useful, misused, or 
abused? Intensive Care Med 1995; 21:770–776. 
Lin Q, Weis S, Yang G, Weng YH, Helston R, Rish K, Smith A, Bordner J, Polte T, Gaunitz F, Dennery PA. 
Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative 
stress. J Biol Chem 2007; 282: 20621–20633. 
Lo YMD, Rainer TH, Chan LYS, Hjelm NM, Cooks RA. Plasma DNA as a prognostic marker in trauma 
patients. Clinical Chemistry 2000; 46: 319–323. 
Lo YMD, Tein MSC, Lau TK, Haines CJ, Leung TN, Poon PMK, Wainscoat JS, Johnson PJ, Chang AM, Hjelm 
NM. Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal 
diagnosis. Am J Hum Genet 1998; 62: 768–775. 
Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-
negative septic shock. Arch Intern Med 2002; 162: 1028–1032. 
Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-
10 expression and survival in critically ill patients. Crit Care Med 2003; 31: 34–38. 
Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YMD: Predominant hematopoietic origin of cell-free DNA 
in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002; 48: 421–427. 
Lui YY, Woo KS, Wang AY, Yeung CK, Li PKT, Chau E, Ruygrok P, Lo YMD. Origin of plasma cell-free 
DNA after solid organ transplantation. Clin Chem 2003; 49: 495–496. 
Ma P, Chen D, Pan J, Du B. Genomic polymorphism within interleukin-1 family cytokines influences the 
outcome of septic patients. Crit Care Med 2002; 30: 1046–1050. 
Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McAnulty RJ, Humphries SE, Hill MR, 
Laurent GJ. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility 
and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 66: 646–650. 
Martins GA, Kawamura MT, Da Costa Carvalho MDG. Detecting of DNA in the plasma of septic patients. Ann 
NY Acad Sci 2000; 906: 134–140. 
Mayr VD, Dünser MW, GreilV, Jochberger S, Luckner G, Ulmer H, Friesenecker BE, Takala J, Hasibeder WR. 
Causes of death and determinants of outcome in critically ill patients. Crit Care 2006; 10: R154. 
Medzhitov R, Preston-Hurlburt P, Janeway Jr CA. A human homologue of the Drosophila Toll protein signals 
activation of adaptive immunity. Nature 1997; 388: 394–397. 
Melley DD, Finney SJ, Elia A, Lagan AL, Quinlan GJ, Evans TW. Arterial carboxyhemoglobin level and 
outcome in critically ill patients. Crit Care Med 2007; 35: 1882–1887. 
Menges T, Hermans PW, Little SG, Langefeld T, Böning O, Engel J, Sluijter M, de Groot R, Hempelmann G. 
Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. 
Lancet 2001; 357: 1096–1097. 
Menges T, König IR, Hossain H, Little S, Tchatalbachev S, Thierer F, Hackstein H, Franjkovic I, Colaris T, 
Martens F, Weismüller K, Langefeld T, Stricker J, Hempelmann G, Vos PE, Ziegler A, Jacobs B, Chakraborty 
T, Bein G. Sepsis syndrome and death in trauma patients are associated with variation in the gene encoding 
tumor necrosis factor. Crit Care Med 2008; 36: 1456–1462. 
Metnitz PGH, Moreno RP, Almeida E, Jordan B, Bauer P, Campos RA, Iapichino G, Edbrooke D, Capuzzo M, 
Le Gall JR on behalf of the SAPS 3 investigators. SAPS 3 -From evaluation of the patient to evaluation of the 
 97  
intensive care unit. Part 1: Objectives, methods and cohort description. Intensive Care Med 2005; 31: 1336–
1344. 
Meyer B, Huelsmann M, Wexberg P, Karth KD. N-terminal pro-B-type natriuretic peptide is an independent 
predictor of outcome in an unselected cohort of critically ill patients. Crit Care Med 2007; 35: 2268–2273. 
Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A 
systematic review. Crit Care 2008; 12: R161. 
Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M,  Teboul JL, Riché F, 
Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JF. Association of TNF2, a TNF- promoter 
polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999; 282: 561–568. 
Mohri T, Ogura H, Koh T, Fujita K, Sumi Y, Yoshiya K, Mtasushima A, Hosotsubo H, Kuwagata Y, Tanaka H, 
Shimazu T, Sugimoto H. Enhanced expression of intracellular heme oxygenase-1 in deactivated monocytes from 
patients with severe systemic inflammation response syndrome. J Trauma 2006; 61: 616–623. 
Moreno R, Metnitz PGH, Almeida E, Jordan B, Bauer P, Campos RA, Iapichino G, Edbrooke D, Capuzzo M, Le 
Gall JR on behalf of the SAPS 3 investigators. SAPS 3- From evaluation of the patient to evaluation of the 
intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive 
Care Med 2005; 31: 1345–1355. 
Moreno R, Morais P. Outcome prediction in intensive care: results of a prospective, multicentre, Portuguese 
study. Intensive Care Med 1997; 23: 177–186. 
Moreno R, Vincent JL, Matos R, Mendonça A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Bruining 
H, Willatts S. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results 
of a prospective multicentre study. On behalf of the Working Group on Sepsis-Related Problems of the 
European Society of Intensive Care Medicine. Intensive Care Med 1999; 25: 686–696. 
Morimatsu H, Takahashi T, Maeshima K, Inoue K, Kawakami T, Shimizu H, Takeuchi M, Yokoyama M, 
Katayama H, Morita K. Increased heme catabolism in critically ill patients: correlation among exhaled carbon 
monoxide, arterial carboxyhemoglobin, and serum bilirubin IX concentrations. Am J Physiol Lung Cell Mol 
Physiol 2006; 290: 114–119. 
Morimoto K, Ohta K, Yachie A, Yang Y, Shimizu M, Goto C, Toma T, Kasahara Y, Yokoyama H, Miyata T, 
Seki H, Koizumi S. Cytoprotective role of heme oxygenase (HO)-1 in human kidney with various renal diseases. 
Kidney Int 2001; 60: 1858–1866. 
Mosser DD, Caron AW, Bourget L, Meriin AB, Sherman MY, Morimoto RI, Massie B. The chaperone function 
of hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol 2000; 20: 7146–7159.  
Mumby J, Upton RL, ChenY, Stanford SJ, Qinlan GJ, Nicholson AG, Gutteridge JMC, Lamb NJ, Evans TW. 
Lung heme oxygenase-1 is elevated in acute respiratory distress syndrome. Crit Care Med 2004; 32: 1130–1135. 
Nakada TA, Hirasawa H, Oda S, Shiga H, Matsuda K, Nakamura M, Watanabe E, Abe R, Hatano M, Tokuhisa 
T. Influence of toll-like receptor 4, CD14, tumor necrosis factor, and interleukine-10 gene polymorphisms on 
clinical outcome in japanese critically ill patients. J Surg Res 2005; 129: 322–328.  
Nelson M, Waldrop RD, Jones J, Randall Z. Critical care provided in an urban emergency department. Am J 
Emerg Med 1998; 16: 56–59. 
Nguyen HB, Corbett SW, Steele R, Banta J, Clark RT, Hayes SR, Edwards J, Cho TW, Wittlake WA. 
Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is 
associated with decreased mortality. Crit Care Med 2007; 35: 1105–1112. 
Nguyen HB, Rivers EP, Havstadt S. Critical care in the emergency department: a physiologic assessment and 
outcome evaluation. Acad Emerg Med 2000; 7: 1354–1361. 
Niskanen M, Kari A, Halonen P. Five-year survival after intensive care -comparison of 12,180 patients with the 
 98  
general population. Finnish ICU study group. Crit Care Med 1996; 24: 1962–1967.  
Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, Moldawer LL. Plasma 
cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 
2005; 23: 488–493.  
O’Keefe GE, Hybki DL, Munford RS. The G3A single nucleotide polymorphism at the -308 position in the 
tumor necrosis factor- promoter increases the risk for severe sepsis after trauma. J Trauma. 2002; 52: 817–826. 
Olsson T, Lind L. Comparison of the rapid emergency medicine score and APACHE II in nonsurgical 
emergency department patients. Acad Emerg Med 2003; 10: 1040–1048. 
Ono K, Goto Y, Takagi S, Baba S, Tago N, Nogoni H, Iwai N. A promoter variant of the heme oxygenase-1 
gene may reduce the incidence of ischemic heart disease in Japanese. Atherosclerosis 2004; 173: 315–319. 
Ono K, Mannamib T, Iwaia N. Association of a promoter variant of the haeme oxygenase-1 gene with 
hypertension in women. J Hypertension 2003; 21: 1497–1503. 
Ortlepp JR, Graf J, Vesper K, Schmitz F, Mevissen V, Sucigan S, Kersten A, Weber C, Janssens U. Relationship 
of five inflammatory gene polymorphisms with morbidity and mortality in 533 patients admitted to an ICU. 
Inflammation 2006; 29: 65–71. 
Otterbein LE, Bach FH, Alam J, Soares M, Lu HT, Wysk M, Davis RJ, Flavell RA, Choi MK. Carbon monoxide 
has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000; 6: 422–
428.   
Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, 
Csizmadia E, Tyagi S, Akamatsu Y, Flavell RJ, Billiar TR, Tzeng E, Bach FH, Choi AMK, Soares MP. Carbon 
monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat 
Med 2003; 9: 183–190 
Overhaus M, Moore BA, Barbato JE, Behrendt FF, Doering JG, Bauer AJ. Biliverdin protects against 
polymicrobial sepsis by modulating inflammatory mediators. Am J Physiol Gastrointest Liver Physiol 2006; 
290: 695–703. 
Pachl J, Duska F, Waldauf P, Fric M, Fanta J, Ždarský E. Apoptosis as an early event in the development of 
multiple organ failure? Physiol Res 2005; 54: 697–699. 
Papathanassoglou ED, Moynihan JA, McDermott PP, Ackerman MH. Expression of Fas (CD95) and Fas ligand 
on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity 
and survival. Crit Care Med 2001; 29: 709–718. 
Pappachan JV, Coulson TG, Child NJ, Markham DJ, Nour SM, Pulletz MC, Rose-Zerilli MJ, de Courcey-Golder 
K, Barton SJ, Yang IA, Holloway JW. Mortality in adult intensive care patients with severe systemic 
inflammatory response syndromes is strongly associated with the hypo-immune TNF -238A polymorphism. 
Immunogenetics 2009; 61: 657–662. 
Parkhe M, Myles P, Leach D, Maclean A. Outcome of emergency department patients with delayed admission to 
an intensive care unit. Emergency Medicine 2002; 14: 50–57. 
Paterson RL, Galley HF, Dhillon JK, Webster NR. Increased nuclear factor kappaB activation in critically ill 
patients who die. Crit Care Med 2000; 28: 1047–1051. 
Peters DL, Barber RC, Flood EM, Garner HR, O’Keefe GE. Methodologic quality and genotyping 
reproducibility in studies of tumor necrosis factor -308 G->A single nucleotide polymorphism and bacterial 
sepsis: Implications for studies of complex traits. Crit Care Med 2003; 31: 1691–1696. 
Pettilä V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 
in critically ill patients with suspected sepsis. Intensive Care Med 2002; 28: 1220–1225. 
 99  
Pettilä V, Kaarlola A, Mäkeläinen A. Health-related quality of life of multiple organ dysfunction patients one 
year after intensive care. Intensive Care Med 2000; 26: 1473-1479  
Phua J, Koay ESC, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus 
cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 2008; 29: 328–
333. 
Purcell S, Cherny SS, Sham PC: Genetic Power Calculator: design of linkage and association genetic mapping 
studies of complex traits. Bioinformatics 2003; 19: 149–150. 
Rainer TH, Chan ACK, Lee LLY, Yim VWT, Lam NYL, Yeung SW, Graham CA, Lo YMDl. Use of plasma 
DNA to predict mortality and need for intensive care in patients with abdominal pain. Clin Chim Acta 2008; 
398: 113–117. 
Rainer TH, Lam NYL, Man CY, .Chiu RWK, Woo KS, Lo YMD. Plasma b-globin DNA as a prognostic marker 
in chest pain patients. Clin Chem Acta 2006; 368: 110–113. 
Rainer TH, Wong LKS, Lam W, Yuen E, Lam NYL, Metreweli C, Lo YMD. Prognostic use of circulating 
plasma nucleic acid concentration in patients with acute stroke. Clin Chem 2003; 49: 562–569. 
Randolph AG, Guyatt GH, Calvin JE, Doig G, Richardson WS. Understanding articles describing clinical 
prediction tools. Crit Care Med 1998; 26: 1603–1612. 
Rapoport J, Teres D, Lemeshow  S, Harris D: Timing of intensive care unit admission in relation to ICU 
outcome. Crit Care Med 1990; 18: 1231–1235. 
Reid CL, Perrey C, Pravica V, Hutchinson IV, Campbell IT. Genetic variation in proinflammatory and anti-
inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med 2002; 30: 2216–
2221. 
Reinikainen M, Niskanen M, Uusaro A, Ruokonen E. Impact of gender on treatment and outcome of ICU 
patients. Acta Anaesthesiol Scand 2005; 49: 984–990.  
Reinikainen M, Uusaro A, Niskanen M, Ruokonen E. Intensive care of the elderly in finland. Acta Anaesthesiol 
Scand 2007; 51: 522–529.  
Reinikainen M, Uusaro A, Ruokonen E, Niskanen M. Excess mortality in winter in finnish intensive care. Acta 
Anaesthesiol Scand 2006; 50: 706–711. 
  
Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA concentration as a predictor of mortality 
and sepsis in critically ill patients. Crit Care 2006; 10: R60. 
Richardson JD, Franklin G, Santos A, Harbrecht B, Danzl D, Coleman R, Smith J, Miller F, McMasters K. 
Effective triage can ameliorate the deleterious effects of delayed transfer of trauma patients from the emergency 
department to the ICU. J Am Coll Surg 2009; 208: 671–678. 
Rivers EP, Kruse JA, Jacobsen G, Shah K, Loomba M, Otero R, Childs EW. The influence of early 
hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Crit Care Med 2007; 35: 
2016–2024. 
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-
directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368–1377. 
Roth GA, Krenn C, Brunner M, Moser B, Ploder M, Spitter A, Pelinka L, Sautner T, Wolner E, Boltz-Nitulescu 
G, Ankersmit HJ. Elevated serum levels of epithelial cell apoptosis-spesific cytokeratin 18 neoepitope M30 in 
critically ill patients. Shock 2004; 22: 218–220. 
Russell JA, Wellman H, Walley KR. Protein C rs2069912 C allele is associated with increased mortality from 
severe sepsis in North Americans of East Asian ancestry. Hum Genet 2008; 123: 661–663. 
 100  
Rustad P, Simonsson P, Felding P, Pedersen M. Nordic reference interval project bio-bank and database 
(NOBIDA): a source for future estimation and retrospective evaluation of reference intervals. Scand J Clin Lab 
Invest 2004; 64: 431–438. 
Ruttiman UE. Statistical approaches to development and validation of predictive instruments. Crit Care Clin 
1994; 10: 19–36. 
Sarady-Andrews JK, Liu F, Gallo D, Nakao A, Overhaus M, Öllinger R, Choi AM, Otterbein LE. Biliverdin 
administration protects against endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol 
2005; 289: 1131–1137. 
Sato T, Takeno M, Honma K, Yamauchi H, Saito Y, Sasaki T, Morikubo H, Nagashima Y, Takagi S, Yamanaka 
K, Kaneko T, Ishigatsubo Y. Heme oxygenase-1, a potential biomarker of chronic silicosis, attenuates silica-
induced lung injury. Am J Respir Crit Care Med 2006; 174: 906–914. 
Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers 
inflammation. Nature 2002: 418: 191–195. 
Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, Zabel P, Dalhoff K. Pneumococcal septic 
shock is associated with the interleukin-10–1082 gene promoter polymorphism. Am J Respir Crit Care Med 
2003; 168: 476–480. 
Schaer DJ, Schaer CA, Schoedon G, Imhof A, Kurrer MO. Hemophagocytic macrophages constitute a major 
compartment of heme oxygenase expression in sepsis. Eur J Haematol 2006; 77: 432–436. 
Schillinger M, Exner M, Minar E, Mlekusch W, Müllner M, Mannhalter C, Bach FH, Wagner O. Heme 
oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. J Am Coll 
Cardiol 2004; 43: 950–957. 
Schipper HM, Chertkow H, Mehindate K, Frankel D, Melmed C, Bergman H. Evaluation of heme oxygenase-1 
as a systemic biological marker of sporadic AD. Neurology 2000; 54: 1297–1304. 
Schlüter B, Raufhake C, Erren M, Schotte H, Kipp F, Rust S, van Aken H, Assmann G, Berendes E. Effect of 
the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 
2002; 30: 32–37.  
Schmidt JE, Morgan JI, Rodriguez-Galindo C, Webb DL, Liang H, Tamburro RF. Heme oxygenase-1 messenger 
RNA expression is induced in peripheral blood mononuclear cells of pediatric cancer patients with systemic 
inflammatory response syndrome. Pediatr Crit Care Med 2004; 5: 554–560. 
Schmidt R, Trischler E, Hoetzel A, Loop T, Humar M, Halverscheid L, Geiger KK, Pannen BH. Heme 
oxygenase-1 induction by the clinically used anesthetic isoflurane protects rat livers from ischemia/reperfusion 
injury. Ann Surg 2007; 245: 931–942. 
Schroeder S, Reck M, Hoeft A, Stüber F. Analysis of two human leukocyte antigen-linked polymorphic heat 
shock protein 70 genes in patients with severe sepsis. Crit Care Med 1999; 27: 1265–1270. 
Shah KB, Nolan MM, Rao K, Wang DJ, Christenson RH, Shanholtz CB, Mehra MR, Gottlieb SS. The 
characteristics and prognostic importance of NT-ProBNP concentrations in critically ill patients. Am J Med 
2007; 120: 1071–1077. 
Sheu CC, Zhai R, Wang Z, Gong MN, Tejera P, Chen F, Su L, Thompson BT, Christiani DC: Heme oxygenase-
1 microsatellite polymorphism and haplotypes are associated with the development of acute respiratory distress 
syndrome. Intensive Care Med 2009; 35: 1343–1351. 
Simpson HK, Clancy M, Goldfrad C, Rowan K. Admissions to intensive care units from emergency 
departments: a descriptive study. Emerg Med J 2005; 22: 423–428. 
Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001; 33: 
358–370. 
 101  
Song F, Li X, Zhang M, Yao P, Yang N, Sun X, Hu FB, Liu L: Association between heme oxygenase-1 gene 
promoter polymorphisms and type 2 diabetes in a Chinese population. Am J Epidemiol 2009; 170: 747–756.
Song M, Pinsky MR, Kellum JA. Heat shock factor 1 inhibits nuclear factor–B nuclear binding activity during 
endotoxin tolerance and heat shock. J Crit Care 2008; 23: 406–415. 
Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Verderio P, Pastorino U. Effects of prolonged storage of whole 
plasma or isolated plasma DNA of the results of circulating DNA quantification assays. J Natl Cancer Inst 2005; 
97: 1848–1850. 
Stanilova SA, Miteva LD, Karakolev ZT, Stefanov CS. Interleukin-10-1082 promoter polymorphism in 
association with cytokine production and sepsis susceptibility. Intensive Care Med 2006; 32: 260–266. 
Stocker R, Yamamoto Y, McDonagh A, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible 
physiological importance. Science 1987; 235: 1043–1046. 
Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of 
circulating DNA. Apoptosis and active DNA release. Clin Chim Acta 2001; 313: 139–142. 
Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, 
Tokics L, Treutiger CJ. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with 
severe sepsis and septic shock. Crit Care Med 2005; 33: 564 –573. 
Suter P, Armaganidis A, Beaufils E, Bonfill X, Burchardi H, Cook D, Fagot-Largeault A, Thijs L, Vesconi S, 
Williams A. Consensus conference organized by the ESICM and the SRLF. Predicting outcome in ICU patients. 
Intensive Care Med 1994: 20: 390–397. 
Sutherland AM, Walley KR, Manocha S, Russell JA. The association of interleukin 6 haplotype clades with 
mortality in critically ill adults. Arch Int Med 2005 a; 165: 75–82.  
Sutherland AM, Walley KR, Russel JA. Polymorphisms in CD14, mannose-binding lectin, and toll-like receptor-
2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005 b; 33: 638–
644. 
Suzuki N, Kamataki A, Yamaki J, Homma Y. Characterization of circulating DNA in healthy human plasma. 
Clin Chim Acta 2008; 387: 55–58. 
Svenson J, Besinger B, Stapczynski S. Critical care of medical and surgical patients in the ED: Lenght of stay 
and initiation of intensive care procedures. Am J Emerg Med 1997; 15: 654–657. 
Swinkels DW, Wiegerinck E, Steegers EAP, de Kok JB. Effects of blood-processing protocols on cell-free DNA 
quantification in plasma. Clin Chem 2003; 49: 525–526. 
Takaki S, Takeyama N, Kajita Y, Yabuki T, Noguchi H, Miki Y, Inoue Y, Nakagawa T, Noguchi H. Beneficial 
effects of the heme oxygenase-1/carbon monoxide system in patients with severe sepsis/septic shock. Intensive 
Care Med 2010; 36: 42–48. 
Tang GJ, Huang SL, Yien HW, Chen WS, Chi CW, Wu CW, Lui WY, Chiu JH, Lee TY. Tumor necrosis factor 
gene polymorphism and septic shock in surgical infection. Crit Care Med 2000; 28: 2733–2736. 
Task force of the American college of critical care medicine, society of critical care medicine. Guidelines for 
intensive care unit admission, discharge, and triage. Crit Care Med 1999; 27, 633–638. 
Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 
1969; 244: 6388–6394. 
Terry CM, Clikeman JA, Hoidal JR, Callahan KS. Effect of tumor necrosis factor- and interleukin-1 on heme  
oxygenase-1 expression in human endothelial cells. Am J Physiol Heart Circ Physiol 1998; 274: 883–891.
Teuffel O, Ethier MC, Beyene J, Sung L. Association between tumor necrosis factor- promoter -308 A/G 
 102  
polymorphism and susceptibility to sepsis and sepsis mortality: A systematic review and meta-analysis. Crit 
Care Med 2010; 38: 276–282. 
Tilluckdarry L, Tickoo S, Amoateng-Adjepong Y, Manthous C. Outcomes of critically ill patients. Based on 
duration of emergency department stay. Am J Emerg Med 2005; 23: 336–339. 
Tiroch K, Koch N, Beckerath N. Heme oxygenase-1 gene promoter polymorphism and restenosis following 
coronary stenting. Eur Heart J 2007; 28: 968–973. 
Tishkoff SA, Yagmur E, Scholten D, Vidacek D, Koch A, Winograd R, Gressner AM, Trautwein C, Wasmuth 
HE, Lammert F. The interleukin-6 (IL6) -174 G/C promoter genotype is associated with the presence of septic 
shock and the ex vivo secretion of IL6. Int J Immunogen 2007; 34: 413–418. 
Torre D, Tambini R, Manfredi M, Mangani V, Livi P, Maldifassi V, Campi P, Speranza F. Circulating levels of 
FAS/APO-1 in patients with the systemic inflammatory response syndrome. Diagn Microbiol Infect Dis 2003; 
45: 233–236. 
Tracz MJ, Juncos JP, Grande JP, Croatt AJ, Ackerman AW, Rajagopalan G, Knutson KL, Badley AD, Griffin 
MD, Alam J, Nath KA. Renal hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in 
HO-1 -/- mice. Am J Pathol 2007; 170: 1820–1830. 
Turpeinen H, Kyllönen L, Parkkinen J, Laine J, Salmela KT, Partanen J. Heme oxygenase 1 gene 
polymorphisms and outcome of renal transplantation. Int J Immunogenet 2007; 34: 253–257. 
Varon J, Jr Fromm RE, Levine RL: Emergency department procedures and length of stay for critically ill 
medical patients. Ann Emerg Med 1994; 23: 546–549. 
Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettilä V for the Finnsepsis Study Group. Predictive value of N-
terminal pro– brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med 2007; 35: 1277–1283. 
  
Villar J, Flores C, Perez-Mendez L, Maca-Meyer N, Espinosa E, Blanco J, Sangüesa R, Muriel A, Tejera P, 
Muros M, Slutsky AS. Angiotensin-converting enzyme insertion/deletion polymorphism is not associated with 
susceptibility and outcome in sepsis and acute respiratory distress syndrome. Intensive Care Med 2008; 34: 488–
495.  
Villar J, Pérez-Méndez L, Flores C, Maca-Meyer N, Espinosa E, Muriel A, Sangüesa R, Blanco J, Muros M, 
Kacmarek RM. A CXCL2 polymorphism is associated with better outcomes in patients with severe sepsis. Crit 
Care Med 2007; 35: 2292–2297. 
Vincent J-L, De Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. 
Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a 
multicenter, prospective study. On behalf of the working group on “sepsis-related problems” of the European 
Society of Intensive Care Medicine. Crit Care Med 1998; 26: 1793–1800. 
Vincent J-L, Ferreira F, Moreno R. Scoring systems for assessing organ dysfunction and survival. Crit Care Clin 
2000; 16: 353–366. 
  
Vincent J-L, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. 
The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of 
the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive 
Care Med 1996; 22: 707–710. 
Walley KR, Russell JA. Protein C -1641 AA is associated with decreased survival and more organ dysfunction 
in severe sepsis. Crit Care Med 2007; 35: 12–17.  
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. conceptual framework and 
item selection. Med Care 1992; 30: 473–483. 
  
Warle MC, Farhan A, Metselaar HJ, Hop WCJ, Perrey C, Zondervan PE, Kap M, Kwekkeboom J, Ijzermans 
JNM, Tilanus HW, Pravica V, Hutchinson IV, Bouma GJ. Are cytokine gene polymorphisms related to in vitro 
 103  
cytokine production profiles? Liver Transpl 2003; 9: 170–178. 
Watanabe E, Buchman TG, Hirasawa H, Zehnbauer BA. Association between lymphotoxin- (tumor necrosis 
factor-) intron polymorphism and predisposition to severe sepsis is modified by gender and age. Crit Care Med 
2010; 38: 181–193. 
Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, Tokuhisa T. Extremely high interleukin-6 blood levels 
and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene 
polymorphisms. Crit Care Med 2005 a; 33: 89–97.  
Watanabe E, Hirasawa H, Oda S, Shiga H, Matsuda K, Nakamura M, Abe R, Nakada T. Cytokine-related 
genotypic differences in peak interleukin-6 blood levels of patients with SIRS and septic complications. J 
Trauma 2005 b; 59: 1181–1190. 
Waterer GW, ElBahlawan L, Quasney MW, Zhang Q, Kessler LA, Wunderink RG. Heat shock protein 70-
2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. 
Crit Care Med 2003; 31: 1367–1372. 
Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-
acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163: 
1599–1604. 
Wattanathum A, Manocha S, Groshaus H, Russell JA, Walley KR. Interleukin-10 haplotype associated with 
increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary 
sepsis. Chest 2005; 128: 1690–1698.  
Wehler M, Geise A, Hadzionerovic D, Aljukic E, Reulbach U, Hahn EG, Strauss R. Health-related quality of life 
of patients with multiple organ dysfunction: Individual changes and comparison with normative population. Crit 
Care Med 2003; 31:1094–1101. 
Weiss YG, Bromberg Z, Raj N, Raphael J, Goloubinoff P, Ben-Neriah Y, Deutschman CS. Enhanced heat shock 
protein 70 expression alters proteasomal degradation of IB kinase in experimental acute respiratory distress 
syndrome. Crit Care Med 2007; 35: 2128–2138. 
Westendorp RG, Hottenga, JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of 
meningococcal septic shock. Lancet 1999; 354: 561–563. 
Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP. 
Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170–173. 
  
Wheeler DS, Fisher Jr LE, Catravas JD, Jacobs BR, Carcillo JA, Wong HR. Extracellular hsp70 levels in 
children with septic shock. Pediatr Crit Care Med 2005; 6: 308–311. 
Wijeratne S, Butt A, Burns S, Sherwood K, Boyd O, Swaminathan R. Cell-free plasma DNA as a prognostic 
marker in intensive treatment unit patients. Ann NY Acad Sci 2004; 1022: 232–238. 
Williams TA, Dobb GJ, Finn JC, Knuiman MW, Geelhoed E, Webb SAR. Determinants of long-term survival 
after intensive care. Crit Care Med 2008; 36: 1523–1530. 
Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. 
Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15: 1318–1321. 
Yachie A, Niida Y, Wada T, Igarashi N. Oxidative stress causes enhanced endothelial cell injury in human heme 
oxygenase-1 deficiency. J Clin Invest 1999; 103: 129–135. 
Yachie A, Toma T, Mizuno K, Okamoto H, Shimura S, Ohta K, Kasahara Y, Koizumi S. Heme oxygenase-1 
production by peripheral blood monocytes during acute inflammatory illnesses of children. Exp Biol Med 2003; 
228: 550–556. 
Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite 
 104  
polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J 
Hum Genet 2000; 66: 187–195, erratum in Am J Hum Genet 2001; 68: 1542. 
Yende S, Angus DC, Ding J, Newman AB, Kellum JA, Li R, Ferrel RE, Zmuda J, Kritchevsky SB, Harris TB, 
Garcia M, Yaffe K, Wunderink RC, for the Health ABC Study. 4G/5G plasminogen activator inhibitor-1 
polymorphisms and haplotypes are associated with pneumonia. Am J Resp Crit Care Med 2007; 176: 1129–
1137. 
Yurgel VC, Ikuta N, Da Rocha AB, Lunge VR, Schneider RF, Fonseca ASK, Grivicich I, Zanoni C, Regner A. 
Role of plasma DNA as a predictive marker of fatal outcome following severe head injury in males. J 
Neurotrauma 2007; 24: 1172–1181. 
Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveldt AB, Caliezi C, van Nieuwenhuijze AE, van 
Mierlo GJ, Eerenberg AJ, Lammle B, Hack CE. Elevated nucleosome levels in systemic inflammation and 
sepsis. Crit Care Med 2003; 31:1947–1951. 
Zhang D, Lavaux T, Voegeli AC, Lavigne T, Castellein V, Meyer N, Sapin R, Aunis D, Metz-Boutigue MH, 
Schneider F. Prognostic value of chromogranin A at admission in critically ill patients: A cohort study in a 
medical intensive care unit. Clin Chem 2008; 54: 1497–1503. 
Zhang K, Calabrese P, Nordborg M, Sun F. Haplotype block structure and its applications to association studies: 
Power and Study Designs. Am J Hum Genet 2002; 71: 1386–1394. 
Zuckerbraun BS, McCloskey CA, Gallo D, Liu F, Ifedigbo E, Otterbein LE, Billiar TR. Carbon monoxide 
prevents multiple organ injury in a model of hemorrhagic shock and resuscitation. Shock 2005; 23: 527–532. 
Öllinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, Csizmadia E, Graça-Souza, Liloia A, Soares MP, 
Otterbein LE, Usheva A, Yamashita K, Bach FH. Bilirubin: a natural inhibitor of vascular smooth muscle cell 
proliferation. Circulation 2005; 112: 1030–1039. 
Appendix 1. 
QUALITY OF LIFE QUESTIONNAIRE (15D©) 
15D©/Harri Sintonen (www.15D-instrument.net) 
Please read through all the alternative responses to each question before placing a cross (x) against the 
alternative which best describes your present health status. Continue through all 15 questions in this manner, 
giving only one answer to each. 
QUESTION 1. MOBILITY 
1 ( ) I am able to walk normally (without difficulty) indoors, outdoors and on stairs. 
2 ( ) I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight difficulties. 
3 ( ) I am able to walk without help indoors (with or without an appliance), but outdoors and/or on stairs only 
with considerable difficulty or with help from others.  
4 ( ) I am able to walk indoors only with help from others.  
5 ( ) I am completely bed-ridden and unable to move about. 
QUESTION 2. VISION 
1 ( ) I see normally, i.e. I can read newspapers and TV text without difficulty (with or without glasses).  
2 ( ) I can read papers and/or TV text with slight difficulty (with or without glasses).  
3 ( ) I can read papers and/or TV text with considerable difficulty (with or without glasses). 
4 ( ) I cannot read papers or TV text either with glasses or without, but I can see enough to walk about without 
guidance.  
5 ( ) I cannot see enough to walk about without a guide, i.e. I am almost or completely blind. 
QUESTION 3. HEARING 
1 ( ) I can hear normally, i.e. normal speech (with or without a hearing aid). 
2 ( ) I hear normal speech with a little difficulty. 
3 ( ) I hear normal speech with considerable difficulty; in conversation I need voices to be louder than normal. 
4 ( ) I hear even loud voices poorly; I am almost deaf. 
5 ( ) I am completely deaf. 
QUESTION 4. BREATHING 
1 ( ) I am able to breathe normally, i.e. with no shortness of breath or other breathing difficulty. 
2 ( ) I have shortness of breath during heavy work or sports, or when walking briskly on flat ground or slightly 
uphill. 
3 ( ) I have shortness of breath when walking on flat ground at the same speed as others my age. 
4 ( ) I get shortness of breath even after light activity, e.g. washing or dressing myself. 
5 ( ) I have breathing difficulties almost all the time, even when resting. 
QUESTION 5. SLEEPING 
1 ( ) I am able to sleep normally, i.e. I have no problems with sleeping. 
2 ( ) I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes waking at night. 
3 ( ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept enough. 
4 ( ) I have great problems with sleeping, e.g. having to use sleeping pills often or routinely, or usually waking at 
night and/or too early in the morning. 
5 ( ) I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of sleeping pills, or staying 
awake most of the night.  
QUESTION 6. EATING 
1 ( ) I am able to eat normally, i.e. with no help from others. 
2 ( ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with special appliances). 
3 ( ) I need some help from another person in eating. 
4 ( ) I am unable to eat by myself at all, so I must be fed by another person. 
5 ( ) I am unable to eat at all, so I am fed either by tube or intravenously.  
QUESTION 7. SPEECH 
1 ( ) I am able to speak normally, i.e. clearly, audibly and fluently. 
2 ( ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or changes of pitch. 
3 ( ) I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or stammering. 
4 ( ) Most people have great difficulty understanding my speech. 
5 ( ) I can only make myself understood by gestures. 
QUESTION 8. ELIMINATION 
1 ( ) My bladder and bowel work normally and without problems. 
2 ( ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with urination, or loose or 
hard bowels. 
3 ( ) I have marked problems with my bladder and/or bowel function, e.g. occasional 'accidents', or severe 
constipation or diarrhea. 
4 ( ) I have serious problems with my bladder and/or bowel function, e.g. routine 'accidents', or need of 
catheterization or enemas. 
5 ( ) I have no control over my bladder and/or bowel function. 
QUESTION 9. USUAL ACTIVITIES 
1 ( ) I am able to perform my usual activities (e.g. employment, studying, housework, free- time activities) 
without difficulty. 
2 ( ) I am able to perform my usual activities slightly less effectively or with minor difficulty. 
3 ( ) I am able to perform my usual activities much less effectively, with considerable difficulty, or not 
completely. 
4 ( ) I can only manage a small proportion of my previously usual activities.  
5 ( ) I am unable to manage any of my previously usual activities. 
QUESTION 10. MENTAL FUNCTION 
1 ( ) I am able to think clearly and logically, and my memory functions well 
2 ( ) I have slight difficulties in thinking clearly and logically, or my memory sometimes fails me.  
3 ( ) I have marked difficulties in thinking clearly and logically, or my memory is somewhat impaired.
4 ( ) I have great difficulties in thinking clearly and logically, or my memory is seriously impaired.
5 ( ) I am permanently confused and disoriented in place and time. 
QUESTION 11. DISCOMFORT AND SYMPTOMS 
1 ( ) I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.  
2 ( ) I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.  
3 ( ) I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
4 ( ) I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
5 ( ) I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
QUESTION 12. DEPRESSION 
1 ( ) I do not feel at all sad, melancholic or depressed. 
2 ( ) I feel slightly sad, melancholic or depressed. 
3 ( ) I feel moderately sad, melancholic or depressed. 
4 ( ) I feel very sad, melancholic or depressed. 
5 ( ) I feel extremely sad, melancholic or depressed. 
QUESTION 13. DISTRESS 
1 ( ) I do not feel at all anxious, stressed or nervous. 
2 ( ) I feel slightly anxious, stressed or nervous.
3 ( ) I feel moderately anxious, stressed or nervous. 
4 ( ) I feel very anxious, stressed or nervous. 
5 ( ) I feel extremely anxious, stressed or nervous. 
QUESTION 14. VITALITY 
1 ( ) I feel healthy and energetic. 
2 ( ) I feel slightly weary, tired or feeble. 
3 ( ) I feel moderately weary, tired or feeble. 
4 ( ) I feel very weary, tired or feeble, almost exhausted. 
5 ( ) I feel extremely weary, tired or feeble, totally exhausted. 
QUESTION 15. SEXUAL ACTIVITY 
1 ( ) My state of health has no adverse effect on my sexual activity. 
2 ( ) My state of health has a slight effect on my sexual activity. 
3 ( ) My state of health has a considerable effect on my sexual activity. 
4 ( ) My state of health makes sexual activity almost impossible.  
5 ( ) My state of health makes sexual activity impossible.  
Appendix 2.  
The locations of the -413A/T, +99G/C, and GTn polymorphisms in the HO-1 gene 
nucleotide sequence (SeattleSNPs. NHLBI HL66682 Program for Genomic Applications, UW-FHCRC, 
Seattle, WA).
Colours: red, -413A/T= rs2071746; green, GTn polymorphism; yellow, +99G/C= rs2071747   
 1 tggatcatcc tgttgcttga ctaaaaagaa ggggaagtca ggaggctgaa tcagcatgcg 
       61 aaagggccac aaattcagcc ctgggacagc ctagaggacc agaacaactc tggcctggcc 
      121 tcttgcaccc cagcaaccca ctgtgtgggg ggctgttcta acgaagtctg gggctcccag 
      181 agaacagtta gaaaagaaag caagcccaga ccggcagcca ggaaccctgg gtcactggag 
      241 gttctctttc caatgggggg catagcctgg ccaagtccct cctgctcttg gggtccctgc 
      301 ttccctgtgt taaataaaaa gggttcagat ctcatgagtt ttaccctcta gggtcgctga 
      361 atggacagac tctggatcta tacacgcaaa ctcatctccc ctaaactcct ggaccctctg 
      421 tgagaagggt tggagtgtgg tggtcaggac tgtggggact ggcttcaaag tgctgtagtt 
      481 tgaatcctgg ctcttccatc attaactgta tgacttggga aaatgactta tcctctttgt 
      541 ccctcagtgc tcatgtgggc aaaatagaga tgaaaatagc ttgcaaggct gttgtcagga 
      601 tgggctgcaa tcacgcgcgt gaagtctctg cacatagtaa attctcaata aaggctggtt 
      661 agaatgacag tttggaattg tggcttggtt ccagcccatt ctatcagccc agcaatatta 
      721 cagcctaaca atattattat tttttcccag aaagagacct tgaagcatct attcattcag 
      781 gcatgcattc agtattaact gtgacctacc aggcactatt ccaggaactg ggaatttaca 
      841 aagcaaagta gtaggcaagg tctccacctt tgtgctttac atgccactgt tggggctcag 
      901 aaagtgatac caggacaact ggtgctttga catgatgaga ggccttagga gctgcctcag 
      961 agtcaaggtc cctgtaagct tgtcttgttc ccccgacaag cacagggaga gacgctctct 
     1021 ggaatttcct tatctgacca agaacacttc tttacaaaag aaatgcaatt gtgttaagtc 
     1081 tttttttcct ttgagacaga gtctcgctct tgtcacccag gctggagtgc agtggcacta 
     1141 tcttggctca ctgcaacctc ctcctcctcc cgggttcaag cgattctcct gcctcagcct 
     1201 cccaaagtgc tgggattaca ggtgtgagcc accgcgcccg gccagtgtta agcccttttt 
     1261 ctagtaatct catcaaatat ccaggaaaga tcaaccactg gagagagaaa gagactggga 
     1321 gtcatcacca gacccagaca gatttacctg ttcttctgag gacagtgcca agagattacc 
     1381 tgggggactt tatctgccta ggacaacctt tgtccctgtg cggctccacc tccaccttcc 
     1441 cttaaagtcg gcctttcacc tccagggcca ttccttcttg ctaatgattt actgtctttc 
     1501 aaaagaattg tctgcattcc ctatctccct tctcccctat aaaaaaggct gggtagcctc 
     1561 tgtactccac tgggttacag ggtcaccatt cttccgtgat taccccatta caatacattt 
     1621 ttgtatgtct tttctcctct taacctgact tttgtcggtt ggttttcggg gaaccttcag 
     1681 aggaagaagg ggaatttttt tcaaggcccc ttagctcacc cttgggagga tgatcctttc 
     1741 caatacaatc tcagaagtgc ctctgggctg tagtggccct aggctgaatt ccaggaagtt 
     1801 tttttttttt ttttttgttt tttttttttt ttgagggaca gcgtcttgtt ctgttgccca 
     1861 ggttagaata cagtagcgtg gtcacagctc actccagcct ctacatccca ggctcaagtg 
     1921 aacctccagc ctcagcctcc caagtagctg ggaccacagg catgtgccac catgcccagc 
     1981 taatttattt tatattttgt agagacgggg tctccctatg ttgcccaggc cagtctcgaa 
     2041 ctcaaagcaa tcttcccacc tcgactgggc tcaaagcgct cttcccacct caacctccca 
     2101 aagtactggg actacaggtg tgagctacca tgccaggcct gaaagccatc ttaaaaaaaa 
     2161 aatcttagaa tgagaatcac agtattggga aaggactgta tgaatcatct ggtccattcg 
     2221 ttttgtcctc tgggttcacc cagtgaccct atttcccccg agttctaagg agtccacctc 
     2281 atgcagaatt gattcaatag gcgatcagca agggccagct ctgctctggg ccctgagcag 
     2341 gcactgagta taagtcagac ctgaatgtgc ctggaagagt gtcccacgca ttccagcagg 
     2401 gaagcagttt gtatgacagg tgtcccagtc caggcggata ccaggtgctg ccagagtgtg 
     2461 gaggaggcag gcggggactt agtctcctcc ctgggtttgg acactggcat cctgctttat 
     2521 gtgtgacacc actgcacccc tctgagcctc ggtttcccca tctgtaaaat agaagcgatc 
     2581 taccctcaca ggtcagttgt agggatgaac catgaaaata ctagagtctc tgttttttga 
     2641 caggaactca aaaaacagat cctaaatgta catttaaaga gggtgtgagg aggcaagcag 
     2701 tcagcagagg attccagcag gtgacatttt agggagctgg agacagcaga gcctggggtt 
     2761 gctaagttcc tgatgttgcc caccaggctt ttgctctgag cagcgctgcc tcccagcttt 
     2821 ctggaacctt ctgggacgcc tggggtgcat caagtcccaa ggggacaggg agcagaaggg 
     2881 ggggctctgg aaggagcaaa atcacaccca gagcctgcag cttctcagat ttccttaaag 
     2941 gttttgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtatgtg tgtgtgtgtg tgtgtgtgtg 
     3001 tgtgttttct ctaaaagtcc tatggccaga ctttgtttcc caagggtcat atgactgctc 
     3061 ctctccaccc cacactggcc cggggcgggc tgggcgcggg cccctgcggg tgttgcaacg 
     3121 cccggccaga aagtgggcat cagctgttcc gcctggccca cgtgacccgc cgagcataaa 
     3181 tgtgaccggc cgcggctccg gcagtcaacg cctgcctcct ctcgagcgtc ctcagcgcag 
     3241 ccgccgcccg cggagccagc acgaacgagc ccagcaccgg ccggatggag cgtccgcaac 
     3301 ccgacaggca agcgcggggc gcgggacgcg ggacgggcgc ctttctctcc caaccctgct 
     3361 tgcgtcctag ccccaccccg ggacactgcc acacagcgac agagcccagg agccagaaac 
     3421 ttgggctctg gagtcaggag gtgcggggtt ctgatcctgc ctgtgcccgt agggtagttg 
     3481 gagggaggaa cggtaattta catgcctggc accctggtat gcggttggtg accaagatgg 
     3541 gagtgtccct agagtatcca gtctttgagg tagccaattt tttttttaat cctactttcg 
     3601 aggtgtgttt ggagttgctc tctgctgaat ctagatctct ggggctctgc cagcctgggg 
     3661 gagcatgctt ggttctcttg gtggcatctg tccctcacta gctacggagg acctgagcca 
     3721 gacatcaccc tggctacggt gttccatgtc tcacagatag cccagttcag ggaggcgaca 
     3781 tgcccaagag tgctcagtta gctggtgtca gaactgggcc ttgaaccttg gtctgcccac 
     3841 ctccaggtct cactcattcc cttctttcaa taatttgtta gtattttttt ttttaactcc 
     3901 tgggcttaag catcctccca cctcagcctc cagagtagct gggacttaca gacatgtgcc 
     3961 atttctcctg agactttgac cagctgtgtt gtagaacagg gaagcagggc aggagaaaag 
     4021 ggaaaaatga caattctgtg gggaggcagg gatacggacc catgacagaa atactcccag 
     4081 aaagactttt tctttgacta aagcagactt tctcaggctt tttaaccctg acgccttcat 
     4141 gatgagcata acatgatagg gggtcatgag atttgcatct ggaactttaa caaaataact 
     4201 gaattaaata ttgggtctaa aagccaatca aagcaattac aaacttggag atgccggttc 
     4261 atggggctgc tgcttcttcc tgggttatgc tgtacctcct cctcctctcc actgcgaact 
     4321 acctgtacca ggatttcccc cttggtttgg gggactgtat tatttagtgt tttaatgact 
     4381 gaagagtgtt tacaaagctg cgagagccac catgcccagc ctgaatttgt tttttgtttt 
     4441 ttgttttttt gtttttttgc ttttttgctt ttcttttttt gagatggagt gttgctctgt 
     4501 tgcccaggct ggagtgcagt ggcgcgatct cggctcactg caacctctgc ctcctgggtt 
     4561 caagcgattc tcctgcctca gcctcccaag tagttgggat tacaggcgcc cactaccatg 
     4621 cccggctatt tttttttttt tttttgtatt tttagtagag atagggtttc accatgttgg 
     4681 ccaggctggg ctcaaactcc tggcctcagg tgatctgccc gcctcagcct cccaaagtgc 
     4741 taggattaca ggcgtgagcc accatgcctg gccctttttt tctttttttt tctttttttg 
     4801 agatggagtc tctctgtcac caagtctgga gtgcagtggt gtgatctcag ctcactgcaa 
     4861 cctctgcctc cgggattcaa gcaattacag gcataattgc tgggattaca ggcacctgcc 
     4921 accatgcccg gctaattttt gtatttttag tagagacggg gtttcaccat gtttgccagg 
     4981 ctggtctcga actcctgacc tcaggtgatc cacctgcctt ggcctcccaa agcgctggga 
     5041 ttacaggcgt gagccaccgt gcccagccac aaggctgcat cttaaagcga ttgagaacgt 
     5101 ggcctgaatg aggatgggag tctcttgaag gcctgcccac aggtgggagg ctcagcagtt 
     5161 gggaaggacc ccacccccag ccagctttgt gttcaccttt cccatttcct cctcagcatg 
     5221 ccccaggatt tgtcagaggc cctgaaggag gccaccaagg aggtgcacac ccaggcagag 
     5281 aatgctgagt tcatgaggaa ctttcagaag ggccaggtga cccgagacgg cttcaaggta 
     5341 tgtggcttgg tgggactagc cctggtggag ggtgtggcag gtgtgggtgg acccaaggct 
     5401 cagaccagtg gtttaagtgg ggatgctgag ggaccagatg ggcatgtcca atagaatcat 
     5461 cttaaaaatg atgacactga ggctcagaga gggaaggtga gttacccaag gtcacacagc 
     5521 aagttcagcc tgctctgtaa tgttgtggag gggctggggc agcagtgccg ttgactgagc 
     5581 accggttcca tgttgggcat tttgtacacg tggtttctaa tctgtgcttc aaccctgacg 
     5641 agaaagatga ggactggaag gctcagagag gttcagtgac taacagaagg tcacacagcc 
     5701 agtaagtgga aaaggctgaa atcaaccaag accgatttca gccttgtact ccttgtattt 
     5761 cagagcttgt actcctgatc taactcgaat ttgcctctga agataaggaa taatataggt 
     5821 tggagtctta acagaaccct tttctaacag tgagactgag ggtgcctcat ctaatctccc 
     5881 taagccacgt tttccccatc tgtaaaagag tatttcaaca gcagggtttt cttaagcacc 
     5941 cactatatgc caggtactga ttttgctgtt tcccagcact gttgtgaaat tcatgcaaat 
     6001 agaaggaaag cacttgatga agaaccggga agatactggg tgttaaaaca tcagcgtggg 
     6061 gaagagcttg ttcaggttga acagagggtg tgggggtggg gagtagggag ctatatccca 
     6121 ccaccttcat cccagtccct tttgcaatct gcaccctctg ccacccccta cttccaacat 
     6181 gagacatgct ttatttattt tattttatct gagacagagt ctcactctgt tgtccgggct 
     6241 ggagtgcaat ggcaagatct cggtgccctg aaacctccgc atcctaagtt caagcgattc 
     6301 tcctgcctca gcctcccaag tagctgggac tacaggtgcc caccaccaca cctggccaat 
     6361 ttttgtattt ttttagtaga gacagggttt taccatgttg gccaggctgg tctcgaactc 
     6421 ctgacctcag atgatccacc cgtcttggtc tcccaaagtg ctgggattag aggtgtgagc 
     6481 caccacccgg ccgagacatg ctttaatgag gagagattta atctgtggtt ccaggctggg 
     6541 tggggtcctt gggcctgtaa tgggtcttcc tcatcctcct cccctctccc ttaaaaagat 
     6601 gaggtacacc cagttgctgc agtgtgactg gagacagtgg gtgcagggag gtgaatgctg 
     6661 gaatatccca tccccagcca gcttagactt tggattttgc ctctaagtca cagggttcta 
     6721 aggaggcgcc aagatccatg agagaatcca gtgctcactt acattaagct ggtggacgtg 
     6781 gcacttatca cagcccttct catgtgagcg ctaagtgcca ggctgccctc tgtgctggcc 
     6841 cagatcctct cacttaatcc tcacaccagc cccatctagt atgtggcagg tgagggaact 
     6901 gactagcaca gttggctagc acagtcacac ggacctcaga tcatctgctc taggatagga 
     6961 taggaagctg ggaccagaga aagcaagtgg ctcacccatg gtcacacagt taaggactgg 
     7021 cagagttggg taagaaccag gtccgtcaca ctcaaaaacc caggctcttt tgtaccagac 
     7081 tgcctggctt tctgtcccct caaggaatag agctgctttg aatgtttgtg gctcagaaat 
     7141 aactcagaaa ctccaaccta aatgtcttaa ctttgttctc cttcaaattt aaacgggcgt 
     7201 attaatgtgt aacgggagtt agtgccccaa gccaaggtac actcaagacc tgttgcctca 
     7261 gcccagcatg cagaggtggt ggggttcaga ataggcctcc aggaaggaga attgtgccct 
     7321 gtagttggtt acgcagaggt caaaagccag aagcacatgg ccaatctcct ttaagcactt 
     7381 tcatttcagc tgttcccctc tcctgagcca tggtgggtcc ctggcaatgc ccggtcttca 
     7441 atctagtttc atttcttact agctgtgcaa cctccatgtc tcataccctc tctgagcctt 
     7501 agtttccttt tctgtaaaat gggaatagca attcctttgt tggatttttt tttttttttt 
     7561 ttctgagaca gggtcttgct cactctgttc cccaagctgg agtacagtga tatgatcaca 
     7621 gctcactgca accttgaaat cctgggctca agtgataccc ctgcctccgc ctctggagta 
     7681 gctgggacta taggcatgca cccccacagc catacctggc tttttttttt tttttttttt 
     7741 ttctgagtca aagtcttgct ctgtcgccca ggctggagcg caatggcgtg atctcggctc 
     7801 actgcaacca ctgcctcctg ggttcaagca attctcctga ctcagcctcc cgagtagctg 
     7861 ggattatagg tgcctgccac catgcctggc caatttttgt gtttttagta gagatagggt 
     7921 ttcaccatat tgcccaggct ggtctcttgg ccaggctggt ctcgaactcc tgatctcgtg 
     7981 atccgcctgc ctcagcctcc caaagtgctg ggattacagg cgtgagccac cgcgtccagc 
     8041 tggctagttt atttatttat ttatttattt ttatttattt ttttgagaca gaatttcgct 
     8101 gtgttgccca ggctggagtg cagtggcgag atctcagctc actgcaagct ccacctcccg 
     8161 ggttcacgcc attctcctgc ctcagcctcc tgagtagctg gaactacagg cgcccgccac 
     8221 cacgcccggc taattttttt gtatttttaa tagagacggg gtttcacctt gttagccagg 
     8281 atggtcttga tgtcctgacc ttgtgatcct cccgcctcgg cctcccaaag tgctgggatt 
     8341 acaggcgtga gccaccgcac ctggccccag ccagctagtt ttttaaaata attttttgta 
     8401 gaggtgggtt ttgggctatg ttgcccaggc tggtctcaga ctcctggctt taagcaatcc 
     8461 tccagcctta gcctcccaaa gtgcagggat tacaggggtt tgagccacca cactgggcca 
     8521 gtttgttaga tctttatata aggattcaat taggctgctt gttttgccca gtggggtaaa 
     8581 aggtttttag gctgagaaag tgcatgatcg tcttttcctc ttgtaaaaac ccctctggct 
     8641 gctgtgtgaa gaggattgta gcgaggggtg gcagaaggag tcagagccca gctgcgaagt 
     8701 gaggagggcc tttccaaagg cagtagtgga cgggacggac agaggtgggg gtcttctatg 
     8761 tggctggcgg cctgacctgc tcactctgct ttcagctggt gatggcctcc ctgtaccaca 
     8821 tctatgtggc cctggaggag gagattgagc gcaacaagga gagcccagtc ttcgcccctg 
     8881 tctacttccc agaagagctg caccgcaagg ctgccctgga gcaggacctg gccttctggt 
     8941 acgggccccg ctggcaggag gtcatcccct acacaccagc catgcagcgc tatgtgaagc 
     9001 ggctccacga ggtggggcgc acagagcccg agctgctggt ggcccacgcc tacacccgct 
     9061 acctgggtga cctgtctggg ggccaggtgc tcaaaaagat tgcccagaaa gccctggacc 
     9121 tgcccagctc tggcgagggc ctggccttct tcaccttccc caacattgcc agtgccacca 
     9181 agttcaagca gctctaccgc tcccgcatga actccctgga gatgactccc gcagtcaggc 
     9241 agagggtgat agaagaggcc aagactgcgt tcctgctcaa catccaggtg agggtcgggc 
     9301 agcctggggc agcctctgcc tccccccgtt gttcctccaa gggacccttc tcattgtagg 
     9361 ggagggtgct ataggtcatg gttaacacag ggaaccagag ttccagcact gccacttact 
     9421 agctgggtga tcttgggcaa atgccttcat ctctctgtac ctcagtttcc ctatctgtaa 
     9481 aatagggata ataatggtac ctatatctta gacttataag gcttgagtga gtttacagca 
     9541 gtaaagtccc cacagcagtg tctggcacag aggaagccct caaacattca ctactgtcat 
     9601 aatgggacat gagaatcagt tgtagctctc tgtgacaaca gtctgtggca atgtataagt 
     9661 tgtgtgtgca ctagtgtata gccaggttgg cactcccagg gttacaggtg gcctctgcct 
     9721 tccagggact ctcagcctag ccagagaggt ttacctcttt ctacaagtgt ctcaaatcca 
     9781 gggggaaggt ggggtttgcg caaagcctgg aaggatgaat tcttgggcag aggtggaggg 
     9841 gtgaggggct ccttctaacc agatgtcata gagccttctc tctctgccac cccctggagg 
     9901 tgccatgggg cctggggctc ggggtcatgc cctcctggct ccctactccc agccgtggat 
     9961 tgcagaagat tctggtcctg gcccctgtta cggaacaagg cctttccctt ccaccctccc 
    10021 ccttcagaaa atccagtccg tcttggagga agaaaatctg tgtctttcag agaagtgtag 
    10081 gcaaaagaaa agggccaggt gcagtggctc gcgcctgtaa tcccagcact ttgggaagcc 
    10141 gaggtgggcg gattgcttga gctcaggagt ttcagaccag cctgagcaac atggtgagac 
    10201 cctgtctcta tcaaaaataa aaaataaaaa aaaatttaaa ggaaaaaaat gtttttaaaa 
    10261 gaaaagggat ttggaatcag aactggctct caggctcgtg cctataatac caacactttg 
    10321 ggaggccaaa gcaggaaaat ggcttgagcc caggagtttg agaccagccc tggcaacaca 
    10381 gtgagacccc atctctacaa aaacatgaaa aaattagcca gacatagtag cgtgcacctg 
    10441 tagtcccagc tacttgggag gctgaggtgg gaggattgct tgagcccagg aggtcaaggc 
    10501 tgcagtaagc catgattatg ctactgcact ccagcctggg caacggcaac agagcaagac 
    10561 tctgtctcaa aaaccaaaaa aacaaaaaca aaaacaaaaa aaaacggctc ttggctggcc 
    10621 gggcgtggtg ggtcacgcct gtaattccag cactttggga ggccgaggcg ggtggatcac 
    10681 gaagtcagga gatcgagacc atcctgacta acacggtgaa accccatctc tactaaaaaa 
    10741 aagaaaatac aaaaaaaatt agctgggcat ggtggtgggc acctgtagtc ccagctactc 
    10801 aggaggctga ggcaggagaa tggcgtgaac ccgggaggcg gagcttgcag tgagcagaga 
    10861 tcgcgccact gcactccagc ctgggagaca gagtgagact ccgtattaaa aacaaaaaac 
    10921 aaacaaaaaa aaacggctct tagtgcctga cctctggatc agtccttggg caaagcactt 
    10981 aacctgtagg agctacagtt tcctcatctg caaggctaac aaataccatt cagcacacct 
    11041 caccaaggct gaatttcaca aatctaaact caagagaaga aagcagcggc agaagagtgc 
    11101 atgtactagg ataccactta atattatttc aaaacaagca acgcagcctt ttgcatggag 
    11161 acacaggcta aggacatggg cggccacagt gaactctaaa tccaggatca ttgttatcgg 
    11221 ttgggagggc aagagcaggc aggggagcca attgggcttg gaacatctta tctcttaagg 
    11281 tggatgaaag ggatatgaat tttctttctt tctttctttc tttctctctt tctttctttc 
    11341 tttctttctt tttctttctt ttctctctct ctctctctct ctctcctctc tctctctctc 
    11401 ttctttcttc tttctttctt tctttctttc ttctttcttt ctttctttct tctccttcct 
    11461 tccttccttc cttccttcct tccttccttc cttccttcct tccttccttt ctttctttct 
    11521 ttctttcttt ctttctttct atctttcttt ctttctttct tttctttctt tcttgcagag 
    11581 tctcgccctg tcacccgggc tggagtgcaa tggggcgatc ttggctcact gcaacctcag 
    11641 cttcccaggt tcaagcattt ctcctgcctc agcctcccga gtagctggga ttacaggcat 
    11701 gcaccaccac gcccggctaa ttttttgtat ctttactaga gatggggttt cactatgttg 
    11761 gctaggctgg tctcaaactt ctgacctcgt gatgtgccca tcttggcctc ccaaagtgct 
    11821 gggattacag gggcgcacca ccgtgtccgg ccaatatttt tcttaccatc ttgttatttc 
    11881 caaagtattt cctaacacaa cttaaggtcc taccttcagc tgggacctgg tagcatctct 
    11941 cactgagata ggcatgtgtg tcttttgtct tttagctctt tgaggagttg caggagctgc 
    12001 tgacccatga caccaaggac cagagcccct cacgggcacc agggcttcgc cagcgggcca 
    12061 gcaacaaagt gcaaggtgag agcatccagg aaggggcact tcctctgggc tacacatgga 
    12121 gggacttggc tgtctgactg tagtatctct attcctctgt tttctgaatg tttggtggtg 
    12181 gtgggtgttg tttcctgctg ccccacccca ctgcccctgt aaggacaggt tctcgctata 
    12241 ttgcccaggc cagtcttgaa cacctgactt caagcaatcc tcttgcctct gcctccccac 
    12301 gtgctgcagt tacaggcgcg agccaccatg ccagcctgaa tgtttgttgt tgttgttgtt 
    12361 tgagatggag tctcacccag gctggagtgc agtggcgcga tctcagctca ctgcaacctc 
    12421 tgcctcccgg gttcaagcaa ttatcctgcc tcagcccccc gagtagctgg gattacaggc 
    12481 gcccaccacc atgcctggct aatttttttt ttgtatgttt agtagagatg gggtttcacc 
    12541 atgttggcca ggctggtctc gaactcctga cctcaggtga tccgcccacc ttggcctccc 
    12601 aaagtgctga gattacaggc gtgagtcact gtgcccggcc acctgcgtgt ttttgtatga 
    12661 gaagtggagt gcaggcaaaa ggacctgggg tcaaccttca gcgtgtggct ctgggcaagc 
    12721 catgagactt ctccctacct cagtttcccc acccgtaaaa tccagtgagg ttcagctact 
    12781 tctagcttat tggctcagaa gtgcacaaga acccctcaga aatcatggga aactcctgcc 
    12841 cccttaattt agactccttt ttaggccttt ggtcccctga tgtgggccag ggagttgggg 
    12901 acctgtatcc agctatgaac ccaccacagg aagatgtccc ttctgagtct tgttgtgtgt 
    12961 gagcccctcc ctcatgtgcc taagaacgat caaggctggc tgtactgaaa catcttggaa 
    13021 acttccaaaa agaccaaagt gctccacaaa atgtaccctc actaagccta aaacactgag 
    13081 ggagggagtg tggctttggg atgggtagca ataaagaggt aaggcttagc tacctcctgg 
    13141 caggttatat taggcctccc ctcctgtgcc accctaacct acctggcttg tggctttctc 
    13201 acttgtgcca gaccacacgg acccctctgc taggggtttg taaccccgga gggcttggct 
    13261 atttggtggg gtagggagac gtcaccctaa tgaagcagtt ctcaaagtgt ggtaccctgg 
    13321 ctgtgggagg tggtaatcct agtatcccct caacggggtc tgtgaggaca angcattttt 
    13381 ataacactac tactattttt ttggtttttt ttttttcgtt tgagacagtc ttgctgtcac 
    13441 ccaggctgga gtgcagtggc atgatctcgg ctcactgcaa gctccgcctc ccaggttcac 
    13501 gccattctcc tgcctcagcc tcccgagtag ctgggactac aggtgcccgc caccatgcct 
    13561 ggctaatttt ttgtattttt agtagagacg gggtttcact gtgttagcca ggatggtctc 
    13621 gatctcctga ccttgtgatc cgcccgcctc ggcctcccaa agtgctgtaa ttacaggtgt 
    13681 gagccaccgc gcccggcctt tttttttttt tttttttttt tttgagacag ggtctcgctc 
    13741 tttcacccag tctggagtgt agtggcacaa tcacagctca ctgcagcttc aacctcccag 
    13801 gttcaaggga ttctcccacc tcagcctcct gagtaactgg gactataggc acgtgccacc 
    13861 acacccagat tttttttttt tttggctttt tttaaaaaag ccaaaaataa atgagaaaat 
    13921 tagagtttca ctttctcatg aatgtgtgtt ggcattttcc aaaggttatg tgacatgtga 
    13981 tgctctctca tggatttgat ggctcatgga atgtgtgcct gtatgttctt gtatgttaag 
    14041 aatttctcag ttttggccgg gcacgatggc tcatgcctgt aatcccagca ctttgggagg 
    14101 ctgaggcacg gggatcactt gaggtaagga gtttgagacc aacctggcca atgtggtgag 
    14161 accccatctc tactaaaata taaaaattag ctgggtgtga tggtgcacac ctgtaatccc 
    14221 agctactcgg gaggctgagg caggagaatc tcctaagtcc gggaggcaga ggttgcagtg 
    14281 agccgagatt gcaccactgt actccatcct gggcgacagc gagactccat ctcaaaaaaa 
    14341 aaaaaaaaag aaagaaaaga aaagaaaaag aatttctcag ttttaatatc taattttgta 
    14401 aatagtgata gctatactca cacaaacaaa agctcttttg gatccttggt tgcatttgag 
    14461 tataaaggag ttttggaacc aaaacatttg agaactgcac ccctaatgca tcagaaggag 
    14521 caggagcctt taatatgaac aacacacatg taaatgtcac agtgtacctg cttgcttgct 
    14581 tgcttgcttg tacttcctgt gaccgcagcc ctgggccacc agacctaagg ccctgttttc 
    14641 tctggggaag cccttctcat agcccagggc ggggctagga ttgaaaccca gctggtctgg 
    14701 ctccagagac ctgccctgga ctctgtcctg cttctaaaga cctagggagc acccactctg 
    14761 tgcctgagga ggcaggtggc acatctaccc aggttgcatg gttggctctg gcctatcatg 
    14821 ttttaaatct tttttttttt tttttttgaa atggagtctc actctgttgc ccaggctgga 
    14881 gtacagtggc gcaatcttgg ctcactgcaa cctctgcctc ctgggttcaa gcaattctct 
    14941 gcctcagcct cccgagtagc tgggattact ggcactcgca accatacccg gctaattttt 
    15001 tgtattttta gtagagacgg ggtttcacca tattggccag gctggtcttg aactcctgac 
    15061 ctcgtgatcc acctgccttg gcctcccaaa gtgctgggat tacaggcgtg agccactgcg 
    15121 cccggcccta tcacatttta ataaccaggg atgggactga acttgaattt tgacctcaga 
    15181 gctcctgctt tctagctcct gccccatcat caccatgctt agcaaacgtg tgagtttgag 
    15241 aggaagattt acagctcaga cctaattgct ggcaaagttt aaggagagga cagggagcag 
    15301 gcagaagtct gaaaaccacg cctgggccca agaatgtttt cacaatgtgg cctggctgca 
    15361 cagggaagaa cagacagctt ggagaagtag tgagctgccc gtctttgaag gtattcaagc 
    15421 agtggctaga gggacacctg tctgtggtct tgcagaatcc tggcgttggg cagtgactgt 
    15481 accacagacc ctgaggccgc tctgctttgc tttcctatga catcagacac cctgatgcac 
    15541 gcccacctgt taatgacctt gccccatttt ctctttcaga ttctgccccc gtggagactc 
    15601 ccagagggaa gcccccactc aacacccgct cccaggctcc gcttctccga tgggtcctta 
    15661 cactcagctt tctggtggcg acagttgctg tagggcttta tgccatgtga atgcaggcat 
    15721 gctggctccc agggccatga actttgtccg gtggaaggcc ttctttctag agagggaatt 
    15781 ctcttggctg gcttccttac cgtgggcact gaaggctttc agggcctcca gccctctcac 
    15841 tgtgtccctc tctctggaaa ggaggaagga gcctatggca tcttccccaa cgaaaagcac 
    15901 atccaggcaa tggcctaaac ttcagagggg gcgaagggat cagccctgcc cttcagcatc 
    15961 ctcagttcct gcagcagagc ctggaagaca ccctaatgtg gcagctgtct caaacctcca 
    16021 aaagccctga gtttcaagta tccttgttga cacggccatg accactttcc ccgtgggcca 
    16081 tggcaatttt tacacaaacc tgaaaagatg ttgtgtcttg tgtttttgtc ttatttttgt 
    16141 tggagccact ctgttcctgg ctcagcctca aatgcagtat ttttgttgtg ttctgttgtt 
    16201 tttatagcag ggttggggtg gtttttgagc catgcgtggg tggggaggga ggtgtttaac 
    16261 ggcactgtgg ccttggtcta acttttgtgt gaaataataa acaacattgt ctgatagtag 
    16321 cttgaagtag ttttcatggg ctttgttatt cttggggaac tgaccttttc ctccctggtt 
    16381 tcttgcgtgc tcggtaggag aagtggtgat agggggttgg caggagctgg tctgtttgag 
    16441 aatacagaag gtgagctttt cttttctttt tttttttttt tgagatggag tctcactctg 
    16501 tcacccaggc tggagtgcag tggcgtgatc ttggttcact gcaagctcca cctcccaggt 
    16561 tcaatcaatt ctcctgcctc agcctcctga gtagctggga ttacagaagt tcatcaccat 
    16621 gcccagctaa tttttgtatt tttagtagag atggggtttc cccatgttgg ccaggctggt 
    16681 ctcgaactcc cgacctcagc tggtccacct gcctcagctt cccaaggtgc tgggattaca 
    16741 ggcgtgagcc accgtgcctg gcccaggagg tgagctttaa gtagctggtg ggcgaatatt 
    16801 tgtgttgaac cctgcttgat gcaattctcg actttatgga agatggggtt gccctgtttg 
    16861 gtggaaatga gcagattctg gggcaaaatt tgtattttct gtccagtgac tattagggac 
    16921 tggagtgaaa ttcttaggtt caaattcctg ctacaccact ttgaggttag tcacttaacc 
    16981 tctctgaggc tccattttat cactggtgac atgaatatag tgatacctaa ctcacctatg 
    17041 tgtcctgaga agcaaacaag atgcaagtga aatgccaacg ccatacacag ttagcaccta 
    17101 ttatgcaaag aaggagacca gtgttttgtg attcttgtac tgtcgagtca cctcatctat 
    17161 gtcatccctg tgttgagggg gtgtttccac tatctgaggg tcaggatgga tttcactgag 
    17221 gtctgtccag ctctaaaacc caagcccttt ctatggccct aagtcaagaa aatactaaat 
    17281 atgtagcctc ccaatctggg aaagtgaaaa accttttgct gaaagtgtcc tgggcagagc 
    17341 atgggacaag attttttttt tttttttttt tttttttttg agacagggtc tggctttgtc 
    17401 ctccacactg gagtgcagtg gtgtgatctt ggctcactgc aacctccacc tcttgggctt 
    17461 aagccatcct ctggcctcag cctcctgagt agctgcggct acaagtgcac accaccatgc 
    17521 ccagttaatt tttgtatttt ttttttagag atggggtttc gctatgttgc ccaggctggt 
    17581 ctcaaactct tgaactaaag tgatcctccc accttggctt cacaaagtgc tgggattaca 
    17641 ggcgtgagtc actgtgcctg gccaaggtgt attttttttt tttttttttt ttttgagatg 
    17701 gagtctcatt ctgttgccca ggctggagtg cagtggtgcg atttcagctc gctgcatcct 
    17761 ctgctgccca ggttcaagca attctcctgc ctcagcctcc caagtagctg ggattataag 
    17821 cacatgacac cgcactcggc taattttttt agttttagta gagacagggt tttaccatgt 
    17881 tggccaggct ggtcttgaac tcctgacctc gtgatccacc tgcctcggcc tcccaaagtg 
    17941 ctgggattac aggtgtgagc cactgtgccc agccaaggtg tttctttata ggaccagtac 
    18001 ctaaggactg gaagtcagga gacctttgtc actagtctga ctatgccact tcaaggctca 
    18061 ttttgttcac tggtaaaatg agaacaatac acatacctct cacagctggt gggaggatcc 
    18121 agtggtgtcc aaacaccagt ctgtgcatgg tggcatcaga attacttgga gatacttaac 
    18181 cacagaatcc agggctccac ctgggatggg gctctagaat tttttttttt tttttttttt 
    18241 ttttgagacg gagtcttgct ctgtcaccca ggctggagtg cagtggcgcg atcttgactc 
    18301 actggaagct ccgcctcccg ggttcacgct attctcctgc ctcagcctcc tgagtagctg 
    18361 ggactatagg cacccaccac catgcccggc taattttttg tatttttagt ggagacggag 
    18421 gtcacaggtt tcaccgtgtt agccaggatg gtctcgatct cctgacctcg tgatccgccc 
    18481 gccttggact cccaaagtgc tgggattaca ggcgcgagcc accgcaccca gcctagaatc 
    18541 agtatttttg aaaagtacct taggagagtc caacgcgcac ccaggtccag gagcacgtat 
    18601 ggtcacgtat gcaaagcata ggcattcaaa tagcagctgg agctgggcac ggtggctcac 
    18661 gactataatc ccaacac 
    

